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Abstract 
 
 The research presented is this thesis entails the study of microarray-based 
bladder cancer data and the development of new model-based data mining 
methodologies for accurate prediction of cancer stage, grade and survival. The main 
focus of the presented research work, from a systems engineering perspective, is on 
producing models that are more accurate, while maintaining a simple computational 
structure, interpretable and with good generalisation performance. Such traits deem the 
developed methodologies as easier to create and use by non-experts.  
The presented data-driven computational modelling framework includes a 
Radial-Basis-Function (RBF) Neural-Fuzzy function, where the universal 
approximation property is utilised to create an accurate, yet simple, model structure.  
The scaling-up performance of the developed model is also examined, resulting in a 
proposal for an enhanced knowledge-capture and model optimisation method. The 
predictive modelling results show that the RBF-Neural-Fuzzy model outperforms 
existing modelling attempts in the literature, while identifying clinically relevant gene 
signatures. 
A major contribution of this thesis is the creation of model-based feature-
selection framework, as an embedded method for gene signature identification for 
bladder cancer. For the first time in the literature, an entropy-based iterative algorithm is 
combined with the previously created RBF model to create an efficient feature selection 
technique. The Tagaki-Sugeno-Kang (TSK) output layer of the RBF model is used as a 
feature discriminator, to estimate the relative contribution of each gene to the overall 
gene signature. The reduced size model (as a result of the iterative feature-selection) 
achieves more than 80% accuracy on the prediction of patient survival on new 
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(“unseen”) patient cohorts, whilst achieving this with less than 25 genes. This is the best 
performing model-based approach in the literature for this type of cancer, for a gene-
signature of less than 25 genes (typical microarray-based signature size in the literature 
is 100-200 genes). 
 An in-depth analysis of the generalisation performance of the developed models 
is carried out by cross-validating distinct microarray data and applying data integration 
techniques. Three data integration approaches are utilised, to address the well-known 
issue of data cohort mismatch (for different microarray technologies), and based on the 
results a model-based non-linear mapping approach is introduced. The obtained results 
demonstrate how data integration methods for model cross-validation can have a 
significant increase in the generalisation performance, and enable previously developed 
models to be used in different patient cohorts. 
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Chapter 1: Motivation 
and thesis overview 
The healthcare professionals community (medical, biology, chemistry, and 
engineering) have improved gradually the quality and length of life. It is expected that 
in developed countries, by year 2020 the female life expectancy will be of around 90 
years, however the male life expectancy is not expected to have a considerable life 
expectancy increase [1]. New vaccinations and novel treatments have been developed 
for diseases years ago where not possible to treat or cure. These advances in medicine 
led to a decrease in the mortality rate in many countries. However, it can be said that 
several diseases are still the focus of research. For example, tobacco-related diseases, 
which include: respiratory diseases, circulatory diseases and several types of cancer [1].   
 In healthcare, it is accepted that: “If we live long enough, at certain point of our 
lives we would develop some type of cancer” [2]. This is why cancer research is of 
paramount importance, if a cure is found quality and length of life for the patients could 
be improved. Cancer analysis used to be an area of research destined only for clinicians 
but as the new technologies emerged and the amount of information increased 
meteorically, Systems Engineering was required to analyse all of this information. The 
research presented in this thesis is based on the study of microarray bladder cancer data. 
Bladder cancer is a highly recursive type of cancer and that it is challenging to treat. 
The classification of the tumour’s behaviour is a crucial point, particularly at the early 
stage of the cancer when clinicians try to decide which treatment strategy to follow. 
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This early categorisation of cancer aggressiveness not only helps the patient 
avoid unnecessary treatment but will also allow substantial cost savings. The focus of 
this research is to produce a data-driven computational model that identifies the genes 
(feature selection) significant to the prediction of stage, grade, and survival of bladder 
cancer while maintaining simplicity, transparency and accuracy.  
1.1 Background and Motivation 
 Bladder cancer is a type of cancer that is extremely recursive, and depending on 
the type it can affect the patient’s life even after being cured [3]. From a medical point 
of view, there are two types of cancer according to the evolution of the tumour: 
aggressive tumours (tumours of poor prognosis and resistant to conventional treatments) 
and non-aggressive tumours (tumours that respond well to conventional treatment and 
with good prognosis). However, currently there are no biological markers or reliable 
parameters to categorise the two types of the disease.  
 Biology methods based on the analysis of clinical history and biopsies studies 
are the only routine tools for identification and confirmation of the stage of the disease. 
From a molecular level since a few years ago genetic profiles and possible markers have 
been studied. These markers may help us discover the cause and development of the 
disease; however research is on-going in this area.  
 Existing analytical techniques, predictive methodologies (regression, prognostic 
nomograms) and statistical data analysis methods struggle to cope with the inherited 
noise and uncertainty associated with this type of clinical data therefore yielding 
average prediction results [4, 5]. 
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  In recent years, new techniques have been developed and the study of genetic 
markers has become more common, however the research is ongoing in this area as at 
the moment there is still no irrefutable list of genetic markers related to bladder cancer 
[4-12]. The main prognostic tools are based on histologic stage and grade, and as 
explained before these tools have their drawbacks. It is logical to assume that there is a 
research gap, and this is where Systems Engineering may be able to contribute and 
improve the diagnosis methods via the analysis of both clinical data sets and gene data, 
in order to find suitable markers that predict cancer stage, grade and survival. The 
Systems Engineering’s aim is to achieve a correct diagnosis, which will lead to the 
optimisation of the patient’s therapy.  
 For certain cancer types the clinicians perform a number of tests to diagnose the 
patient. This involves clinical data, chemical tests, and medical examinations and more 
recently there is interest to investigate gene expression data. Unfortunately, these 
tests/data are not very well understood. This is where systems engineering and data-
driven modelling come in. If hybrid models are built from the test data along with 
behaviour from cancer biopsies and gene expression data, the understanding of how 
these tests relate to cancer prediction could be improved, and a treatment therapy could 
be informed; part of this study is focused on the analysis of microarray data. Microarray 
is a new technique to analyse tissue samples, and this will be explained in detail in the 
Chapter 2. Microarray data analysis has opened new possibilities for diagnosis and 
treatment of numerous diseases, including cancer; however microarray data comes with 
its limitations. For example, high-dimensionality, low sample size, noisy, missing data 
and the necessity of applying feature selection methods to identify relevant markers. 
The diagnosis of numerous malignancies has been improved by the use of microarrays. 
Chapter 1: Motivation and Thesis Overview                                                                                        4 
  
 
 
For this reason, the search for a robust classifier for the tumours’ categorisation and 
feature selection algorithm has been intensive.  
1.2 Research Objectives and Contributions 
 
One of the biggest challenges in bladder cancer prediction is the accurate and 
early classification; in recent years microarray technologies and related research have 
helped with this task with feature selection and systems engineering models. Current 
clinical diagnostic methods are not definitive enough; to date the search for conclusive 
markers to lead to a precise classification is still ongoing [9, 13, 14]. 
The main challenges that microarray studies run across are the thousands of 
genes combined with a small number of samples (patients) and the uncertainty of raw 
data due to measurement process and variation in the technology. This presents a 
challenging Systems Engineering classification and identification problem (high 
dimensionality, low number of samples). To tackle the challenge of high number of 
features, feature selection algorithms have become indispensable components of the 
data mining process [15].  
 The objectives of this research are to:  
1. Introduce a Radial-Basis-Function Neural-Fuzzy modelling structure for the 
analysis of noisy high dimensional low sample size data; the main characteristics 
of the model are transparency and simplicity. 
2. Investigate the scaling-up performance of Radial Basis Function Neural-Fuzzy 
models using a standard PC and a High Performance Computing (HPC) server. 
The aim of the research is to find the limit for the maximum number of inputs to 
use in the model while maintaining low computational complexity and high 
accuracy.  
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3. Introduce a new model-based iterative method for feature selection that directly 
links the relative contribution of each feature to the system’s performance.  
4. Improve the generalisation performance in microarray bladder cancer data 
5. Maintain simplicity, transparency and accuracy. 
 The main novelty of this research relies on producing models that are accurate, 
simpler, interpretable, with good generalisation performance (robust) and easier to 
develop and to be used by non-experts given their simplicity and transparency.  
 A Neural-Fuzzy algorithm was chosen because it possesses the learning abilities 
of Neural-Networks, the interpretability of Fuzzy logic and can model non-linearity. 
Furthermore, Neural-Fuzzy models require less data than Neural-Networks [16].  Apart 
from the previously mentioned characteristics, Neural-Fuzzy models already proved to 
make accurate bladder cancer classification [7, 16-19]. Compared to Neural-Networks, 
Support Vector Machines (SVM) or Logistic Regression, Neural-Fuzzy models deliver 
comparable or improved accuracy in classification with the advantage of being more 
interpretable [17]. A drawback of Neural-Fuzzy models is that they encounter problems 
when the dimensionality is relatively high [20].  
 In this thesis, the following research contributions have been made:  
1. Reduction in the complexity of the model: number of inputs of the model 
(features) and linguistic statements to describe the model (fuzzy rules).  
2. An enhanced rule-base extraction framework is proposed to improve the 
model’s performance for high-dimensional low sample size data (microarray 
data). With the enhanced rule-base, the scaling-up performance of Radial Basis 
Function (RBF) Neural-Fuzzy models was improved.  
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3. For the first time, a Neural-Fuzzy model (Radial-Basis-Function with a TSK 
output) was applied to microarray bladder cancer data to make a feature 
selection in the training phase (embedded feature selection): the aim of the 
iterative feature selection method is to use a measure of uncertainty (fuzzy 
entropy) to select relevant features during the model-training phase, whilst 
maintaining the system’s simplicity and interpretability and taking into account 
the interactions between the genes.  
4. The inclusion of the cancer stage and grade as extra features of the predictive 
model is evaluated, thus producing a hybrid gene-clinical data model. 
5. Improve the generalisation performance in microarray bladder cancer data: two 
different data integration approaches were presented for the first time: median 
adjust and NN mapping of input-output. The results obtained prove that the data 
integration methods for cross validation of the models helps to have a 
considerable increase in the performance. 
 Considering the aforementioned objectives and contributions, and the impact of 
this disease in the society, the research work described in this thesis is underpinning for 
the development of new methods of diagnosis and prediction of the behaviour of 
bladder cancer. 
1.2.1 Publications: 
Each publication is linked to a Chapter and objective within the thesis and study 
respectively, for example: 
 Chapter 3 is linked to publications 1 and 4 and objectives 1 and 5.  
 Chapter 4 is linked to publications 2 and 2b and objective 2. 
 Chapter 5 is linked to publications 1, 3 and 4 and objectives 1,3 and 5 
 Chapter 6 is linked to objective 4 and 5.   
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1.3 Thesis Outline 
The rest of this thesis is organised as follows: 
 Chapter 2: definition of cancer, microarrays and a brief literature review is 
presented. Previous methods used for microarray data analysis, either for feature 
selection or cancer classification are also covered in this Chapter. 
 Chapter 3: This Chapter introduces a Radial-Basis-Function Neural-Fuzzy 
modelling structure, aiming to maintain simplicity and transparency in the form 
of a linguistic Fuzzy-Logic rule-base. The proposed methodology is validated by 
selecting a signature for the identification of the stage, grade and survival of 
bladder cancer. The signature selection and predictive modelling results are 
compared to previous research work on the same dataset, showing that the RBF-
NF model outperforms the previous modelling attempts by achieving high 
predictive accuracy (>80% on average).  
 Chapter 4: the scaling-up performance of Radial Basis Function Neural-Fuzzy 
models is investigated. Based on the findings, an enhanced rule-base extraction 
framework is proposed to improve the model’s performance for high-
dimensional low sample size data. To overcome the challenges present when 
high dimensional data is used, a Weighted Fuzzy C-means (WFCM) algorithm 
for the analysis of high-dimensional low sample size data is introduced. A 
second contribution of this chapter is a cluster optimisation algorithm based on 
the Xie-Beni cluster validity index to improve the quality of the initial clusters 
(rule-base) calculated by the WFCM. Via the proposed framework the scaling-
up performance of RBF Neural-Fuzzy models is enhanced, hence the predictive 
modelling framework can be used without the use of filter-based feature 
selection methods. The aim is to find the rational limit for the maximum number 
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of useful inputs (genes) to use in the model while still maintaining low 
computational complexity and high accuracy.   
 Chapter 5: In this chapter, a new model-based iterative method for feature 
selection based on fuzzy entropy measures is introduced. The presented 
approach is based on a Radial Basis Function – Neural-Fuzzy which is designed 
to be equivalent to a Fuzzy Logic TSK-based system. A fuzzy entropy measure 
is used to directly link the relative contribution of each feature to the system’s 
performance. An iterative algorithm is then used to identify the most relevant 
features of the process under investigation; the modelling-feature selection is 
performed in one iterative process. In predicting the patients’ survival as a result 
of their bladder cancer gene signature, the inclusion of the cancer stage and 
grade as extra features of the predictive model is evaluated, thus producing a 
hybrid gene-clinical data model. The simulation results confirm that the new 
approach outperforms existing predictive models in the literature for bladder 
cancer survival based on gene signature only; the additional novelty of the 
presented approach relies on the added benefit of producing models that are 
simpler (considerably less genes in the signature), interpretable, with good 
generalisation performance and easier to develop and use by non-experts due to 
the absence of complex pre-processing which is common in this field.  
 Chapter 6:  In this Chapter, the generalisation performance of the developed 
models is investigated. The approach studied in this chapter is to cross-validate 
distinct microarray data by applying data integration techniques. Three different 
data integration approaches were analysed: quantile discretisation, median adjust 
and NN mapping of input-output. The latter two approaches are introduced for 
the first time to a bladder cancer classification algorithm. The results obtained 
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demonstrate that the data integration methods for cross validation of the models 
helps to have a significant increase in the performance.  
 Chapter 7: Conclusions and future research directions: the conclusions of the 
thesis and the direction for future research. This covers performance 
summarisation of the presented work and research proposals towards multi-
cohort modelling approaches. 
 
 
Chapter 2: Microarray 
technologies and data-
driven modelling for 
cancer 
 Case Study on Bladder Cancer; definition of cancer, microarrays and a brief 
literature review is presented. This Chapter also presents previous methods used for 
microarray data analysis, either for feature selection or cancer classification. 
2.1 Cancer Overview 
In order to assess the complexity of the problem of cancer and cancer research in 
the world a brief literature review is presented here. There are more than 200 types of 
cancer and millions of new cases of cancer are recorded each year [21-24]. According to 
[23], the most common cancers occurring in the UK are:  
 Female breast  
 Lung 
 Prostate Cancer 
 Bowel 
 Malignant Melanoma 
 Non-Hodgkin Lymphoma  
 Bladder 
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As stated in [23], “More than 331000 people were diagnosed with cancer in the 
UK in 2011. More than 1 in 3 people in the UK will develop some type of cancer during 
their lifetime”.  
For the UK, the survival rates for cancer have increased considerably in the last 
decades; nevertheless cancer is the cause of more than 25% of  all deaths [23]. 
2.2 Bladder Cancer 
 Bladder cancer is the 11
th
 most common type of cancer in the world [21, 25]. In 
the UK, is the 7
th
 most common type of cancer [21, 23].  
The bladder is an organ (Figure 2.1) [26] that stores urine and it is located in the 
abdomen, the majority of the bladder cancer forms in the tissues of the bladder.  
  
Figure 2.1: Bladder and nearby organs 
The risk factors linked to bladder cancer are [27, 28]: 
 Age 
 Cancer therapies 
 Ethnicity 
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Cancer occurs when something goes wrong with the cell reproduction and the 
cells do not die but instead they continue reproducing. If those cells are not dying and 
new cells are reproducing, eventually a tumour may form [23]. The correct 
classification of future tumour behaviour is one of the biggest challenges in cancer. 
Whilst it is crucial to avoid unnecessary treatment for indolent tumours, delays in 
radical intervention for aggressive disease lead to worsening survival and quality of life 
[29-31]. The prediction of outcome is best performed using pathological stage, grade 
and various other histological and clinical parameters.  
The cancer Stage encoding is based on the staging system that uses numbers to 
indicate the stage of the cancer, this is defined as follows: 
“Stage 0a, there is a small area of cancer only in the bladder 
lining. 
Stage 0, the cancer cells are confined to the inside layer of the 
lining of the bladder. 
Stage 1, the cancer has grown into the layer of connective tissue 
beneath the bladder lining. 
Stage 2, the cancer has grown into the muscle of the bladder wall 
under the connective tissue layer. 
Stage 3, the cancer has grown through the muscle of the bladder 
and into the fat layer surrounding it. It may have spread to other 
organs. 
Stage 4, the cancer has spread to the wall of the abdomen or 
pelvis, the lymph nodes or to other parts of the body” [32].  
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Similar to the encoding applied to the previous model for the prediction of stage; 
three grades are used to rate cancer. The Grading of bladder cancer tumours is defined 
according to:  
Grade 1 or low-grade cancer 
Grade 2 or moderate/intermediate grade 
Grade 3 or high-grade cancer [22]. 
The risk of disease-progression, as well as the frequent reoccurrences, require 
extensive clinical monitoring of bladder cancer patients, making this disease one of the 
most expensive to manage [33]. One of the challenges in the screening of cancer is the 
search for markers that identify tumour of aggressive and non-aggressive behaviour. 
This is a crucial point, especially at the early stage of the cancer when clinicians try to 
decide which treatment strategy to follow. This early categorisation of cancer 
aggressiveness not only helps the patient avoid unnecessary treatment (often avoiding 
serious side-effects) but will also allow substantial cost savings.  
There is a high lifetime cost on patients with superficial tumours. Removing the 
bladder can treat the disease, but it may result in various complications that the person 
has to live with for the rest of their life [28] . Current clinical diagnostic methods are not 
definitive enough; at this time there are no determinant markers to do a precise 
detection. Biology methods based on the analysis of clinical history and biopsies studies 
are the only routine tools for identification and confirmation of the stage of the disease. 
From a molecular level since a few years ago genetic profiles and possible markers have 
been studied. These markers may help discover the cause and development of the 
disease; however research is on-going in this area. Limitations in the accuracy of 
clinical diagnostic methods have led to the search for more robust biomarkers such as 
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those derived from gene expression data [7, 34, 35]. In recent years microarray 
technologies and related research help with the task of making an accurate and early 
classification of the cancer and with the identification of clinically relevant genes.   
 
2.3 Microarray Analysis 
Microarray is a technique to analyse tissue samples. Microarrays make possible 
the analysis of thousands of genes simultaneously; since thousands of genes are 
analysed, the data generated from each microarray is enormous. This literature review 
will focus on giving the basic concepts of microarray and explain what the data 
represents. 
The present section is divided into 3 sub-sections:  
1. Microarray Basic concepts.   
2. Representation and extraction of information 
3. Analysis of Gene Expression Data; different methods for the analysis of 
microarrays, from statistical to soft computing.  
 
2.3.1 Microarrays Basic Concepts:  
Deoxyribonucleic acid (DNA) microarrays are a technology to simultaneously 
monitor the expression levels for thousands of genes [36]. The process of transcription 
of genes into messenger Ribonucleic acid (mRNA) and subsequent conversion to form 
proteins is called Gene expression [36]. DNA microarrays are used to identify disease 
biomarkers in many applications, for example: in neurological diseases, Alzheimer, 
multiple sclerosis, diabetes [37, 38]. As shown in Figure 2.2 [39], DNA microarrays are 
solid supports where gene sequences are immobilised [38].  
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Figure 2.2: DNA microarray 
 In a microarray, the gene sequences must be attached to their support in a 
permanent way, since scientists use the position of each spot in the array to detect a 
gene sequence [38]. The entire process is based on hybridisation probing, defined in 
[40] as: “a technique that uses fluorescently labelled nucleic acid molecules to 
identify complementary molecules and sequences that are able to base-pair with one 
another.”  
Once the hybridisation is complete, a ‘scanner’ will examine the microarray. A 
laser stimulates the fluorescent tags, and the scanner produces a digital image of the 
array. The image is stored and, as explained in Section 2.3.2, is subsequently analysed.  
2.3.2 Representation and Extraction of Information  
i. Image Processing and analysis 
As mentioned in section 2.3.1, the expression level for each gene can be stored 
as an image. The processing of the image is the initial step in the analysis of microarray 
data.  
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Image processing involves:  
 Identification of the spots 
 Determination of the area to be analysed  
 Assigning the spot intensity [41].  
After the image processing and analysis, normalisation is necessary to adjust for 
any bias that arises from differences in the microarray process [38, 41].  
ii. Gene Expression Data Matrices 
As stated in [41], there are several representations for the measurements of 
microarray data: 
 Absolute; the expression level of the gene is represented in abstract units.  
 Relative; the gene expression of a gene in abstract units is normalised with 
respect to its expression in a reference.  
 Log2; the gene expression values are converted to log2 to eliminate the high 
variations between the gene’s intensities.  
 Discrete; the gene expression values are converted to discrete numbers. 
Microarray data can be also seen as a vector, where the gene expressions are 
represented in a vector space [41].  
2.4 Feature selection methods applied to microarray  
One of the biggest challenges in cancer is the correct classification of future 
tumour behaviour and it may be achieved via a number of information sources, 
including clinical and radiological data and potentially, biochemical or molecular tests. 
However, limitations in the accuracy of these data have led to the search for more robust 
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biomarkers such as gene expression data. In recent years microarray technologies and 
related research help with this task. A reliable predictor capable of an accurate 
assessment at an early stage of the cancer will undoubtedly avoid unnecessary 
treatment, save costs and in general would improve the patients’ quality of life.  
Current clinical diagnostic methods are not definitive enough; to date the search 
for the conclusive markers to lead to a precise classification is still ongoing [9, 13, 14]. 
The main challenges that these types of studies run across are a) the high 
dimensionality, translated into tens of thousands of genes combined with a small 
number of samples (patients) and b) uncertainty of the raw data due to measurement 
process and variation in the technology. This presents a challenging Systems 
Engineering classification and identification problem (high dimensionality, low number 
of samples). To tackle the challenge of high number of features, feature selection 
algorithms have become indispensable components of the data mining process [15]. The 
objective of feature selection is to improve the performance of the predictor, provide 
faster and more computationally inexpensive predictor. There are numerous benefits of 
feature selection: simplifying data understanding, decreasing the computational 
complexity, and most importantly decreasing training times [42]. There are three 
categories for feature selection: filters (typically applied as a pre-processing step), 
wrappers (optimise a classifier as part of the feature selection procedure) and embedded 
methods (perform feature selection in the process of training). The goal of this literature 
review is to offer an analysis of the current feature selection methods applied to 
microarray data (high dimensional low sample size).  
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2.4.1 Filter Methods 
Filter methods evaluate the correctness of the proposed feature subset by 
analysing the relation of each gene with the class by the calculation of basic statistics 
[43, 44]. Filter approaches are the most used feature selection method in microarray 
literature for gene selection [36, 45]. 
Filter methods rank the features depending on a score: then, the features with the 
highest score are chosen and applied as inputs for the classifier [44]. Filter feature 
selection methods can be separated in two categories: multivariate and univariate. 
Multivariate methods consider, to some extent, the dependencies between the features; 
on the contrary, univariate filter methods consider each feature individually [43, 44]. 
The costs of considering the dependency is being slower, loose some scalability while at 
the same time still not has interaction with the classifier [24].  
i. Univariate Filter Feature selection Methods 
The majority of the filter methods belong to the univariate category. The advantages 
of Univariate filter feature selection methods are that they are fast, scalable and 
independent from the classifier [24]. The disadvantages of using univariate feature 
selection methods are that they ignore feature dependencies and lack interaction with 
the classifier [24]. Some of the most common examples of univariate filter feature 
selection methods are t-test [46], ANNOVA [46], Information Gain [47].  
ii. Multivariate Filter Feature selection Methods 
Examples of filter methods applying correlation for feature selection are the 
Correlation-Based feature selection (CFS) [48] and the fast correlation-based filter 
method [49].  
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In [48], the method selects the feature (genes) subsets based on correlation or 
dependence. The method’s objective is to select subsets of genes that show a high 
correlation with the class but no correlation between the genes. The CFS method reports 
results (breast cancer) comparable or better than wrapper approaches, with the benefit of 
being faster.  
In [49], the filter method is based on measuring the ‘predominant correlation’, 
identifying the features relevant to the class and minimising the redundancy between the 
selected features. The method is applied to lung cancer, reporting high classification 
results.  
Numerous multivariate filter feature selection approaches [50-53] have been 
applied to microarray analysis, reporting similar or improved results compared to more 
specialised methods.  
iii. Recent approaches  
Recent approaches [54, 55] are considering applying discretisation followed by a 
filter feature selection algorithm.  The authors report an increase in the classification 
accuracy and the complexity of the model (applied to prostate cancer).  
The benefits of using filter techniques are that they can be applied without 
difficulty to high-dimensional datasets (microarray data); they are computationally 
inexpensive and fast [24]. A drawback of filter methods is that most techniques consider 
each feature separately, ignoring feature dependencies, and that they do not interact with 
the classifier [44]. This could result in an inferior performance of the classifier when 
compared to more complex methods [44].  
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2.4.2 Feature Selection: Wrapper Methods 
 Wrapper feature selection methods optimise a predictor as part of the selection 
procedure; their computational complexity is high because it grows with the number of 
features [24]. Consequently, wrapper feature selection approaches have been avoided in 
recent years. In wrapper feature selection methods, several subsets are produced and 
assessed [24]. The assessment of each subset is achieved by training and testing each 
classification model [43]. Wrapper feature selection approaches are popular in machine 
learning, however due to its large computational cost they are not popular in microarray 
analysis [43].   
Most of the work applying wrapper methods was done in the early years of microarray 
analysis, and that wrapper methods have not evolve as the same speed as filter or 
embedded feature selection methods [44]. Despite their high computational cost, several 
authors [56, 57] state that they have better predictive accuracy.   
 In [58], the authors evaluate widely applied wrapper feature selection algorithms 
finding that by using these algorithms the accuracy is improved and the number of 
genes of the classification model is considerably reduced in size.  
 In [59], the authors introduce a procedure named successive feature selection. 
The proposed algorithm consists on separating the genes into subsets (of size s), and 
subsequently selecting smaller subsets (of size bs) containing the best genes from each 
subset (of size bs<s) based on their classification accuracy. Afterwards, all the selected 
genes are merged to obtain the ‘top genes subset’.  
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2.4.3 Embedded Methods 
  
 Embedded methods perform feature selection in the process of training the 
classifier [44]. Similar to wrapper methods, embedded methods also have interaction 
with the classifier, which increase the computational complexity. However, compared to 
wrapper methods, the computational complexity is smaller. Embedded methods can be 
seen as an intermediate solution for feature selection with less computational burden 
than wrapper methods but higher computational burden than filter methods, without 
being independent from the classifier [44].  
 Perhaps the most applied embedded method is a SVM using Recursive Feature 
Elimination (SVM-RFE) [60]. SVM-RFE is a weighted-based method that trains a 
SVM with a set of genes and eliminates the genes that are not significant to the solution 
based on a feature ranking criteria. However, as reported by [44] in their study for 
breast and cancer prediction, the SVM-RFE achieves comparable or inferior 
classification accuracy compared to simpler feature selection techniques.  
 A different SVM approach presented in [61], consists of simultaneously 
determining a classifier with good classification performance and an small number of 
features by ‘penalising’ the usefulness of each feature in the elicitation of the model. 
The approach selects the relevant features according to the width of a Gaussian 
function, where a small width represents that a feature is important.  
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2.5 Feature selection methods in high dimensional low sample size 
data  
 Although microarray data can be considered as the most representative and 
complex case of high dimensional data low sample size data (HDLSS), it must not be 
overlooked that in many different areas HDLSS data is present. Several publications 
[24, 43, 44, 51, 58, 62-64] have reviewed feature selection algorithms in different areas, 
for example: image processing, text recognition, financial data, and climate data.  
 As stated in, [24], the analysis of HDLSS has evolved simultaneously for all the 
different areas. All the areas come to an agreement that the limitations of the study must 
be defined: filter feature selection methods are faster but they do not take into account 
the interactions between the features, wrapper methods consider the interactions but the 
computational complexity and the necessary time for the calculations augments 
exponentially, embedded methods suffer from computational high complexity (smaller 
than wrapper methods but still considerable).  
 For microarray gene expression feature selection, the interaction of the features 
is of paramount importance; moreover a low complexity is desirable to work closer with 
clinicians. Nevertheless, it is essential not to fail to recall that feature selection is half of 
the necessary work for making a correct classification. Typically, feature selection is 
done and subsequently a much smaller subset of features is analysed to make the 
classification. In section 2.6: Machine-learning models for microarray cancer 
classification, an overview of the most important methods for cancer classifications is 
presented.  
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2.6 Machine learning models for microarray Cancer Classification 
 
It is stated previously that the classification of microarray gene expression data 
is data dependent; furthermore cancer classification is also dependent on the type of 
cancer. The most common types of cancer analysed are: 
 Breast 
 Prostate 
 Lung 
While breast cancer may report high accuracies (circa 90-95 of accuracy) for the 
prediction of survival using machine learning algorithms, bladder cancer (which is one 
of the least popular and more recursive) report accuracies approximately 65-80% for the 
prediction of survival.  
2.6.1 Computational Intelligence Modelling for Cancer Classification  
 
Computational Intelligence (CI) can be defined as “the study of adaptive 
mechanisms to enable or facilitate intelligent behaviour in complex problems” [65]. CI 
algorithms have proven to be popular in the analysis of microarray data because they 
can detect complex nonlinear associations between the different variables and offer 
substantial benefits in terms of tolerance to imprecision and system interpretability. 
Computational Intelligence includes techniques such as Neural Networks (NN), Fuzzy 
Logic (FL), Neural-Fuzzy Logic, Support Vector Machine and Bayesian Networks. A 
review of a number of CI techniques applied to bioinformatics is presented in [66].  
In, [7, 17, 18], the authors compared different CI approaches for cancer 
classification and state that traditional analytic methods fail to give accurate results in 
microarray data applications because this methods assume biological linearity and use 
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correlation or dependence to find the relationship between a gene and its class. Within 
CI there is an area of study called Soft computing. Soft computing could be seen as a 
number of methods so that real problems could be solved in a similar way as humans 
solve them [67]. This is one of the most important reasons for the use of Soft 
Computing, to apply the human reasoning to solve a problem and a human 
understandable explanation of the model.  
Soft Computing includes techniques such as Neural Networks, Fuzzy Logic, 
Neural-Fuzzy Logic, and Support Vector Machine. 
i. Fuzzy Logic  
 Fuzzy Logic is a linguistic method based on a number of rules that describe the 
system. The transparency of FL and the possibility of easily interpret the results makes 
it an attractive and effective method for the analysis of gene expression data [68-71].  
 An important aspect to take into account at the moment of reducing the number 
of rules is that in fact is important reduce the rules but the most important is to prove 
that the reduction of rules does not affects the accuracy of the model. The goal is to 
have a minimum number of rules with the best accuracy of prediction, not one rule per 
input.  
 That is the same case with the number of genes; there is a discussion between 
the effectiveness of using a large or a small number of genes. As stated previously in 
this chapter, microarray data is composed of thousands of genes so the main purpose is 
to find the best genes that could lead us to make a good prediction.  
 Recent research has shown that a small number of genes are enough for 
accurate prediction of most cancers, nevertheless the number of genes vary between 
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diseases [72]. A large set of gene expression will decrease the classification accuracy 
due to the curse of dimensionality [73]. In this phenomenon, the classification accuracy 
decreases as the dimensionality increases. 
 A list with the advantages of Fuzzy Logic method: 
 Transparency because of the linguistic rules.  
 Easy interpretation of the output because of the Low, Low Medium, Medium, 
Medium High, High states.  
 Rules explaining the model, making easier to clinicians to understand the 
model.  
 Due to the characteristics of microarray data (high dimension and low sample 
size) Fuzzy logic models (as many other methodologies) struggle to make an accurate 
classification [68]. 
ii. Neural Networks  
 
Neural Networks are inspired by how the human brain learns and processes 
information, they have the capability to solve complex tasks [74]. Their concept 
simulates the behaviour of a biological neural network [74]. While in humans, 
learning is done by adjusting the synaptic connections between neurons; in NNs, 
learning is done by adjusting the weights existing between the processing elements of 
the network [74]. 
 Neural networks can obtain a good performance with higher learning speed in 
many applications. However, a high complexity of the network (large number of 
hidden nodes) translates into a slower response of the trained network [75]. 
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 A possible disadvantage of neural networks, especially with microarray data, is 
overtraining. In overtraining, a model can learn a local solution for each example as 
opposed to finding a global solution [76].  
 Neural Networks have been successfully applied to the prediction of cancer 
[77, 78], but some of the informed disadvantages are that the elicited network is hidden 
within a ‘black box’, consequently deeming the gain of any insight into the process 
aspects and into a clinical interpretation [7].   
iii. Neural-Fuzzy  
 
 The characteristics of Fuzzy Logic and Neural Networks have been discussed 
in this Chapter; these two methodologies can be combined to form a hybrid Neural-
Fuzzy (NF) model. Neural-Fuzzy models combine the learning ability of Neural 
Networks and the interpreting ability of Fuzzy systems [72]. The fuzzy logic rules of 
this type of models can be translated into linguistic statements to allow understanding 
and interrogation of the model. 
Neural-Fuzzy systems, are a popular approach for addressing tolerance to 
imprecision and system simplicity (interpretability) and is widely used in literature [79-
82] and more recently also used for the prediction bladder cancer [7, 16-18]. Neural-
Fuzzy systems take advantage of the simplicity and tolerance to imprecision of Fuzzy 
Logic structures and the adaptive learning ability of NN while the inclusion of 
knowledge to the model is still possible. In general, fuzzy set theory [83] has been 
extensively applied to pattern classification and FL system have been proven to perform 
well on uncertain information [84-86]. In terms of their simplicity and interpretability, 
Neural-Fuzzy models allow model knowledge to be represented in the form of just a 
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few simple linguistic rules thus rendering such modelling structures appropriate for 
systems oriented towards human-reasoning (human-centric systems) e.g. clinical 
decision support systems [87-89]. 
iv. Support Vector Machines 
 
 The support vector machine was initially created to solve classification 
problems and has been successfully applied to a number of real world problems.  
Support Vector Machines has exhibited outstanding performance in classification 
tasks. SVM aims at searching for a hyper plane that separates the two classes of data 
with largest margin. SVM is shown to be a good classifier for microarray data [90]. 
Support Vector Machine is a popular method in microarray analysis because it is 
possible to deal with data with a large number of features and a small number of 
samples [91]. One of the drawbacks for this method is the high algorithm complexity 
and the extensive computing requirements of the large-scale quadratic programming 
tasks. A second problem often mentioned is the poor interpretability as compared to 
other methods [92, 93].  
v. Bayesian Networks 
 
 Bayesian  networks (BNs) reflect the random  nature of gene expression and 
use Bayes’ rule [94]. They are also known as probabilistic networks or probabilistic 
graphical models. The hypothesis in BN is that gene expression values can be defined 
by random variables that follow probability distributions [94].   
 Bayesian networks provide a flexible framework for combining expert 
knowledge into the modelling process [95, 96]. An additional advantage of  BNs is that 
they are good with modelling the randomness and noise associated with  microarray 
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data [97]. Bayesian networks deal with probabilities but the ‘causality’ or factors that 
generated the solution are also important for the network [97].  
 Bayesian Networks have also been applied to Cancer Prediction [98-101] in 
particular in the form of a Bayesian Neural Networks (BNN). Bayesian Networks are 
modelling structures for expressing multidimensional joint probability distributions. 
The main challenge in using BNN is the necessity to estimate the topology of a BNN 
from observations, which is not a trivial problem due to the large amount of 
uncertainty and high computational complexity even for moderate sizes of networks 
[98, 102, 103].  
2.6.2 Machine learning models specific to microarray bladder cancer Stage, Grade 
and Survival Classification 
Specifically, in bladder cancer prediction with microarray, Statistical regression 
methods (Logistic Regression, Linear Regression) can estimate the progression rate of a 
population of tumours with limited accuracy (around 70%) [4, 5, 7]. One of the 
difficulties of statistical methods is that they do not take into account the interaction 
between the genes; they are only concerned about linear relations between the input and 
the output.  
Specifically to bladder cancer, there are examples in the literature that 
demonstrate the use of microarray biomarkers (gene signatures) for the prediction of 
Stage, Grade, Survival, Recurrence and Progression [7, 17, 18, 35, 104-112]. Lauss 
[113] and Riester [114] demonstrate the use of a SVM to model and predict bladder 
cancer progression. In [113, 114], the authors identify the most relevant genes for 
bladder cancer (feature selection) and subsequently develop a model to predict the 
Stage, Grade, Progression and Survival. In [113] an average prediction accuracy was 
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reported in the range of 70% to 90%, concluding that signatures with more than 150 
genes are needed to obtain robust performance in validation sets.  
In [114] it is reported that the simplicity of a predictive modelling structure for 
bladder cancer survival can be improved by the use of nomograms [115] combined to 
just 20 genes; however this was achieved at the expense of model accuracy (56% to 
75%). Specifically in predicting bladder cancer progression the publications [7, 17-19] 
report interesting results using a Neural-Fuzzy model that aims to be accurate and 
transparent, and contrary to the study presented in this thesis, the computational 
simplicity is not essential.  
In this Thesis, the use of a Radial Basis Function Neural-Fuzzy (RBF-NF) 
structure is proposed to address the challenges of: model simplicity, model 
generalisation and low computational cost. The proposed approach will consist of an 
embedded method based on a RBF-NF system. The proposed iterative feature selection 
method takes advantage of a Fuzzy-entropy measure to select relevant features during 
the model-training phase, whilst maintaining the system’s simplicity and 
interpretability. The biggest strengths of the proposed approach are that the feature 
selection occurs in the training phase, taking into account the interactions and making it 
recursive. The proposed approach will be applied to identify suitable gene signatures 
and predict bladder cancer survival. 
2.7 Summary 
 In this Chapter, the extensive use of microarray in the prediction and treatment 
of several diseases [9, 105, 107, 113, 114, 116-121] has been discussed. For that reason, 
there is an increasing amount of data sets available in the public domain; the next 
logical step would be to validate the results from those experiments. Making these 
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comparisons may help to obtain more valid and reliable results; however, several 
difficulties might arise due to the differences in technologies, protocols or analysis used 
to create each data set.  
 Several approaches had been made in the past years for analysing microarray 
data.  As described before one of the difficulties that microarray analysis has is the large 
number of genes, the method has to be effective, fast and as transparent as possible. An 
important feature of this type of systems is that they are effective working with noisy 
data. Joined to the trend of low number of genes, researchers are also focused on the 
robustness of the results and for that reason the cross validation of the results has also 
become of paramount importance. K-fold validation, Leave-one-out cross validation 
and Distribution optimally balanced stratified cross-validation are among the most used 
methods to overcome this issue [122].     
As stated in [123],the features in a dataset can be categorised into: 
 Relevant: features that help with the classification 
 Misleading: features that have a negative effect in the classification 
 Irrelevant: features that do not affect (either negatively or positively) the 
classification 
 Redundant: features of a class that has other relevant features. 
 As stated in [123], “the presence of misleading features will reduce the 
classification accuracy and, the presence of irrelevant and redundant features will 
increase the computational burden”.  
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 The use of microarrays for cancer classification still represents a great challenge 
for biologists, clinicians and researchers in general. It must not be forgotten that the 
amount of information coming from these data is massive and there are still some 
difficulties when the information is acquired. The biggest challenges to defeat are: 
1. There is no standard to make comparable the data obtained from various 
experiments.  
2. The quality of the samples needs to be standardised. 
3. Missing values in microarrays 
4. Errors and/or noise made in every step of the analysis. From the biologist to the 
image analysis. 
5. The classes are imbalanced 
To deal with imbalanced classes bootstrap [124] methods have been used in the 
literature. Bootstrap refers to resample from the sample data and create an n number of 
‘phantom samples’.   
What can be improved in bladder cancer classification is to provide sufficient 
information and description of any activity in a model, in other words, transparency and 
simplicity in the model. In the next chapters, a model with main characteristics of 
transparency and simplicity will be introduced; this human-centric approach aims to 
work closer with clinicians in order to identify new combination of genes to predict 
bladder cancer. This transparency and simplicity can be achieved, at a certain degree, 
via a RBF Neural-Fuzzy model. Nevertheless, it must never be overlooked that the data 
modelling performance is at the mercy of the quantity and quality of the measurements 
of the studied data, in this case the microarray data.   
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In the next Chapter, a Radial-Basis-Function Neural-Fuzzy modelling structure 
for the prediction of stage, grade and survival in bladder cancer via microarray data is 
presented. The resulting model maintains its simplicity and transparency in the form of 
a linguistic Fuzzy-Logic rule-base. The proposed methodology is validated using a real 
biomedical case-study, which concerns the signature selection for the identification of 
the stage, grade and survival of bladder cancer. 
34 
 
Chapter 3: Modelling of 
microarray gene signatures 
via Radial Basis Function 
networks 
  This Chapter introduces a Radial-Basis-Function Neural-Fuzzy modelling 
structure for the prediction of stage, grade and survival in bladder cancer via microarray 
data. The resulting model maintains its simplicity and transparency in the form of a 
linguistic Fuzzy-Logic rule-base. The proposed methodology is validated using a real 
biomedical case-study, which concerns the signature selection for the identification of 
the stage, grade and survival of bladder cancer. The signature selection and predictive 
modelling results are compared to previous research work on the same dataset, and it is 
shown that the RBF-NF model outperforms the previous modelling attempts by 
achieving high predictive accuracy (>80% on average) for a similar-sized gene 
signature. Crucially, the model is shown to maintain its good performance even when 
using just 20 genes in the gene based signature. 
3.1 Introduction 
In the previous chapters the advantages and disadvantages of Neural Networks 
and Fuzzy Logic have been discussed. It could rather be said that these systems are 
complementary: Fuzzy logic can deal with inaccurate information on a linguistic level 
while Neural Networks provide learning and optimisation abilities.  
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This Chapter describes a Radial Basis Function Neural-Fuzzy Network; this 
method is a combination of a Radial Basis Function Neural Network and a TSK Fuzzy 
Model [125].      
This combination is possible thanks to their functional equivalence [126]. One 
of the main characteristics of this type of Neural-Fuzzy is that the output is a linear 
combination of the inputs; this output is given as polynomial. For the first time, this 
method is applied to the prediction of bladder cancer stage, grade and survival based on 
microarray data analysis by means of a low number of inputs (20 as a minimum) and 
low number of linguistic statements or rules to describe the model (5 rules as a 
minimum); nevertheless the performance of the model is not sacrificed. As explained in 
previous chapters, microarray data analysis is challenging because of its dimensionality, 
complexity and high noise.  
An essential characteristic, which is the fundament of the method proposed in 
this chapter, is to provide enough information and description of any activity in the 
model. In other words, transparency in the model; and this can be achieved at a certain 
degree via an RBF Neural-Fuzzy model. Nevertheless, it must never be overlooked that 
the data modelling performance is at the mercy of the quantity and quality of the 
measurements of the studied data, in this case the microarray data.   
The proposed methodology is based on a systematic algorithmic procedure that 
aims to pre-process and clean the data, assign initial conditions to the modelling 
structure and finally iteratively optimise the model. The Radial Basis Function Neural-
Fuzzy Network structure addresses the challenges of: a) model simplicity (use of low 
number of features) b) model generalisation ability (performance in ‘unseen-new’ data 
and c) low computational cost. The proposed approach is successfully applied to predict 
bladder cancer survival, stage and grade in three independent data sets.  
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Figure 3.1: Radial Basis Function-Neural-Fuzzy Modelling Structure 
The data mining workflow is divided as follows: Data Pre-processing and gene 
selection with T-Test, Initial Rule-Base Creation via Fuzzy C- Means (FCM), RBF-
Based Neural-Fuzzy System, Optimisation of the predictor, Results and Conclusion. 
The overall approach is presented in Figure 3.1.  
The remainder of this chapter is organised as follows: Section 3.2 Data pre-
processing and initial gene selection, Section 3.3 Initial rule-base elicitation, Section 3.4 
RBF-Neural-Fuzzy Systems, Section 3.5 Levenberg-Marquardt Optimisation Method , 
Section 3.6 Simulation Results, Section 3.7: Summary. 
3.2 Data Pre-processing and Initial Gene Selection 
The case-study presented is focused on the prediction of bladder cancer stage, 
grade and survival using three different bladder data sets: Sanchez-Carbayo [106], Kim 
[107] and Blaveri [110] (Table 3.1) all of which consist of gene expression data and are 
considered some of the most complete literature data on bladder cancer gene expression. 
All the datasets are treated with the same pre-processing procedure. 
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Table 3.1: Bladder cancer – microarray gene intensity data sets 
 
Data Set 
Microarray 
platform 
Number of genes Number of Samples (patients) 
Blaveri CDNA microarray 10368 80 
Sanchez-Carbayo Affymetrix U133A 22283 90 
Kim Illumina human-6v2.0 43148 165 
 
3.2.1 Normalisation and Missing Values 
Prior to any modelling work the data-set is normalised in order to eliminate the 
high variances between the gene’s intensities or the differences in the way that 2 
samples are measured [41]. Normalisation is required to remain certain that the 
differences in two measurements are because different expression values and not 
because of the different conditions when the measurement was taken [127] .  There are 
numerous normalisation techniques (i.e. local normalisation, normalisation by 
regression, normalisation by inferring covariates); circa 2003 quantile normalisation 
gained popularity because it is fast and simple but works equally well than more 
complex procedures [127]. Quantile normalisation is the process of ordering the values 
in ascending order in one array, calculate the average between the probes and substitute 
that intensity with the average and finally change the order to its original [128]. 
However, no normalisation procedure is flawless; one of the possible drawbacks of 
quantile normalisation is that the intensities that are greater are forced to fit to the same 
distribution, decreasing the dissimilarities caused by technical or biological conditions 
[127]. 
Quantile normalisation has become a regular procedure [129, 130] to analyse 
microarrays because it is the default procedure to a very popular software for 
microarray analysis (Bioconductor [131]).  For that reason, the data sets were quantile 
normalised and then transformed to a log2 scale. The log2 scale allows us to adjust the 
difference in the intensities to be similar in all the data sets, perhaps it can be said that it 
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is standard to display the intensities in this scale. The gene expression values were 
subtracted by the mean intensity to obtain gene-centred log2 values. If the data set had 
missing values, they were filled using the median, the values with more than 20% 
missing data were omitted. Missing values are extremely common in this type of data 
because some of the microarray spots have no expression of the gene at that place or 
because of errors in the measurement.  
To perform the data analysis, Survival outcome is encoded according to Table 
3.2.  
Table 3.2: Encoding of the Survival Outcome 
Survival Code 
No Evidence of Disease (NED) -1 
Dead Of Disease (DOD) 1 
The cancer Stage values are ‘encoded’ into -1 and 1 according to Table 3.3. The 
Stage encoding is based on the staging system presented in Chapter 2.  
Table 3.3: Cancer Stage 
Encoded value Phenotype Stage 
 
-1 
 
Non-invasive 
PTA 
PT1 
 
 
 
1 
 
 
Muscle invasive 
PT2 
PT3A 
PT3B 
PT4 
PT4A 
Similar to the encoding applied to the previous model for the prediction of stage; 
three grades are used to rate cancer and are encoded according to Table 3.4.  
Table 3.4: Cancer Grade 
Value  Grade 
-1 Low/moderate 
grade 
Grade 1 
Grade 2 
1 High grade Grade 3 
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3.2.2 Initial Gene Selection with T-Test 
Microarray data set typically have thousands of inputs (genes) and a low number 
of patient’s samples, which added to the previously stated problems, make the 
classification a challenging task. For that reason, it is necessary to perform an input 
selection to delete the irrelevant features that are not related to the performance of a 
classifier. The process of identifying significant features and removing the irrelevant 
ones is called Feature selection.   
The data samples were randomly separated into ‘Training’ and ‘Testing’ 
datasets. The training set is only used to train the model. The testing dataset is only 
used after the model training is finished in order to test the generalisation performance 
of the model (i.e. on ‘unseen’ by the model data), as a form of cross-validation [132].   
Training data. The model trains with this data. They have the best performance 
and represent around 70% of the complete data set.  
Testing data. After the model is trained the training data makes predictions on 
the testing data, represents around 30% of the complete data set. This is the most 
important parameter to review.   
After the pre-processing of the data, the student’s distribution t-test is used as an 
initial feature selection gene based on the p-values.  
This is a common pre-processing step in microarray gene selection [128, 133], 
aiming at removing the irrelevant – ‘easily identifiable’ – to the process genes. The t-
test is a statistical test used to test premises regarding a population. Essentially, a level 
of significance (what the p-value will be compared to) was selected in order to 
determine how likely the hypothesis being tested may occur purely by chance[134]. The 
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disadvantage of using the t-test feature selection method is that it ignores feature 
dependencies and lacks of interaction with the classifier. 
A selection of the genes is made, individually, for the data sets of: Sanchez-
Carbayo, Blaveri and Kim, using the top 20 genes for the prediction of survival and 150 
genes for the prediction offstage and grade, as selected with the t-test. 
3.3 Initial rule-base elicitation via Fuzzy C-Means 
To ‘translate’ the raw datasets into knowledge a Fuzzy C-means algorithm was 
applied for the elicitation of the initial rule-base. The FCM method [135, 136] is 
frequently used in pattern recognition; the main justification for using it at this point is 
because the resulting clusters-rules can be used directly in the form of an RBF model 
thus simplifying the model creation process, as shown in [137, 138]. This rule-base is 
then ‘translated’ into a Radial-Basis-Function Neural-Fuzzy structure, and is finally 
parametrically optimised via the Levenberg-Marquardt function-minimisation 
algorithm. The essence of FCM is the exemplification of the similarity that a point 
shares with each cluster (rule); this exemplification is made with a function 
(membership function). FCM is based on the following objective function: 
 Jm= ∑ ∑ u
C
j=1
N
i=1 ij  
m
‖xi   - cj ‖
2
, 1 ≤ m < ∞        (3.1) 
where m is any real number greater than 1, uij is the membership degree of xi in the 
cluster j, xi is the measured data, cj is the centre of the cluster. The membership uij and 
the cluster centres cj are calculated by: 
𝑢𝑖𝑗 =
1
∑ (
‖𝑥𝑖   − 𝑐𝑗‖
‖𝑥𝑖   − 𝑐𝑘‖
)
2
𝑚−1
𝑐
𝑘=1
  
  ,      𝑐𝑗 =
∑ 𝑢𝑖𝑗
𝑚∗𝑥𝑗𝑁𝑖=1
∑ 𝑢𝑖𝑗
𝑚𝑁
𝑖=1
     (3.2) 
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Each sample will have a membership in every cluster; a higher membership 
would translate into a higher degree of similarity between the sample and the cluster. 
Each derived information granule (data-cluster) depicts a process rule in the Fuzzy 
Logic domain. Figure 3.2 illustrates the ‘information granules’ divided into three steps: 
raw data; 1) each data point is considered into the input space, 2) input space 
granulation via FCM; the initial clusters (information granules) are produced via FCM, 
3) Neuro-Fuzzy Rules; the third sub figure shows the initial values for the membership 
function after the granulation, these values are going to be optimised later.  
 
Figure 3.2: Data clustering towards ‘information granules’ in the Fuzzy Logic domain 
The data to be introduced is composed by all the patients and genes plus the real 
stage, grade and survival outcome. The output from Fuzzy C-Means contains the 
centres of the cluster, sigma and weights of the outputs. In this approach a threshold for 
the sigma (width of the membership function) is applied, this will help to make the rules 
more general, i.e. less specific to the training data, improving the performance in the 
testing data set.   
Another characteristic of Fuzzy C-Means is that the number of clusters (rules) 
needs to be specified. As explained in the introduction, the proposed model would be 
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computationally simple and with the lowest number of inputs. To ensure the low 
computational complexity 5, 10 and clusters (rules) are selected as the initial number of 
clusters.  
An interesting remark is that there is a constraint in the number of genes that can 
be applied to FCM, if more than a thousand (1000) genes are used, the centres of the 
clusters became the same among all the samples and only just vary between genes. This 
means that the clustering thought that the centre was the same for all the samples; it 
gave a centre for every gene. The next step of the process is the Radial Basis Function 
calculation. 
3.4 RBF- Neural-Fuzzy System  
Microarray datasets pose a significant data-mining challenge because of the 
associated high dimensionality, low number of samples, as well as complexity, non-
linearity and high noise (uncertainty). A Neural-Fuzzy system is basically a system that 
represents information in an interpretable approach but also have the learning ability of 
a Neural Network, reducing the disadvantages showed by both methods when they are 
applied by themselves.  An RBF-Neural-Fuzzy system offers a good balance of 
performance and simplicity while being tolerant to some imprecision and being capable 
of accurate model representations even when few samples are available [87, 88]. In 
addition, the Fuzzy Logic rule-base (‘model knowledge’) can be easily interpreted by 
clinicians as this is in the form of simple linguistic sentences (IF-THEN rules).  
The linguistic statements are given in the form: 
IF Gene 1 is 𝑥 intensity and Gene 2 is 𝑦 intensity THEN Output is 𝑍.  
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 The intensities of the Genes are divided in 7 categories according to their value, as in 
Table 3.5: 
Table 3.5: Interpretation of the Normalised Gene Intensity Range 
Gene Intensity Range 
Very Low -1.00 to -0.72 
 
Low 
-0.71 to -0.44 
Low Medium -0.43 to -0.16 
Medium -0.15 to 0.12 
Medium High 0.13 to 0.4 
High 0.5 to 0.68  
Very High 0.69 to 1.00 
If a Fuzzy logic system is considered. The consequent part of the linguistic 
statement (…THEN Output is) can be: 
a) Fuzzy Set ( Mamdani rule-base); output is given as a membership function 
b) Singleton (Mamdani singleton); output is given as a single point 
c) Lineal Function (Takagi-Sugeno-Kang, TSK); output is given as a polynomial 
The main justification to choose TSK type of Neural-Fuzzy is because the output 
of this system is a linear combination of the inputs; this output is given as a polynomial. 
In this fashion, it can be analysed how each individual input behaves in the system, 
allowing the clinicians to interrogate the model. In the Chapter 5 (Chapter 5: A new 
RBF-NF entropy approach for model-based input selection) a model that analyses the 
behaviour of a gene in the model and based on that, identifies if that gene may or may 
not be significant for the classification stage as it is not ‘involved’ in the training of a 
particular linguistic rule in the rule-base is presented. A new feature selection could be 
generated; this new feature selection approach would take into account the interactions 
between the genes.   
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   The method proposed in this Chapter is based on Fuzzy Logic systems having 
the centre of gravity (COG) defuzzification, the product inference rule and a TSK fuzzy 
output space, which can be expressed as follows [139]: 
𝑦 =  ∑ 𝑍𝑖
𝑝
𝑖=1 [
∏ 𝜇𝑖𝑗 (𝑥𝑗)
𝑚
𝑗=1
∑ ∏ 𝜇𝑖𝑗 (𝑥𝑗)
𝑚
𝑗=1
𝑝
𝑖=1
 ]                    (3.3) 
where 𝜇𝑖𝑗 (𝑥𝑗) is the RBF function of 𝑥𝑗 that belongs to the i-th rule: 
𝜇𝑖𝑗 (𝑥𝑗) = 𝑒
−(
(𝑥𝑗− 𝑐𝑖𝑗)
2
𝜎𝑖𝑗
2 )
         (3.4) 
where 𝑐𝑖𝑗 and 𝜎𝑖𝑗 are the centre and the width of each membership function, 
respectively, m the number of inputs and p the number of rules. Equation 3.3 can be re-
written as follows: 
          𝑦 =
∑ 𝑧𝑖
𝑝
𝑖=1 𝑚𝑖 (𝑥)
∑ 𝑚𝑖 (𝑥)
𝑝
𝑖=1
                    (3.5) 
where 𝑚𝑖 (𝑥) = 𝑒
(−‖𝑥−𝑐𝑖‖
2/ 𝜎𝑖
2) is the degree of membership of the current input 
vector x to the i-the fuzzy rule. Finally, using the radial basis function (RBF) definition: 
                                𝑔𝑖(𝑥) =
𝑚𝑖(𝑥)
∑ 𝑚𝑖(𝑥)
𝑝
𝑖=1
                                          (3.6) 
The neural-fuzzy input–output relationship then becomes: 
    𝑦 = ∑ 𝑧𝑖
𝑝
𝑖=1 𝑔𝑖(𝑥)                                                   (3.7) 
𝑧𝑖 = 𝑎1𝑥1 + 𝑎2𝑥2 + 𝑎3𝑥3 + ⋯ 𝑎𝑗𝑥𝑗                 (3.8) 
Figure 3.3 shows the equivalent NN structure of the RBF model, where the 
input, rule-base (hidden layer) and output layers can be identified.  The input layer is 
composed by the number of inputs of the system; the middle layer of the RBF is 
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calculated with the sigmas, output weights and centres of the membership function. 
Only one output is obtained, this process is repeated for 𝑞 (number of samples) times. 
 
Figure 3.3: Radial Basis Function Neural-Fuzzy Structure 
RBF-NF have been used for different applications in microarray analysis, 
including: breast cancer classification [117, 140], cancer classification in colon and 
leukaemia [141], multiple sclerosis [119], and lung cancer [142]. 
Every aspect of the a data-driven modelling approach is important and in the 
analysis process it was discovered how normalisation affects the data, the number of 
inputs a method can work with (complexity dependant). Taking these challenges into 
account, The Levenberg-Marquardt (LM) algorithm was applied for the optimisation 
[143]. The developed model was parametrically optimised via a suitable function 
minimisation algorithm.  In this approach, the Root Mean Square Error (RMSE) 
between the training data and the model predicted data was used as the cost function to 
be minimised. The RMSE is defined as: 
𝑅𝑀𝑆𝐸(∅) = √𝑀𝑆𝐸(∅) = √
∑(∅̂−∅)2
𝑛
                (3.9) 
where ∅̂, is the Real Stage, grade or survival of cancer, ∅ the Predicted value 
and 𝑛  the number of elements.   
Chapter 3: Modelling of microarray gene signatures via Radial Basis Function networks           46 
 
 
 
3.5 Levenberg Marquardt  Optimisation 
The Levenberg-Marquardt [144, 145] algorithm is a standard technique to solve 
non-linear least-squares problems [146], with this optimiser it is possible to go from a 
modelling structure to and optimised predictor. In this approach, the RMSE between the 
training data and the model predicted data is used as the cost function to be minimised. 
The algorithm is a combination of the steepest (gradient) descent and the 
Gauss-Newton method, depending on how far from the solution the method is. The 
assumption is that if the error is increasing, steepest descent should be used, if the error 
is decreasing, the algorithm should gradually shift to Gauss Newton.    
The Levenberg-Marquardt algorithm is described by the following equation: 
𝑤𝑖+1 = 𝑤𝑖 − (𝐻 + 𝑙 𝑑𝑖𝑎𝑔|𝐻|)
−1𝑑                (3.10) 
The equation is a variation of the deepest descent equation, adding the H, 𝑙 
and 𝑑. H is an approximation to the Hessian, which is obtained by averaging outer 
products of the first order derivative (gradient).  The derivative is expressed by 𝑑 and 𝑙 
is the blending factor that determines the mix between steepest descent and the 
quadratic approximation.  
 It is important to emphasise that the optimisation approach is a standard 
technique; the Levenberg-Marquardt algorithm is beyond the scope of this Chapter. In 
this approach, the total variables to optimise for the optimisation are: 
 Centres of inputs  
 Sigma of inputs  
 Output weights (TSK polynomial) 
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The minimum value of sigma is set to 0.3; this approach would allow us to 
exploit the generalisation abilities of a Neural-Fuzzy model. The wider the rules are, 
the more general the model, increasing the performance to the unknown data (testing).    
Overall, the presented data-mining workflow provides an efficient and fast 
method for capturing numerical data-based information and converting it to a linguistic 
knowledge-base with a predictive capability.  
3.6 Simulation Results 
This section is sub-divided into three different parts as follows: 
A. Simulation results for Survival: a model is produced and validated using the 
previously mentioned data sets for the prediction of survival of bladder cancer.  
B. Simulation results for Stage and Grade: the model is validated using a real 
biomedical case-study, which concerns the prediction of the stage and grade of 
bladder cancer. 
C. Comparison to existing literature results: the obtained results for the prediction of 
stage, grade and survival are compared to previously published results.  
D. Fuzzy Logic-type linguistic rule-base: an example of the fuzzy rule-base 
describing the behaviour of the model.  
This section is focused on the prediction of Cancer Survival, stage and grade; the 
main focus is to identify the best possible combination of rules and training iterations 
for their prediction.  
The number of inputs used in this study is equal to the results for comparison of 
the models; Lauss[113] (150 inputs stage and grade) and Riester [114]  (20 inputs 
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survival). In this study, the RBF Neural-fuzzy model is applied to the Sanchez-Carbayo, 
Blaveri and Kim data set to predict Survival rate. At the same time the number of rules 
and iterations to train the model is assessed to identify how the performance is affected. 
 As mentioned earlier, there are several unknown parameters that should be taken 
into account for the prediction of survival; the number of rules for the model, the 
number of iterations for the trained model. The following plan for the prediction of 
Survival rate in the Sanchez-Carbayo, Blaveri and Kim data sets was produced, the 
intention was to be systematic with the computational time required. The methodology 
applied to this study is explained below (Figure 3.4):  
 
Figure 3.4: Modelling structure for the prediction of survival in bladder cancer. 
 
Train the model with; 5, 10 and 25. Train the model with the selected genes: 
 20 (Survival) 
o 10-50 iterations  
o Cross validation (10 models)  
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 The Survival rate was chosen because it is one of the most complex parameters 
to predict, the Training structure (number of rules) obtained from the modelling with 
Survival was later tested with the prediction of Stage and Grade. 
3.6.1 Survival Prediction 
The RBF-NF model was developed using microarray data intensities only for 
patients with Muscle-Invasive Cancer, this is to make a fair comparison with the 
previously published results from Riester [114].  
The classification functions of Specificity, Sensitivity and Accuracy are used as 
measures of performance [147]. The data samples were randomly separated into 
‘training’ (70% of the patients) and ‘testing’ (30 % of the patients) data-sets. The 
training set is only used to train the model, and the testing data-set is only used after the 
model training is finished in order to test the generalisation performance of the model 
(i.e. on ‘unseen’ by the model data), as a form of cross-validation. The model was 
trained with 20 inputs, 5, 10 and 25 rules and cross-validated 10 times. Survival was 
encoded according to Table 3.3. In order to select the best model it is relevant to analyse 
the behaviour of each individual model. From a modelling perception, the best model 
should be a combination of the best performance, lowest computational complexity and 
practical. The first model to analyse is Sanchez-Carbayo. 
a) Sanchez-Carbayo Data Set 
The results shown in Table 3.6 are the median of the 10 models for Accuracy, 
Specificity and Sensitivity respectively, the standard deviation is also shown to have an 
awareness of how large is the deviation between the values. 
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Table 3.6: Sanchez-Carbayo performance for Survival 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
5 
rules 
Performance 
(%) 
98 100 97 82 82 82 
Standard 
Deviation 
1 0 3 7 10 14 
10 
rules 
Performance 
(%) 
99 100 99 80 75 86 
Standard 
Deviation 
7 0 1 5 7 9 
25 
rules 
Performance 
(%) 
99 100 98 84 80 87 
Standard 
Deviation 
1 0 2 5 13 8 
5 rules 
The testing accuracy performance had a variation from 81 to 84% (Table 3.6), 
showing that with a higher number of iterations the performance for testing decreases, 
having the point where the Accuracy, sensitivity and sensibility were more balanced at 
30 iterations. An interesting remark is that because of the low complexity of the number 
of rules and inputs, this model is trained and 10 fold cross validated in less than 60 
minutes.  
10 rules 
The performance of the model when the number of rules was increased did not 
affect the performance; in fact they were similar to the results obtained with 5 rules.  
On the other hand, the complexity of the model did increase the modelling time 
to the double (two hours) but because the number of inputs used (twenty) is not high, it 
is still practical. Compared to the results obtained with five rules (Table 3.6), the results 
with ten rules do not shown an improvement in the performance or the similar balance.  
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25 rules 
 As shown in Table 3.7, with twenty five rules the performance of the model was 
slightly better but less balanced if it is compared to the previous results with less 
number of rules. Nevertheless, the complexity and the increase in training time that the 
increase of rules brought are not reasonable.  
b) Blaveri Data Set 
The Blaveri data set is the smallest in number of samples (patients) making the 
computational complexity even lower, these models was trained and 10 fold cross 
validated in less than 50 minutes. 
Table 3.7: Blaveri performance for Survival 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
5 
rules 
Performance 
(%) 
100 100 100 90 90 90 
Standard 
Deviation 
0 0 0 6 16 5 
10 
rules 
Performance 
(%) 
100 100 100 91 96 90 
Standard 
Deviation 
0 0 0 3 10 2 
25 
rules 
Performance 
(%) 
100 100 100 89 86 90 
Standard 
Deviation 
0 0 0 3 17 2 
 
5 rules 
The results shown in Table 3.7 reflect a similar behaviour that the one shown for 
five rules in the Sanchez-Carbayo data set, at 50 iterations the model is more balanced. 
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10 rules 
Similar to the behaviour with the Sanchez-Carbayo data set, the added 
complexity of the model increases the modelling time to the double but compared to the 
results obtained with five rules (Table 3.7), the results with ten rules do not shown a 
significant improvement in the performance or the balance.    
25 rules 
With twenty five rules the performance of the model was not better if it is 
compared it to the previous results with less number of rules. With the results of 
performance and the increase in complexity and in training time is not reasonable to 
select this model as the top one.  
c) Kim Data Set 
Table 3.8: Kim performance for Survival 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
5 
rules 
Performance 
(%) 
97 95 99 67 64 70 
Standard 
Deviation 
2 4 1 10 23 20 
10 
rules 
Performance 
(%) 
98 98 99 65 57 70 
Standard 
Deviation 
1 2 1 10 14 11 
25 
rules 
Performance 
(%) 
96 93 97 68 63 74 
Standard 
Deviation 
3 6 2 8 2 2 
5 rules 
The results shown in Table 3.8 reflect a dissimilar behaviour that the one shown 
for five rules for the Sanchez-Carbayo and Blaveri data sets. The Kim data set is the 
largest in number of samples (patients) making the computational complexity higher. 
Another important remark is that this data set had more missing values than any other 
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from the previous results shown. An interesting remark is that the standard deviation 
between the ten models is high.   
10 rules 
The performance of the model when the number of rules was increased did not 
affect the performance in a positive manner; in fact they were similar to the results 
obtained with 5 rules. Compared to the results obtained with five rules (Table 3.8), the 
results with ten rules do not shown an improvement in the performance or the balance.  
25 rules 
As shown in Table 3.8, with twenty five rules the performance of the model was 
not better or balanced if it is compared to the previous results with less number of rules.  
The analysis of the results for the prediction of survival reveals that is possible 
to generate a simple model with five rules, reducing the complexity and training time. 
The generation of a model with more than five rules is not justified; the results revealed 
a number of disadvantages from the increase of the number of rules, such as; not 
significant improvement in the performance, increase in the training time, unnecessary 
computational complexity.  The Stage and Grade will be done with five rules and from 
10-50 iterations.  
The computational complexity of the models would be superior since one 
hundred and fifty inputs are going to be used.  
3.6.2 Stage and Grade Prediction 
From the previous results for the prediction of survival, it can be concluded that 
the elicitation of a model using five rules is adequate to obtain comparable or improved 
performances to the ones obtained with a higher number of rules (ten or twenty five). 
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The model will also benefit from the reduced of the number of rules by reducing the 
training iterations, making the model simpler. Applying the same methodology to the 
prediction of stage and grade for Sanchez-Carbayo, Blaveri and Kim tested the 
proposed hypothesis and the results were similar to the obtained with Survival. Stage 
and grade were encoded according to Table 3.3 and 3.4, respectively. The results 
presented in this section correspond to a model with 5 rules and 150 inputs.  
I. Stage 
Table 3.9: Performance for Stage 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
99 99 100 94 97 92 
Standard 
Deviation 
.05 1 0 2 4 3 
Blaveri Performance 
(%) 
100 100 100 60 75 57 
Standard 
Deviation 
0 0 0 8 22 9 
Kim Performance 
(%) 
88 90 81 70 79 56 
Standard 
Deviation 
5 9 12 6 16 19 
a) Sanchez-Carbayo 
For Sanchez-Carbayo, the results showed in Table 3.9 demonstrate that the 
increase in the number of inputs did not decrease the performance or increase the 
iterations for the model to be trained. Similar to the results for survival, the best 
performance was found at 10 iterations. 
b) Blaveri 
Differing to the results found for survival, the results for the prediction of stage 
in the Blaveri data set are less than average. This is an interesting remark; perhaps the 
complexity of the increase in the number of inputs affected the model.  
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Nevertheless, it would be highly unpractical to produce a model with a higher 
number of rules because the computational complexity would increase exponentially. 
With 10 iterations, the best performance for Accuracy, sensitivity and specificity is 
shown in Table 3.9.   
c) Kim 
As explained in the previous section, Kim’s data set is the largest in the number of 
samples. There was no surprises in the performance of the model for the prediction of 
stage, it was similar to the one obtained for the prediction of survival.  The best 
performance is shown in Table 3.9.  
II. Grade 
Table 3.10: Performance for Grade 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
99 98 99 94 97 92 
Standard 
Deviation 
1 2 1 3 4 3 
Blaveri Performance 
(%) 
99 99 100 97 76 98 
Standard 
Deviation 
6 2 0 2 25 1 
Kim Performance 
(%) 
91 93 89 80 83 74 
Standard 
Deviation 
4 4 10 4 7 18 
a) Sanchez-Carbayo 
For Sanchez-Carbayo, the results showed in Table 3.10, demonstrate the 
constant performance for all the prediction models (survival, stage and grade) produced. 
The increase in the number of inputs did not decrease the performance or increase the 
iterations for the model to be trained. Similar to the results for survival and stage, the 
best performance was found at 10 iterations. 
Chapter 3: Modelling of microarray gene signatures via Radial Basis Function networks           56 
 
 
 
b) Blaveri 
 Differing to the results found for stage and similar to the results for the 
prediction of survival stage, the results for the prediction of grade in the Blaveri data set 
are high. With 10 iterations, the best performance for Accuracy, sensitivity and 
specificity is shown in Table 3.10.   
c) Kim 
The results for the prediction of grade in Kim’s data set are the highest produced 
by all the predictor models in this study. The best performance was obtained at 30 
iterations; it is shown in Table 3.10. 
3.6.3 Fuzzy Logic-type linguistic rule-base 
The models presented in this Chapter maintain a transparent Fuzzy Logic-type 
linguistic rule-base. Figure 3.5 shows a sample of the rule-base describing the behaviour 
of the model. For simplicity, just two rules are shown (one for ‘negative outcome’ and 
one for ‘positive outcome’); these are shown for five out of the 20 genes in the gene 
signature.  
Two of the linguistic IF-THEN rules that describe the model are shown below to 
demonstrate the transparency (interpretability) of the modelling method. The 
corresponding numerical values of the linguistic hedges ‘high’, ‘medium’ etc. are 
determined by the optimisation algorithm via the training data-set. The equivalent 
linguistic-numerical interpretation of the normalised gene intensity is shown in Table 
3.5. 
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Figure 3.5: Example of a Radial Basis Function-Neural-Fuzzy rule base, here for simplicity just two 
rules are shown. 
Rule 5 (DOD): 
IF the intensity of  
the Gene ‘Secretoglobin, family 2A, member 1’ is Low Medium  and 
the Gene ‘Deoxyribonuclease I’ is Medium and 
the Gene ‘KLRC4-KLRK1 readthrough/// killer cell lectin-like receptor subfamily K, 
member 1’ is Medium and 
the Gene ‘Cannabinoid receptor 1 (brain)’ is Medium and 
the Gene ‘Intercellular adhesion molecule I’ is Medium High 
THEN the Patient will decease as results of the disease   
3.6.4 Comparative Study 
a) Survival Outcome 
Table 3.11 shows the performance of the RBF Neural-Fuzzy model compared to 
previous results published by Riester [114]. The Riester study makes use of three 
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independent datasets (Sanchez-Carbayo [106], Blaveri [110] and Kim [107]) to develop  
a hybrid model using both SVM and a clinical nomogram [115] to assist with the 
predictions based on 20 inputs. The RBF-NF model exhibits a better balanced 
performance (Area under the Curve of the Receiver operating characteristic curve) in 
two of the three cohorts (other performance indicators were not published).  It is 
important to note that the RBF-NF model achieves a superior or performance in the 
Sanchez-Carbayo and Blaveri case.  
The simplicity of the RBF-NF modelling structure could be crucial for developing 
easy to use clinical advisory tools. For example, the NF-based structure allows the 
direct interpretation of the system’s rule base to natural language (via Fuzzy Logic 
linguistic statements – see Figure 3.5), which can aid the development of human-centric 
systems for use in healthcare. 
Table 3.11:Performance of Survival using microarray data. For comparison purposed the results in 
this example are shown as the area under the curve (AUC) of a ROC plot 
  Survival 
 Riester [114] 
(SVM + Nomogram 
20 genes) 
 
RBF Neural-Fuzzy 
20 Inputs 
Sanchez-Carbayo 
 
0.74 0.82 
Blaveri 
 
0.76 0.90 
Kim 0.75 0.67 
 
b) Stage and Grade Outcome 
Tables 3.12 and 3.13 show the performance obtained from prediction of Stage 
and Grade. The presented model obtained better or comparable performances to 
previously published results [113] with a SVM approach using 150 genes. Table 3.12 
shows a comparison between a SVM model with 150 inputs and the RBF model with 
150 inputs. The RBF model performed better for the Sanchez-Carbayo data set but for 
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Blaveri Lauss had a better performance. No results for Kim were found to make a 
comparison.  
Table 3.12: Comparison of results from the prediction of Stage to existing publications in the 
literature 
Stage (Accuracy) 
 Lauss (SVM-150 genes) [113] RBF Neural-Fuzzy (150 genes) 
Sanchez-Carbayo 
 
87 % 94 % 
Blaveri 85 % 60 % 
Kim - 70 % 
 
Table 3.13 shows a comparison between the same Lauss SVM model with 150 
genes and the RBF Neural-Fuzzy model with 150 genes. The RBF model performed 
better for the Blaveri data set and or Sanchez-Carbayo. No results for Kim were found 
to make a comparison.  
Table 3.13: Comparison of results from the prediction of Grade to existing publications in the 
literature (Accuracy) 
Grade 
 Lauss (SVM-150 genes) [113] RBF Neural-Fuzzy (150 genes) 
Sanchez-Carbayo 
 
80 % 94 % 
Blaveri 86 % 97 % 
Kim - 80 % 
 
3.7 Summary  
The study of Cancer is of great significance due to several factors; including the 
increasing mortality rate, to help avoid unnecessary treatment and from a 
Bioinformatics perspective to help clinicians to understand these studies. There are 
several methods used in present days that do not take in account the subtle relation 
between the genes and the complexity of Gene Expression data, for that reason it is 
relevant to investigate this subject. The main problem that these types of studies run 
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across is the high dimensionality, translated in thousands of genes but a small number 
of samples.  
As there are no equations that represent the behaviour of the genes, a predictor 
model must be produced. With high dimensionality also comes noise in the intensities, 
a large presence of irrelevant and redundant genes.  The goal of these studies is to 
produce a model capable of making a prediction based on the existing data that is 
efficient, could be understood by clinicians (transparent) and with the lowest 
computational cost. Joined to the above description there is another quality that the 
predictor must give, the selected genes must be relevant from a clinical point of view. 
For that reason medical and engineering expertise must work together, to validate the 
performance of the study.   
The proposed RBF-NF methodology has successfully been applied to the case 
study of bladder cancer prediction with respect to the patient’s stage, grade and 
survival.  A list with the advantages of this method: 
 Transparency because of the linguistic rules.  
 Easy interpretation of the output because of the Very Low, Low, Low Medium, 
Medium, Medium High, High, Very High states.  
 Minimum number of rules explaining the model, making easier to clinicians to 
comprehend the model.  
 Universal approximation ability (RBF) 
 Low computational cost 
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Compared to previous modelling attempts from Martin Lauss [113] and Riester 
[114] based on SVM, the RBF-NF method shows improved performance in the same 
datasets. However, the attractiveness of this method is on the transparency that the 
rule-base exhibits and the good generalisation performance (even with just 20 genes 
and 5 rules) as compared to previous modelling attempts on the same dataset. The rule-
base’s transparency and interpretability, can aid the clinicians to directly interrogate 
the resulting model (human-centric system) and examine how the model uses 
individual genes and their intensity to provide predictions on the stage, grade and 
survival of bladder cancer.  
Chapter’s summary of achievements: 
 Development of a Radial-Basis-Function Neural-Fuzzy Linguistic 
Modelling algorithm (from data clustering to optimisation) 
 An RBF-NF model was applied for the accurate prediction of stage, grade 
and survival of bladder cancer.  
 The predictive modelling results show that the RBF-NF model outperforms 
the previous modelling attempts by achieving high predictive accuracy 
(>80%).  
 The model is shown to maintain its good performance even when using just 
20 genes in the gene based signature. 
The achievements summarised above are linked to one conference publication 
(Biostec 2013), and The University of Sheffield Engineering Symposium - USES 2013, 
Sheffield, UK (2013). 
On the next chapter, the scaling-up performance of Radial Basis Function Neural-
Fuzzy models is investigated. The aim is to find the rational limit for the maximum 
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number of useful inputs (genes) to use in the model while still maintaining low 
computational complexity and high accuracy. Nevertheless, it must not be overlooked 
that are several challenges to defeat:  
 the computational complexity of this models will increase exponentially and 
the ideal number of inputs to make the prediction must be found 
 Fuzzy C-means clustering which is known for having problems with a high 
number of inputs.  
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Chapter 4: Scaling-up of 
RBF models in bladder 
cancer prediction 
 In this chapter, the scaling-up performance of Radial Basis Function Neural-
Fuzzy models is investigated. The work presented is based on the challenge of 
analysing microarray data for the prediction of the patients’ cancer survival. The aim is 
to find: 1) the limit for the maximum number of inputs to use in the model while 
maintaining low computational complexity and high accuracy. Based on the simulation 
results presented in this Chapter, the combination of Fuzzy C-means and RBF-Neural-
Fuzzy models presents the challenge of scaling-up when more than a thousand inputs 
are used. To overcome this challenge a Weighted Fuzzy C-means algorithm is 
introduced. 2) A second contribution is a cluster optimisation algorithm based on the 
Xie-Beni cluster validity index to improve the quality of the clusters calculated by the 
WFCM.  
4.1 Introduction 
 The analysis of high dimension-low sample size data represents a systems 
engineering classification and identification challenge. This is due to the noisy 
characteristics of high dimensional data and the fact that the number of replications for 
the experiment is very low (not enough samples for the model’s training algorithm to 
use).  The study presented in this chapter is based on the healthcare informatics 
challenge of analysing large-scale microarray cancer data (high dimension-low sample 
size data) for the prediction of the patient’s cancer survival outcome.  
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 To tackle the challenge of high number of features, feature selection algorithms 
have become indispensable components of the data mining process [15]. As mentioned 
in Chapter 2, there are three categories for feature selection: filters, wrappers and 
embedded methods. Generally, filter feature selection methods are used in combination 
with wrapper methods to diminish the computational cost of examining the complete 
data set. The question raised is if the combination of filter and wrapper methods offers 
significant advantages in terms of tolerance to imprecision and accuracy in the 
prediction, compared to using only a wrapper method and a higher number of inputs. 
The combination of filter-wrapper methods have proven to be an effective method for 
classification [148] . 
 A number of challenges associated with the theme of this chapter can be 
addressed; it is important to know if it is possible to avoid the use of feature selection 
techniques. Specifically, avoid the use of univariate filter-based feature selection 
techniques that do not assess if there is interdependency in the data, but only assess one-
to-one variable dependence. Existing studies suggest that best classification results are 
obtained by selecting 100-500 genes in a Support Vector Machine model [149, 150]. 
However, is this limitation a result of the modelling characteristics of SVM models or 
would a different method provide a better outcome?    
 In this chapter, an assessment is performed of the scalability of Radial Basis 
Function Neural-fuzzy models with high dimensionality and low number of samples. 
An RBF-Neural-Fuzzy system was chosen because it offers a good balance of 
performance and simplicity while being tolerant to some imprecision and crucially 
being capable of accurate model representations even when few samples are available 
[87]. The aim is to assess if it is possible to avoid the use of filter-based feature 
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selection methods; and conclude if the proposed modelling approach scales-up (i.e. 
performs well when the number of genes is increased).  
 As stated in [151]: “One should not rely on clustering results alone for high 
dimensional data and one should do feature selection”. Clustering is a form of data 
analysis where the data is divided into groups or subsets where the objects present in 
that subset share some similarities.  
 Clustering can be divided into two types: hard clustering and fuzzy clustering. 
Hard clustering refers to an inflexible boundary for the partitions compared to the 
vagueness showed in fuzzy clustering where a data point may belong to different classes 
with different membership values [152]. Numerous methodologies have been applied to 
the problem of clustering HDLSS data, for example: based on p values [153], k-means 
clustering [154]. In [153] the authors propose a hard clustering algorithm based on p-
values as a measure of similarity where no optimisation is necessary. Nevertheless, it is 
believed that fuzzy clustering is a more appropriate method to find clusters due to its 
robustness to noise, which is evident in microarray data [120].  
 In this chapter, the change in the variation of the predictive accuracy of the 
models, when the number of inputs is increased or reduced, is evaluated using a model 
for the prediction of survival in bladder cancer [106]. As a pre-input selection the t-test 
statistical method was used to systematically reduce the large initial dataset. This is a 
widely applied pre-processing step in microarray gene selection, aiming at eliminating 
the ‘easy to identify’ and obviously irrelevant to the process genes.  
 The method used in the proposed approach, is based on Fuzzy Logic and a 
Radial-Basis-Function Neural-Fuzzy computational structure. An hybrid Neural-Fuzzy 
model was chosen for the reason that they have the learning ability of Neural Networks 
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and the interpretability of Fuzzy Systems. Three different approaches are used in this 
study to assess the effectiveness of modelling HDLSS data:  
a) Fuzzy C-Means and RBF-NF modelling structure;  
b) Weighted Fuzzy C-Means  and an RBF-NF modelling structure 
c) Weighted Fuzzy C-Means and an RBF-NF modelling structure with the help 
of a cluster validation index.  
 All the proposed approaches use the Levenberg-Marquardt [144] algorithm for 
the model’s parametric optimisation.  
 The remainder of this chapter is organised as follows: Section 4.2 Methodology: 
A description of the data-mining and modelling methodology is presented. Section 4.3 
Scaling-up performance of RBF-NF models: Results are shown for the three different 
modelling approaches applied to the prediction of survival in a bladder cancer, Section 
4.4 Analysis of predictive performance and Section 4.5: Summary. 
4.2 Methodology 
 The methodology is organised in three, incremental, parts, whereby a FCM-
based RBF-NF modelling approach is presented, then enhanced with measures of 
weighted-clustering followed by a cluster validity approach. 
4.2.1 FCM and RBF-NF function model  
 The data-mining workflow consists of an initial data pre-processing step, where 
data normalisation is performed followed by a student’s distribution t-test to eliminate 
easy to identify irrelevant to the process genes. The following step consists of applying 
Fuzzy C-means clustering for the creation of the initial rule-base. This rule-base is then 
‘translated’ into a Radial-Basis-Function Neural-Fuzzy structure (one multi-dimensional 
cluster corresponds to one Fuzzy Logic rule), and the modelling structure is finally 
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parametrically optimised via the Levenberg-Marquardt function-minimisation algorithm 
[144].  
In the same way as in the preceding chapters, the data to be analysed is 
composed of all the patients and genes plus the survival outcome. Another characteristic 
of the weighted Fuzzy C-Means is that the number of clusters (rules) needs to be 
specified, to ensure the low computational complexity; the number of clusters is fixed to 
5 (rules). Based on previous research work presented in Chapter 3, five rules in this case 
study offers a good balance of performance and model simplicity. 
4.2.2 WFCM and RBF-NF function model  
FCM algorithms consider each object equally important in the cluster solution. 
For that reason, when FCM is applied to a high number of inputs (more than a 
thousand), the rule-base loses clarity due to the high dimensional space and the values 
of the membership degree become truly small. The challenge that arises is that the FCM 
clusters are the initial conditions for the RBF Neural-Fuzzy and because of their poor 
quality, the optimisation algorithm fails. By applying Weighted FCM the relative 
importance of each object to the clustering solution is defined.  This weighted factor is 
applied to the output of the data to improve the membership degree of each cluster. This 
modification improves the quality of the initial Membership functions of the RBF 
Neural-Fuzzy model. The second contribution presented in this Chapter (Figure 4.1) 
consists of applying a Weighted Fuzzy C-means clustering algorithm for the creation of 
the initial rule-base and applying the rule-base directly to the RBF Neural-Fuzzy model. 
The rule-base is then ‘translated’ into a Radial-Basis-Function Neural-Fuzzy structure, 
and is parametrically optimised via the Levenberg-Marquardt function minimisation 
algorithm [144].  
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The weighted FCM (WFCM) is based on the minimisation of the following 
objective function: 
 𝐽𝑚= ∑ ∑ 𝑢
𝐶
𝑗=1
𝑁
𝑖=1 𝑖𝑗  
𝑚
𝑤𝑖   ‖𝑥𝑖   −  𝑐𝑗  ‖
2
, 1 ≤ 𝑚 < ∞   (4.1) 
where m is any real number greater than 1, uij is the membership degree of xi in 
the cluster j, xi is the measured data, cj is the centre of the cluster, and 𝑤𝑖 is a weighted 
factor applied to the output of the data and is equal to the number of inputs.  
The membership uij and the cluster centres cj are calculated by: 
𝑢𝑖𝑗 =
1
∑ (
‖𝑥𝑖   −  𝑐𝑗‖
‖𝑥𝑖   −  𝑐𝑘‖
)
2
𝑚−1
𝑐
𝑘=1
  
  ,  
𝑐𝑗 =
∑ 𝑤𝑖 𝑢𝑖𝑗
𝑚 ∗ 𝑥𝑗𝑁𝑖=1
∑ 𝑤𝑖 𝑢𝑖𝑗
𝑚𝑁
𝑖=1
 
(4.2) 
 
Figure 4.1: Data-mining workflow for the WFCM and RBF-NF model 
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Each sample will have a membership assigned (uij) in every cluster; a higher 
membership would translate into a higher degree of similarity between the sample and 
the cluster. Each derived information granule (data-cluster) depicts a process rule in the 
Fuzzy Logic domain. The weighted FCM is similar to the one proposed in [155, 156], 
however, the novelty of the present work is that the weighting factor changes in relation 
to the number of genes that are used by the model.  
4.2.3 WFCM, validation index and RBF-NF function model  
In this section, a cluster-validity index is introduced to the data-mining process 
to further improve the quality of the rule-base. Figure 4.2 depicts the validity index 
data-mining workflow. There are multiple indices for validation of the fuzzy clusters; 
partition coefficient [157], partition entropy[158] , Fukuyama and Sugeno [159], Xie-
Beni[160] . Most of the validation indices aim to find the optimal number of clusters, 
but in this Chapter a modification of the Xie-Beni index is used, as presented in [155], 
to improve the quality of the clusters calculated by the WFCM. A reliable validation 
index should take into consideration the compactness or how close each point of the 
cluster is and the separation of the FCM clusters, which is the case in the Xie-Beni 
index;  
𝐼𝑑 =
∑ ∑ 𝑤𝑘(𝑢𝑘𝑗)
𝑚 ‖𝑥𝑘 − 𝑐𝑗‖
2𝑐
𝑗=1
𝑁
𝑘=1
𝑛 𝑚𝑖𝑛𝑗≠𝑖 {‖𝑐𝑗 − 𝑐𝑖‖
2
}
 
(4.3) 
The measure of Compactness (𝐶𝑡) is given by: 
𝐶𝑡 =
∑ ∑ 𝑤𝑘(𝑢𝑘𝑗)
𝑚 ‖𝑥𝑘 − 𝑐𝑗‖
2𝑐
𝑗=1
𝑁
𝑘=1
𝑛 
 
(4.4) 
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The measure of separation is given by: 
𝑆𝑒𝑝𝑎𝑟𝑎𝑡𝑖𝑜𝑛 = 𝑚𝑖𝑛𝑗≠𝑖 {‖𝑐𝑗 − 𝑐𝑖‖
2
} (4.5) 
where 𝐶 is the number of clusters, 𝑢𝑘𝑗 is the membership degree, 𝑤𝑘 is the 
weight of significance assigned to 𝑥𝑘, which is the complete data, and 𝑐𝑖 are the centres 
of the clusters. The optimal partition clusters would have to be as compact as possible, 
while they maintain a good balance between separation and coverage of the input space 
[152]; these characteristics would translate into a high quality rule-base.  
 
Figure 4.2: Flow chart of the processing of the data with weighted FCM and the validation index 
4.3 Scaling-up performance of RBF-NF models 
 In this section the healthcare-based case study is first introduced, and then the 
scaling-up simulation results of the modelling methodology are presented.  
The introduction of microarray-based technologies for analysing patient tissues 
has produced a significant challenge for healthcare clinicians as well as data analysis; 
the challenge of understanding and using efficiently thousands of gene-based data and 
linking them to clinically useful information. The case study presented in this chapter is 
focused on bladder cancer microarray data, specifically the ones presented in the 
Sanchez-Carbayo study [106].  
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For modelling purposes the survival outcome of the patients was numerically 
encoded as ‘-1’ for ‘No Evidence of Disease – NED’ and ‘1’ for ‘Dead of Disease - 
DOD’. 
The data samples were randomly separated into ‘training’ (70% of the patients) 
and ‘testing’ (30% of the patients) datasets. The training set is only used to train the 
model, and the testing dataset is only used after the model training is finished to test the 
generalisation performance of the model, as a form of cross-validation [147].  
In modelling such a dataset, gradually increasing the number of inputs (genes 
used in the model) also would increase the computational requirements of the process – 
this may or may not be an issue depending on the application. However, does a larger 
more complex model (in terms of number of inputs and structure) correspond to an 
enhanced performance? In the following section (scaling-up performance of RBF-NF 
models) a comparison between models of 25 to 5000 genes is presented. During this 
comparison, a number of computational and model performance-related challenges were 
identified, and it is shown how with the introduction of the proposed data mining and 
modelling framework helps resolve such challenges. The training time of each model 
depends on the number of samples and inputs. On average, using a standard PC with an 
Intel ® Core ™ i7 CPU 870 @ 2.93 GHz processor with 8 GB of RAM, it takes 
minutes to process (train, test) 25 inputs. The computational requirements increase 
dramatically, as the number of genes is also increased, to more than 24 hours for 1000 
genes. For the models that use 2000 to 5000 genes it was necessary to make use of a 
High Performance Computing (HPC) server with multiple computing cores [161]. 
 The RBF-NF model was developed as described in section II. The methodology 
was applied to the data set of Sanchez-Carbayo [106] for the prediction of survival in 
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bladder cancer. The research question raised at the beginning of this Chapter is if the 
combination of filter and wrapper methods offers significant advantages in terms of 
tolerance to imprecision and accuracy in the predictions, compared to using only a 
wrapper method and a higher number of inputs. 
 The results shown in this section confirm if it is possible to avoid the use of 
feature selection techniques. In the case that this premise is true, the rational limit for 
the maximum number of inputs to use in the model needs to be established. In terms of 
the modelling structure, five (5) fuzzy rules are maintained throughout the modelling 
study for comparison purposes. Based on previous research work presented in Chapter 
3, five rules in this case study offers a good balance of performance and model 
simplicity. 
Results with 25 inputs and 5 rules 
 The methodology was applied to the data set of Sanchez-Carbayo to predict the 
patient’s survival of bladder cancer. The results shown in Table 4.1 are the AUC of the 
models.  
Table 4.1: Performance of the model using 25 inputs and 5 rules 
Genes FCM WFCM WFCM and 
validation 
index 
 AUC AUC AUC 
 Train Test Train Test Train Test 
25 0.96 0.80 0.98 0.63 0.98 0.55 
 The highest performance is obtained with the FCM model. Also, if these results 
are compared, both models performed better using FCM. The model with the validation 
for the initial clusters shows an inferior performance compared to the model that did not 
used the validation index.  
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The Gene Signature obtained for the prediction of Survival is shown in Table 
4.2. Table 4.2 shows the 25 top ranked genes. For example: Gene RNF1RNF113A is 
associated to prostate cancer; HLA-A is associated to melanoma; WDR18 is associated 
with breast cancer; AP3D1 is associated to prostate cancer; ID2 is associated to 
tumours, cancer and colon carcinoma; PTENP1 is associated to lung cancer; TES is 
associated to prostate, gastric and ovarian cancer; MCRS1 is associated to breast cancer; 
GRM8 is associated to prostate cancer; NACC2 is associated to gastric cancer; 
DNAJC12 is associated to breast cancer; TBCC is related to breast cancer.  
Table 4.2:  Gene Signature for Bladder Cancer Survival in Sanchez-Carbayo Data Set 
Rank Gene 
Symbol 
Gene Title 
1  stage 
2 CNR1 cannabinoid receptor 1 (brain) 
3 RNF113A ring finger protein 113A 
4 ZHX3 zinc finger homeobox 3 
5 HLA-A major histocompatibility complex, class I, A 
6 WDR18 WD repeat domain 18 
7 TPST1 tyrosylprotein sulfotransferase 1 
8 KLF7 Kruppel-like factor 7 (ubiquitous) 
9  grade 
10 PRX periaxin 
11 AP3D1 adaptor-related protein complex 3, delta 1 subunit 
12 ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
13 C2orf55 Chromosome 2 open reading frame 55 
14 PTENP1 phosphatase and tensin homolog pseudogene 1 
15 TES testis derived transcript (3 LIM domains) 
16 MCRS1 microspherule protein 1 
17 NR1H3 nuclear receptor subfamily 1, group H, member 3 
18 GRM8 glutamate receptor, metabotropic 8 
19 FTO fat mass and obesity associated 
20 SLAMF8 SLAM family member 8 
21 NACC2 NACC family member 2, BEN and BTB (POZ) domain containing 
22 DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 
23 TBCC tubulin folding cofactor C 
24 KLHL4 kelch-like 4 (Drosophila) 
25 TMEM132A transmembrane protein 132A 
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Results with 50 inputs and 5 rules 
 The results shown in Table 4.3 are the AUC of the models. Once more, the 
model using FCM was the highest between the three models. The FCM model shows a 
slight increase in the performance. The model with the WFCM and validation for the 
initial clusters shows a better performance compared to the WFCM model that did not 
used the validation index. It also shows a notable improvement compared to the results 
obtained using 25 inputs. 
Table 4.3: Performance of the model using 50 inputs and 5 rules 
Genes FCM WFCM WFCM and 
validation 
index 
 AUC AUC AUC 
 Train Test Train Test Train Test 
50 0.92 0.83 0.98 0.81 0.96 0.82 
The Gene Signature obtained for the prediction of Survival is shown in Table 
4.4. Table 4.4 shows the 50 top ranked genes. For example: Gene C18orf8 is associated 
with prostate and colon cancer; GLI1 is associated with pancreatic cancer; SVIL is 
associated with prostate cancer; SIK1 is associated with breast and colon cancer; 
NUCB2 is associated with gastric cancer; PRSS3 is associated with lung and pancreatic 
cancer; AACS is associated with tracheal cancer; COL16A1 is associated with oral 
cancer; CEACAM5 is associated with colon cancer. 
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Table 4.4:  Gene Signature for Bladder Cancer Survival in Sanchez-Carbayo Data Set 
Rank Gene 
Symbol 
Gene Title 
1  stage 
2 CNR1 cannabinoid receptor 1 (brain) 
3 RNF113A ring finger protein 113A 
4 ZHX3 zinc finger homeobox 3 
5 HLA-A major histocompatibility complex, class I, A 
6 WDR18 WD repeat domain 18 
7 TPST1 tyrosylprotein sulfotransferase 1 
8 KLF7 Kruppel-like factor 7 (ubiquitous) 
9  grade 
10 PRX periaxin 
11 AP3D1 adaptor-related protein complex 3, delta 1 subunit 
12 ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
13 C2orf55 Chromosome 2 open reading frame 55 
14 PTENP1 phosphatase and tensin homolog pseudogene 1 
15 TES testis derived transcript (3 LIM domains) 
16 MCRS1 microspherule protein 1 
17 NR1H3 nuclear receptor subfamily 1, group H, member 3 
18 GRM8 glutamate receptor, metabotropic 8 
19 FTO fat mass and obesity associated 
20 SLAMF8 SLAM family member 8 
21 NACC2 NACC family member 2, BEN and BTB (POZ) domain containing 
22 DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 
23 TBCC tubulin folding cofactor C 
24 KLHL4 kelch-like 4 (Drosophila) 
25 TMEM132A transmembrane protein 132A 
26 DUSP2 dual specificity phosphatase 2 
27 NUP107 nucleoporin 107kDa 
28 CDK14 cyclin-dependent kinase 14 
29 MEIS3P1 Meis homeobox 3 pseudogene 1 
30 GJA1 gap junction protein, alpha 1, 43kDa 
31 LHPP phospholysine phosphohistidine inorganic pyrophosphate phosphatase 
32 FAM208B family with sequence similarity 208, member B 
33 FGF14 fibroblast growth factor 14 
34 IBTK inhibitor of Bruton agammaglobulinemia tyrosine kinase 
35 C18orf8 chromosome 18 open reading frame 8 
36 GLI1 GLI family zinc finger 1 
37 CPLX3 complexin 3 
38 NECAB3 N-terminal EF-hand calcium binding protein 3 
39 NUP210 nucleoporin 210kDa 
40 FAM192A family with sequence similarity 192, member A 
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41  receptor (TNFRSF)-interacting serine-threonine kinase 1 
42 KIAA1462 KIAA1462 
43 SVIL supervillin 
44 SIK1 salt-inducible kinase 1 
45 NUCB2 nucleobindin 2 
46 PRSS3 protease, serine, 3 
47 AACS acetoacetyl-CoA synthetase 
48 COL16A1 collagen, type XVI, alpha 1 
49 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 
50 COQ7 coenzyme Q7 homolog, ubiquinone (yeast) 
 
Results with 100 inputs and 5 rules 
 The FCM has the highest performance compared to the other two WFCM 
models. The difference in performance between the two models using WFCM is 
however not significant.  
Table 4.5:Performance of the model using 100 inputs and 5 rules 
Genes FCM WFCM WFCM and 
validation 
index 
 AUC AUC AUC 
 Train Test Train Test Train Test 
100 0.98 0.86 0.96 0.80 0.94 0.79 
 
The Gene Signature obtained for the prediction of Survival is shown in Table 
4.6. Table 4.6 shows the 100 top ranked genes. For example: Gene NFX1 is associated 
with gastric cancer; B3GAT1 is associated with carcinoma; SECISBP2L is associated 
with lung cancer; GMPS is associated with oral cancer; ST3GAL5 is associated with 
ovarian cancer; ADRBK2 is associated with colorectal cancer; PEMT is associated with 
gastric and breast cancer; TMSB10 is associated with breast and ovarian cancer; TAF12 
is associated with colorectal cancer; APEH is associated with lung cancer; CLDN1 is 
associated with breast cancer; FOXN2 is associated with colon cancer; RNF5 is 
associated with breast cancer; MBOAT7 is associated with bladder carcinoma; TYK2 is 
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associated with prostate carcinoma; SYDE1 is associated with pancreatic cancer; UBA7 
is associated with lung cancer; RPS26 is associated with breast and prostate cancer; 
LDOC1 is associated with pancreatic cancer; KARS  is associated with gastric cancer. 
Table 4.6:  Gene Signature for Bladder Cancer Survival in Sanchez-Carbayo Data Set 
Rank Gene 
Symbol 
Gene Title 
1  stage 
2 CNR1 cannabinoid receptor 1 (brain) 
3 RNF113A ring finger protein 113A 
4 ZHX3 zinc finger homeobox 3 
5 HLA-A major histocompatibility complex, class I, A 
6 WDR18 WD repeat domain 18 
7 TPST1 tyrosylprotein sulfotransferase 1 
8 KLF7 Kruppel-like factor 7 (ubiquitous) 
9  grade 
10 PRX periaxin 
11 AP3D1 adaptor-related protein complex 3, delta 1 subunit 
12 ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
13 C2orf55 Chromosome 2 open reading frame 55 
14 PTENP1 phosphatase and tensin homolog pseudogene 1 
15 TES testis derived transcript (3 LIM domains) 
16 MCRS1 microspherule protein 1 
17 NR1H3 nuclear receptor subfamily 1, group H, member 3 
18 GRM8 glutamate receptor, metabotropic 8 
19 FTO fat mass and obesity associated 
20 SLAMF8 SLAM family member 8 
21 NACC2 NACC family member 2, BEN and BTB (POZ) domain containing 
22 DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 
23 TBCC tubulin folding cofactor C 
24 KLHL4 kelch-like 4 (Drosophila) 
25 TMEM132A transmembrane protein 132A 
26 DUSP2 dual specificity phosphatase 2 
27 NUP107 nucleoporin 107kDa 
28 CDK14 cyclin-dependent kinase 14 
29 MEIS3P1 Meis homeobox 3 pseudogene 1 
30 GJA1 gap junction protein, alpha 1, 43kDa 
31 LHPP phospholysine phosphohistidine inorganic pyrophosphate phosphatase 
32 FAM208B family with sequence similarity 208, member B 
33 FGF14 fibroblast growth factor 14 
34 IBTK inhibitor of Bruton agammaglobulinemia tyrosine kinase 
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35 C18orf8 chromosome 18 open reading frame 8 
36 GLI1 GLI family zinc finger 1 
37 CPLX3 complexin 3 
38 NECAB3 N-terminal EF-hand calcium binding protein 3 
39 NUP210 nucleoporin 210kDa 
40 FAM192A family with sequence similarity 192, member A 
41  receptor (TNFRSF)-interacting serine-threonine kinase 1 
42 KIAA1462 KIAA1462 
43 SVIL supervillin 
44 SIK1 salt-inducible kinase 1 
45 NUCB2 nucleobindin 2 
46 PRSS3 protease, serine, 3 
47 AACS acetoacetyl-CoA synthetase 
48 COL16A1 collagen, type XVI, alpha 1 
49 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 
50 COQ7 coenzyme Q7 homolog, ubiquinone (yeast) 
51 PRAMEF10 PRAME family member 10 
52 DET1 de-etiolated homolog 1 (Arabidopsis) 
53 NXF1 nuclear RNA export factor 1 
54 B3GAT1 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) 
55 SECISBP2L SECIS binding protein 2 
56 ACTB actin, beta /// uncharacterized LOC100505829 
57 ASPHD1 aspartate beta-hydroxylase domain containing 1 
58 GMPS guanine monphosphate synthetase 
59 RGS9 regulator of G-protein signaling 9 
60 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 
61 ADRBK2 adrenergic, beta, receptor kinase 2 
62 PEMT phosphatidylethanolamine N-methyltransferase 
63 GPER1 G protein-coupled receptor 1 
64 FOCAD focadhesin 
65 TMSB10 thymosin beta 10 
66 TAF12 TAF12 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, 20kDa 
67 NAGPA N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase 
68 MS4A1 membrane-spanning 4-domains, subfamily A, member 1 
69 ERVH-6 endogenous retrovirus group H, member 6 
70 PYROXD1 pyridine nucleotide-disulphide oxidoreductase domain 1 
71 TMCC3 transmembrane and coiled-coil domains 3 
72 PALLD palladin, cytoskeletal associated protein 
73 APEH N-acylaminoacyl-peptide hydrolase 
74 CD40 CD40 molecule, TNF receptor superfamily member 5 
75 CLDN1 claudin 1 
76 FOXN2 forkhead box N2 
77 RNF5 ring finger protein 5, E3 ubiquitin protein ligase 
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78 ZBTB48 zinc finger and BTB domain containing 48 
79 KCNK13 potassium channel, subfamily K, member 13 
80 GPM6B glycoprotein M6B 
81 MBOAT7 membrane bound O-acyltransferase domain containing 7 
82 ZNF259P1 zinc finger protein 259 pseudogene 1 
83 TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 
84 TYK2 tyrosine kinase 2 
85 SYDE1 synapse defective 1, Rho GTPase, homolog 1 (C. elegans) 
86 VCL vinculin 
87  disabled homolog 1 (Drosophila) 
88 IL11 interleukin 11 
89 KLHDC8A kelch domain containing 8A 
90 PPP6R3 protein phosphatase 6, regulatory subunit 3 
91 AEN apoptosis enhancing nuclease 
92 UBA7 ubiquitin-like modifier activating enzyme 7 
93 COL5A1 collagen, type V, alpha 1 
94 RPS26 ribosomal protein S26 
95 FAM172A family with sequence similarity 172, member A 
96 ELMO3 engulfment and cell motility 3 
97 LDOC1 leucine zipper, down-regulated in cancer 1 
98 EXOC5 exocyst complex component 5 
99 KARS lysyl-tRNA synthetase 
100 MBTPS1 membrane-bound transcription factor peptidase, site 1 
 
Results with 300 inputs and 5 rules 
 The results shown in Table 4.7 are the AUC of the model with 300 inputs. In the 
same manner that the models behave with 100 inputs, the highest performance was 
obtained by the model using FCM and the difference in performance between the two 
WFCM models is not significant. Moreover, a trend of increase for the AUC can be 
perceived for all the models. 
Table 4.7:Performance of the model using 300 inputs and 5 rules 
Genes FCM WFCM WFCM and 
validation 
index 
  AUC AUC AUC 
  Train Test Train Test Train Test 
300 0.96 0.87 0.98 0.81 1.00 0.82 
Chapter 4: Scaling-up of RBF models in bladder cancer prediction                                                  80 
 
 
 
 
 The Gene Signature obtained for the prediction of Survival contained the 300 
top ranked genes. Additional forty two (42) of the included genes that are related with 
bladder cancer are: Gene THRAP3, TUFM, SERPINB3, GLYR1, TOP2B, FUT6, 
ICAM2, GLTSCR2, MDC1, C1QBP, MIP, SPG7, CALD1, ITPR1, POLE2, SEC14L2, 
ITGA5, IL1RN, GRN, FBL, ESRRG, PARP4, MAP2K2, CDH17, NID1, RALA, 
PCDH7, ISL1, BICD2, EPHX2, MUC3A, FLOT2, PTHLH, APOBEC3A, ASH2L, 
GOLIM4, ACTN1, GALNT2, ATIC, ALPP, UBC, LIMA1.  
Results with 500 inputs and 5 rules 
 The results shown in Table 4.8 include the AUC of the model with 500 inputs.  
Table 4.8: Performance of the model using 500 inputs and 5 rules 
Genes FCM WFCM WFCM and 
validation 
index 
  AUC AUC AUC 
  Train Test Train Test Train Test 
500 0.94 0.73 0.96 0.75 0.98 0.87 
 
 The WFCM model with the validation index for the initial clusters outperforms 
the WFCM model that did not use the validation index and the FCM model. The 
WFCM model with the validation index keeps the same trend of an increase in the AUC 
while the AUC for the WFCM and the FCM model start having a decrease in the 
performance. The Gene Signature obtained for the prediction of Survival the 500 top 
ranked genes. Additionally, 37 of the included genes that are related with bladder cancer 
are: Gene ID3, ZFHX4, POLR2E, OXA1L, BNIP2, PHF17, F2RL2, RBP1, GSTA4, 
MARS, HEXIM1, NMU, GHITM, IGF1R, NRIP1, IL17RA, MAP2K7, CD2AP, 
GDF15, CTSE, PENK, IGFBP3, BHMT, PSAP, ELK1, PDE1A, CD3EAP, TFF3, 
CDKN1C, LONP1, HAL, ALDH4A1, MUC16, CLIC4, AKR1A1, BYSL, TRPC1. 119 
 
Chapter 4: Scaling-up of RBF models in bladder cancer prediction                                                  81 
 
 
 
 
Results with 1000 inputs and 5 rules 
Table 4.9: Performance of the model using 1000 inputs and 5 rules 
Genes FCM WFCM WFCM and 
validation 
index 
 AUC AUC AUC 
 Train Test Train Test Train Test 
1000 0.96 0.65 0.96 0.69 0.98 0.80 
 Similar to the results obtained for the model with 500 inputs, the WFCM model 
with the validation index for the initial clusters clearly outperforms the WFCM model 
and the FCM model (Table 4.9). The WFCM model with the validation index now had a 
decrease in the AUC, the same case presents for the WFMC and the FCM. The Gene 
Signature obtained for the prediction of contains the 1000 top ranked genes.  
Results with 2000 inputs and 5 rules 
 As discussed earlier in the Chapter, the FCM fails to converge as the complexity 
increase to more than 2000 genes. This is noted as ‘N/A’ in the Table 4.10.   
Table 4.10: Performance of the model using 2000 inputs and 5 rules 
Genes FCM WFCM WFCM and 
validation 
index 
  AUC AUC AUC 
  Train Test Train Test Train Test 
2000 N/A N/A 0.75 0.67 0.75 0.73 
 The WFCM models have similar performance for training however testing 
performance is higher for the WFCM model with the validation index. The results also 
show a general trend of decrease in the performance for both models. The Gene 
Signature obtained for the prediction of Survival contains the 2000 top ranked genes. 
Additionally, 181 of the included genes that are related to bladder cancer (Appendix A). 
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Results with 5000 inputs and 5 rules  
Table 4.11: Performance of the model using 5000 inputs and 5 rules 
Genes FCM WFCM WFCM and 
validation 
index 
  AUC AUC AUC 
  Train Test Train Test Train Test 
5000 N/A N/A 0.57 0.52 0.57 0.52 
As shown in Table 4.11, both models have a significant decrease in the AUC, 
however they perform the same. Overall, up to around 300 genes, a simple FCM 
clustering technique is adequate to resolve the modelling complexity of RBF modelling 
structures. As the number of genes increases, but number of samples remains the same, 
the WFCM and WFCM with the validity index are needed to model the gene microarray 
data with a good level of performance. Above 500 genes the WFCM with the validity 
index starts to outperform the WFCM; however the modelling structure appears to reach 
its limit in terms of resolving complexity above 5000 genes, where there is a dramatic 
drop in performance. The Gene Signature obtained for the prediction of Survival 
contains the 5000 top ranked genes. A total of eight hundred and thirty eight (838) of 
the included genes that are related to bladder cancer are shown in Appendix A. 
4.4 Analysis of predictive performance 
 Figure 4.3 summarises all the results presented in this section. A clear trend of a 
decrease in the performance when the number of inputs is increased can be seen. The 
best performances were obtained when using 300 inputs for FCM and 500 for WFCM 
with the validation index. Which is consisting to the findings of [150] and [149]. 
 Nevertheless, if the model is produced using less than 300 inputs, the 
performance is considerably higher for the FCM models; even when using 25 inputs.  
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Figure 4.3: Behaviour of the performance for the 3 models. 
4.5 Summary 
 In this chapter, the scaling-up performance of Radial Basis Function (RBF) 
Neural-Fuzzy models is investigated. RBF-Neural-Fuzzy models offer balance of 
performance and simplicity (while being tolerant to imprecision); these are traits that are 
important in healthcare informatics. An enhanced rule-base extraction framework was 
proposed to improve the model’s performance for high-dimensional low sample size 
data. The work presented in this Chapter is based on the healthcare informatics 
challenge of analysing large-scale microarray cancer data for the prediction of the 
patients’ cancer survival outcome. The simulations obtained for the prediction of 
bladder cancer’s survival provides a better understanding of the scalability performance 
for RBF Neural-Fuzzy models.    
 From the results obtained it can be concluded that the RBF model using FCM 
alone performs best when less than 300 genes are used. Due to the characteristics of 
high-dimension low sample size data, as the number of genes increases but number of 
samples remains the same, the WFCM and WFCM with the validity index are needed to 
model the microarray data with a good level of performance. Above 500 genes the 
WFCM with the validity index starts to outperform the WFCM. A dramatic drop in the 
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performance is observed above 5000 genes, where the modelling structure appears to 
reach its limit in terms of resolving complexity. Maximum accuracy for the prediction 
was obtained by using five hundred inputs for the WFCM and the validation index (0.87 
AUC) and three hundred inputs for the FCM (0.87 AUC).  
 The developed models maintain the simple structure with just five (5) rules, but 
with very good performance (up to 2000 genes). The simple linguistic-based structure 
of the Fuzzy-logic system could be used in human-centric decision support systems. It 
is essential to remember that the training time for the models can still be up to 3-4 days 
on a high performance computing server, however other –more efficient- optimisation 
algorithm can be used instead.  
It must not be forgotten that the models are produced to work closer with 
clinicians: therefore, apart from a good performance in term of accuracy of AUC the 
model needs to be comprehensible.  
Chapter’s summary of achievements: 
 Investigate the scaling-up performance of Radial Basis Function Neural-
Fuzzy models using a standard PC and a High Performance Computing 
(HPC) server,  
 Find the limit for the maximum number of inputs to use in the model while 
maintaining low computational complexity and high accuracy.  
 An enhanced rule-base extraction framework is proposed to improve the 
model’s performance for high-dimensional low sample size data 
(microarray data). With the enhanced rule-base, the scaling-up performance 
of Radial Basis Function (RBF) Neural-Fuzzy models was improved. 
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The achievements summarised above are linked to one conference publication 
(International Conference on Computer and Computational Intelligence) and a journal 
publication in the International Journal of Machine Intelligence and Computing 
(IJMLC) (post-conference volume-invited).   
Based on the modelling structure found on Chapters 3 and 4 (5 rules and 300 
inputs using a filter feature selection), a new input selection method will be introduced 
in the next Chapter; this new method is be based on the polynomial output of the 
model. The hypothesis behind the New Input selection is to monitor the values of the 
output weights and membership degree during the training of the structure. 
Specifically, how the output weights change with every iteration. The assumption is 
that if the output weight of that particular gene in a certain rule is high that means that 
it is highly involved in the final output. However, the output not simply is subject to 
the output weight, the membership degree of certain rule tells us the strength with 
which that rules is fired. Because of the polynomial output of the model, it is 
conceivable to distinguish how much a gene is involved in the final output and if that 
rule is important for the system.   
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Chapter 5: A new Fuzzy 
entropy model-based 
feature selection 
framework 
 
 In this chapter, a new model-based iterative method for feature selection based 
on fuzzy entropy measures is introduced. The presented approach is based on a Radial 
Basis Function – Neural Fuzzy modelling structure. A fuzzy entropy measure is used to 
directly link the relative contribution of each feature to the system’s performance. An 
iterative algorithm is then used for the first time in RBF literature to identify the most 
relevant features of the process under investigation. In terms of predicting the patients’ 
survival as a result of their bladder cancer gene signature, the inclusion of the cancer 
stage and grade as extra features of the predictive model is also evaluated, thus 
producing a hybrid gene-clinical data model. The simulation results confirm that the 
new approach outperforms existing predictive models in the literature for bladder cancer 
survival based on gene signature only; the additional novelty of the presented approach 
relies on the added benefit of producing models that are simpler (considerably less 
genes in the signature), interpretable, with good generalisation performance and easier 
to develop and use by non-experts due to the absence of complex pre-processing which 
is common in this field. The hybrid gene-clinical data model achieves on average 80% 
accuracy on the prediction of patient survival on “unseen” (new) patient cohorts, 
confirming the good generalisation of the model. The proposed iterative feature 
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selection method selects relevant features during the model-training phase, whilst 
maintaining the system’s simplicity and interpretability.  
5.1 Introduction 
The statement behind the present Chapter is that, as stated in [42]: “a variable 
that is completely useless by itself can provide a significant performance improvement 
when taken with others.”  
As opposed to univariate feature selection, the proposed approach is to generate 
an embedded model that takes into account the interaction between genes to produce 
powerful combinations of genes that perhaps are not good by their own, but without 
overlooking the good prediction performance of the model. In this Chapter, the use of a 
Radial Basis Function Neural-Fuzzy structure is proposed. The proposed approach 
consists of an embedded method based on a Radial Basis Function Neural-Fuzzy system 
[139], which is designed to be equivalent to a Fuzzy Logic Takagi-Sugeno-Kang -based 
system. A fuzzy entropy measure is used to directly link, for the first time in this 
modelling structure, the relative contribution of each feature to the system’s 
performance.  An iterative model-pruning algorithm is then used to identify the most 
relevant features of the process under investigation; in this case, a gene signature. The 
proposed method takes advantage of the link between the output layer of the TSK fuzzy 
logic modelling structure and each individual rule in the model’s rule-base to identify 
the most relevant genes in each rule of the rule-base. The signature identification is 
performed in an iterative procedure, thus eliminating the need to pre-process the data-
set before developing the process model. The proposed system is tolerant to 
imprecision, with good generalisation properties and ability to produce accurate 
predictions even with a low number of features. Because of the low number of features 
and the simple modelling structure the computational cost is also reduced. The RBF-NF 
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examines the relationship between gene expression and the outcome (survival, grade or 
stage) and because is based from fuzzy rules is open for scrutiny and it is possible to 
understand how the outputs are generated. The biggest strengths of the proposed 
approach are that the feature selection occurs in the training phase, taking into account 
the interactions and making it recursive, and that the model is accurate but at the same 
time interpretable and simple. 
The proposed approach is successfully applied to identify suitable gene 
signatures and predict bladder cancer stage, grade and survival. In three independent 
data sets [106, 107, 110] the model achieved accuracies ranging from 70% to 99%.  
The remainder of this Chapter is organised in four more sections as follows: 5.2 
Radial Basis Function for microarray signature identification; 5.3 Entropy Measures; 
5.4 RBF Neural-Fuzzy Entropy; 5.5 Simulation Results and 5.6 Summary.  
5.2 Radial Basis Function Model for microarray signature 
The overall RBF model approach presented in detail in the previous chapter is 
shown in Figure 3.1, this modelling framework is the core facet of the new Fuzzy 
Entropy Feature Selection. The new feature selection will be explained in detail in 
section 5.4 as illustrated in Figure 5.1, the Fuzzy Entropy Feature Selection takes place 
parallel to the RBF-Modelling and the Levenberg-Marquardt optimisation of the output.  
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Figure 5.1: RBF-NF Modelling Structure 
The datasets are normalised in order to eliminate the high variances between the 
gene’s intensities (quantile normalisation). After normalisation, the student’s 
distribution t-test is used as an initial gene-filter. Based on the p-values the genes from 
the Sanchez-Carbayo, Blaveri and Kim dataset were reduced from the original number 
of genes down to a set of 250 genes. Fuzzy C-means algorithm was applied for the 
elicitation of the initial rule-base. The second stage consists of applying the RBF-NF 
and optimisation method proposed in Chapter 3.  
5.3 Entropy Measures 
In this section the concept of entropy as a degree of randomness is used to 
quantify the fuzziness in a fuzzy system. There is a large dissimilarity between the 
classical entropy proposed by Shannon that deals with probabilistic uncertainties and 
the fuzzy entropy that deals with vagueness and ambiguous uncertainties [162].   
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5.3.1 Definition of Entropy  
The introduction of Entropy was made in thermodynamics; it was done by 
Rudolf Clasius [163] and later expanded by James Clerk Maxwell [164]. The definition 
of entropy is given by: 
S=Q/T                                (5.1) 
where S is the entropy, Q is the heat content of the system and T is the 
temperature of the system.  
Claude Shannon was one of the first ones to apply entropy outside a 
thermodynamics or physics. Shannon is acknowledged as the father of  Information 
theory [165]. Information theory deals with the amount of information transferred in an 
event and is determined by the probability of the event [162], this is referred as quantity 
of information. It is defined by Equation 5.2: 
𝐼(𝐴) = −log 𝑃(𝐴)                 (5.2) 
where 𝐴 is an event, 𝑃(𝐴) is the probability of the event.   
The average of information in all the events is called Entropy [162]. It is 
typically referred as Shannon’s entropy, defined by Equation 5.3: 
H(X) = -∑ 𝑃𝑖  log 𝑃𝑖
𝑛
𝑖=1                             (5.3) 
where X is a set of variables and 𝑃𝑖 is the set of the probabilities in X.  
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5.3.2 Fuzzy Entropy  
Fuzzy entropy is also a measure of information but it is specifically referred as 
fuzzy information measure [162]. The presented method is based on two features of the 
RBF-NF model:  The Fuzzy Entropy [166] and the Tagaki-Sugeno-Kang (TSK) [125] 
type of the output layer for the NF system. The fuzzy entropy is calculated via the 
membership degree of a given input vector to the rule-base of the system. There are 
various fuzzy entropy measures used in the literature, De Luca and Termini [166] 
defined the following Fuzzy Entropy measure, which is an average amount of fuzziness 
and it is based on Shannon’s entropy definition; De Luca and Termini introduced a set 
of properties that Fuzzy Entropy should satisfy: 
𝐻𝐴𝑖 =  −𝐾 ∑ {𝜇𝑗 log(𝜇𝑗) + (1 − 𝜇𝑗) log(1 − 𝜇𝑗)
𝑚
𝑗=1 }                      (5.4) 
where: 
𝐻𝐴𝑖 = 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑝𝑒𝑟 𝑟𝑢𝑙𝑒, 𝐾 = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 
𝑚 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛𝑝𝑢𝑡𝑠, 𝜇𝑗 = 𝑚𝑒𝑚𝑏𝑒𝑟𝑠ℎ𝑖𝑝 𝑑𝑒𝑔𝑟𝑒𝑒 
In the current literature, there are examples of use of Fuzzy Entropy in 
combination with several techniques for feature selection, including: Fuzzy-rough 
dimensionality reduction [167], microarray and image datasets [123], microarray [70], 
microarray breast cancer [168], credit scoring [169]. 
5.4 RBF- Neural-Fuzzy Entropy Feature Selection 
As presented in Chapter 3, the RBF modelling structure achieved good results in 
predicting cancer stage, grade and survival, but one of the best characteristic of this 
model is the transparency that it give us, translated into high interpretability due to the 
linguistic rules. In the introduction of this chapter it was discussed how it might be 
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conceivable to form more powerful combinations by using a combination of genes that 
do not have a linear or statistic strong dependence to the output, and as an alternative 
take an approach based on how different combinations of inputs (genes) can give an 
improved performance. To understand the basic reasoning behind how the New Fuzzy-
Entropy feature selection is made it is necessary to monitor the values of the output 
weights and membership degree during the training of the structure. What is significant 
to consider is how the output weights change with every iteration, for example if the 
stay constant or have large variations.  
If a weight that relates to a gene stays always constant, that gene may not be 
significant for the classification stage as it is not “involved” in the training of a 
particular linguistic rule in the rule-base. On the other hand if one gene fluctuates (either 
positively or negatively) it may be significant as it contributes towards the prediction 
strength (entropy) of a particular rule. 
The assumption is that if the output weight of that particular gene in a certain 
rule is high that means that it is highly involved in the final output. However, the output 
not simply depends on the output weight, the membership degree of certain rule 
expresses us the strength with which that rules is fired. Because of the characteristics of 
the RBF-NF model, it is conceivable to identify how strongly a gene is involved in the 
final output and if that rule is essential for the system.   
The method has several challenges to defeat, the number of iterations until a 
gene is marked as being not significant, or the number of genes the model can handle 
without losing interpretability and still make a good prediction.  
As found in Chapter 4, one of the drawbacks found for FCM clustering is that 
with high dimensional data, the effectiveness of creating clusters decreases, often 
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resulting in indistinguishable centres for all of the inputs. The first step is to analyse the 
dimension that FCM can handle, how many inputs, at what point is not possible to make 
difference between the clusters. The idea is to monitor the performance of every input 
of the system and based in the analysis remove the genes that show poor performance.   
There are some aspects to take into account: 
 The maximum number of inputs used in the model 
 Decide if FCM is adequate to calculate the initial clusters  
 Optimise the number of rules or clusters 
 Best performance of the model , with how many genes 
 Selected genes that have medical relevance 
 The number of iterations to review the model 
The presented methodology is based on two features of the RBF-NF model:  The 
Fuzzy Entropy described in the section 5.3 and the TSK [125] type of the output layer 
for the NF system described in the previous chapter. The novelty of the approach 
presented in this chapter is that the fuzzy entropy is used in combination with the 
antecedent of the RBF fuzzy rule-base (TSK output layer) to assign a relative 
importance (relevance) to each feature in the dataset (in this case, to each gene). Each 
single input of the system is analysed in a separate manner to produce a ‘factor’ that 
adjusts the aforementioned input based on the behaviour in the system, this is calculated 
via the fuzzy entropy that takes into account the interaction of the inputs. For the first 
time in bladder cancer analysis the relevance of input in the model is used to make a 
ranking of the inputs and a prediction of the cancer’s outcome.  
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While the RBF-NF model optimises the RMSE (see Figure 5.2) via the 
Levenberg-Marquardt optimisation to make an accurate prediction, the output of the 
model is analysed to make an input selection at the same time. Providing a distinctive 
additional characteristic to the embedded model because of the low level of pre-
processing needed with the added benefit of maintaining the model’s simplicity and low 
computational cost. 
 
  It is vital to emphasise that the data was separated into Training (70% of the 
data) and Testing (30% of the data) to constantly check if the performance parameters 
show any sign of over-fitting.  
The initial step for the Fuzzy Entropy based input selection is to analyse the 
TSK output layer of an RBF-NF model (see Figure 5.3). The TSK output layer 
represents a sum of polynomials that are a linear combination of its inputs (Equation 
3.8).   
Figure 5.2: RMSE behaviour 
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Figure 5.3: TSK output layer of RBF Linear combination of the inputs and each  𝒁𝒊 weight is 
directly linked to 𝒈𝒊 rule. 
Each TSK weight, zi, is directly linked to a corresponding rule gi. The 
contribution 𝑎𝑗 (output weight) of each input 𝑥𝑚 can be therefore associated to each rule 
𝑔𝑖 by the product ‘𝑎𝑗𝑥𝑗’. Hence, a relative measure of how important each input is to a 
specific rule is obtained. Based on the output weights [𝑎1, 𝑎2, … , 𝑎𝑗] it is possible to link 
how important each feature [𝑥1, 𝑥2, … , 𝑥𝑗] is to a specific rule.  
It would be possible to sum all the weights for a specific feature for all the rules 
to establish a cumulative importance for each feature, however not all the rules of the 
system contribute in the same way to each prediction. Therefore each rule’s 𝑔𝑖(firing 
strength) and the 𝐻𝐴𝑖 (entropy) of each fired rule are used to identify the contribution of 
each rule to the overall prediction of the model. 
The output weights for each rule are then adjusted based on the contribution of each 
rule, thus the rule-specific significance ‘𝐵𝑖𝑗’ of each gene ‘j’ per rule ‘i’ is formulated:  
𝐵𝑖𝑗 = (?̅?𝑖/𝐻𝐴𝑖) ∗  |𝑎𝑖𝑗|                   (5.5) 
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where ?̅?𝑖 is the median value of the firing strength 𝑔𝑖 of each rule, and 𝐻𝐴𝑖 is the 
entropy as defined in Eq. (5.4). Therefore, a rule is important if it has a high firing 
strength (high relevance to the data sample) and low entropy (fuzziness or uncertainty).  
The overall importance of each gene (variable) is then calculated by summing up all the 
rule-specific variable significance (Eq.5.6).  
                            𝐵0 = ∑ 𝐵𝑖𝑗
𝑝
𝑖=1                   (5.6) 
where 𝐵0 is the overall importance of each gene, 𝐵𝑖𝑗 is the contribution of each gene 
in a rule and p is the number of rules.    In the algorithmic process proposed here, the 
model is trained for ‘T’ iterations, while at ‘t’ iterations (t<T) the training can be 
‘paused’ and the model can be reviewed in terms of the gene ranking order.  
Figure 5.4 depicts the overall gene feature selection as a flowchart.  
 
Figure 5.4: Fuzzy Entropy Feature Selection 
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Described with more detail bellow:  
1. The first step is to rank the genes for each rule, based on the output weights 
(from highest to lowest). Only the top ‘n’ genes are selected and passed on to 
the second step. The threshold parameter (to select the top genes) may vary 
(process-specific). However, as it will be shown in the results section, it was 
established that, in this study, using twenty five (25) inputs offers a good 
balance between model simplicity and performance.  
2. Calculate the ?̅?𝑖 and the Fuzzy Entropy 𝐻𝐴𝑖 (fuzzy entropy Eq. 5.4).  
3. The next step is to calculate the rule-specific significance of each gene 𝐵𝑖𝑗 
(Eq. 5.5). The 𝐵𝑖𝑗 value represents the behaviour of a gene in a certain rule. 
For that reason a value of 𝐵𝑖𝑗 is obtained for each gene in all the rules.  
4. Now that the rule-specific significance (𝐵𝑖𝑗value) per gene is obtained, a new 
ranking is produced. If a gene is shown in several rules its value of 𝐵𝑖𝑗 is 
summed up. If a gene is shown in several rules that mean that this specific 
gene is involved a lot in the final output (hence significant). This measure is 
not an absolute one; however it provides a relevant measure of significance 
for the features (genes) in the database, which can be used to provide a feature 
selection mechanism.   
 The hypothesis of this algorithmic procedure is similar to using a regression 
model alone to identify relevant features from the regression coefficients of the 
polynomial model [170], with the difference here that the RBF-NF consists of multiple 
polynomials each weighted differently due to its corresponding rule. The advantage of 
the proposed approach is that here, a model-based approach is considered, where the 
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importance of each feature is derived by also considering the effect of the rest of the 
features – as opposed to filter-based approaches where each gene is considered alone, 
without the effect of the rest of the genes/features. 
 This procedure is repeated until the desired number of genes is obtained. The 
model’s performance can also be used as a criterion to stop the iterative gene 
elimination procedure. 
 During the model training it is possible to observe the cumulative weight of each 
feature; as the optimisation routine adjusts/optimises the weights of the model the most 
important genes can be visually identified by the absolute value of their weights (Figure 
5.5). The horizontal axis represents the training iterations of the model and the vertical 
axis the output weights[𝑎1, 𝑎2, … , 𝑎𝑚]. Genes, CHPT1, POLE2 and HGFAC are 
considered important to this example rule as they have a higher contribution compared 
to Genes, BIC2 or MIP.  
 
Figure 5.5: Example of the behaviour of the Output weights of 5 Genes in Rule 3. 
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5.5 Simulation Results 
The case-study presented in this Chapter is focused on the prediction of bladder 
cancer Stage, Grade and patient survival using three different bladder data sets: 
Sanchez-Carbayo [106], Kim [107] and Blaveri (Table 3.1 Chapter 3). This section is 
sub-divided into four different parts as follows: 
A. Simulation results for Stage and Grade: the model is validated using a real 
biomedical case-study, which concerns the prediction of the stage and grade of 
bladder cancer. 
B. Simulation results for Survival: a model is produced and validated using the 
previously mentioned data sets for the prediction of survival of bladder cancer. 
The present chapter also attempts to identify the best possible combination of 
clinical data and gene data for the prediction of survival. 
C. Fuzzy Logic-type linguistic rule-base: an example of the fuzzy rule-base 
describing the behaviour of the model.  
D. Comparison to existing literature results: the obtained results for the prediction of 
stage, grade and survival are compared to previously published results.  
All the datasets are treated with the same pre-processing procedure as described in 
the previous Chapter. A pre-selection of the genes was made using the top 250 genes 
as selected with the t-test.  Following the pre-processing stage each dataset is used 
separately to produce a predictive / feature selection model consisting of 25 inputs, 
with the results described in the following sections. The training iterations were 
defined according to the analysis of the results presented in the previous Chapter, 
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where it was concluded that someplace between 15 to 30 iterations would be 
sufficient for the model to be trained.  
5.5.1 Prediction of patient stage and grade for bladder cancer using microarray data 
a) Prediction of patient Stage 
The RBF-NF model is developed as described in section 5.2 and 5.4. The 
methodology was applied to the Sanchez-Carbayo, Kim and Blaveri datasets for the 
prediction of stage of bladder cancer. The cancer Stage values were ‘encoded’ into -1 
and 1 according to Table 3.4 from Chapter 3. The classification functions of Specificity, 
Sensitivity and Accuracy are used as measures of performance [147].   The resulting 
model consisted of 5 rules and 25 inputs. The data samples were randomly separated 
into ‘training’ (70% of the patients) and ‘testing’ (30% of the patients) data-sets. The 
training set is only used to train the model, and the testing data-set is only used after the 
model training is finished to test the generalisation performance of the model, as a form 
of cross-validation [147]. The results shown in Table 5.2 are the mean % of the 10 
models for Accuracy, Specificity and Sensitivity respectively. The highest performance 
was obtained with the Sanchez-Carbayo Data Set, the lowest with Blaveri. Kim had the 
more balanced performance. For simplicity, only one Gene Signature for the prediction 
of Stage is shown in Table 5.1. It shows the 25 top ranked genes, the signature has been 
confirmed from clinicians that is medically relevant.  
For example: Gene CEBPD is associated with prostate cancer; ITGB5 is 
associated with breast and ovarian cancer; HGF is associated with carcinoma; THBS2 is 
associated with breast cancer and melanoma; RGS1 is associated with melanoma and 
leukaemia; PVT1 is associated with leukaemia, pancreatic, breast, prostatic and gastric 
cancer; DUSP1 is associated with ovarian, breast and gastric cancer; SFRP4 is 
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associated with oral cancer; GADD45B is associated with ovarian cancer and 
leukaemia; CYR61 is associated with breast and endometrial cancer; NNMT is 
associated with thyroid, colorectal and gastric cancer; COL10A1 is associated with lung 
cancer and adenocarcinoma; TAGLN is associated with prostate, colorectal and lung 
cancer; FLNC is associated with gastric cancer and melanoma; MAPK4 is associated 
with pancreatic, lung and breast cancer. 
Table 5.1:  Gene Signature for Bladder Cancer Stage in Sanchez-Carbayo Data Set 
Rank Gene 
Symbol 
Gene Title 
1 CEBPD CCAAT/enhancer binding protein (C/EBP), delta 
2 NLGN1 neuroligin 1 
3 ITGB5 integrin, beta 5 
4 HGF hepatocyte growth factor (hepapoietin A; scatter factor) 
5 THBS2 thrombospondin 2 
6 COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) 
7 RGS1 regulator of G-protein signaling 1 
8 FMO1 flavin containing monooxygenase 1 
9 TMEM231 transmembrane protein 231 
10 PVT1 Pvt1 oncogene (non-protein coding) 
11 DUSP1 dual specificity phosphatase 1 
12 SFRP4 secreted frizzled-related protein 4 
13 AEBP1 AE binding protein 1 
14 CHD8 chromodomain helicase DNA binding protein 8 
15 GADD45B growth arrest and DNA-damage-inducible, beta 
16 CYR61 cysteine-rich, angiogenic inducer, 61 
17 NNMT nicotinamide N-methyltransferase 
18 RGS2 regulator of G-protein signaling 2, 24kDa 
19 COL10A1 collagen, type X, alpha 1 
20 TAGLN Transgelin 
21 CYHR1 cysteine/histidine-rich 1 
22 TPST1 tyrosylprotein sulfotransferase 1 
23 FLNC filamin C, gamma 
24 KANK1 KN motif and ankyrin repeat domains 1 
25 MAPK4 mitogen-activated protein kinase kinase kinase kinase 4 
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In Section 5.5.4 a comparison between the results shown in Table 5.2 and 
previous publications is presented. The resulting models use a low number of genes (25) 
and rules (5).  
Table 5.2: Prediction of Stage using 5 rules and 25 inputs 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
99 100 98 93 100 89 
Standard 
Deviation 
2 0 3 4 0 7 
Blaveri Performance 
(%) 
96 99 91 70 93 67 
Standard 
Deviation 
10 3 27 5 12 5 
Kim Performance 
(%) 
90 89 91 76 75 80 
Standard 
Deviation 
3 4 3 6 5 10 
b) Prediction of patient grade 
The same pre-processing process applied to the data for the prediction of stage 
was applied. The RBF-NF model was developed as described in Section 5.2 and 5.4.  
Three grades are used to rate cancer and are encoded according to Table 4.4.  
The gene signature for Grade is presented in Table 5.3, only common gene 
between the two signatures for stage and grade is secreted frizzled-related protein 4, 
which is associated with oral cancer.  
Other genes associated to different types of cancer include: EPHB4 is associated 
to prostate, ovarian and colon cancer; PCSK5 is associated with colon cancer; STX10 is 
associated with gastric cancer; AGFG1 is associated with melanoma; SFRP4 as 
mentioned before is associated with oral cancer; NID2 is associated with ovarian 
cancer; TMEM184C is associated with thyroid cancer and prostatitis, a disease linked 
with prostate cancer; CAMK2B is associated with breast cancer; CDC25B is associated 
with prostate, lung, neck and colon cancer; LAMB4 is associated with lung cancer; 
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TMPRSS6 is associated with prostatic and breast cancer and prostatitis; NOTCH2 is 
associated with prostatic and breast cancer and leukaemia; DHRS11 is associated with 
laryngeal cancer; COL6A3 is associated to colorectal and gastric cancer.  
Some of these genes (i.e. SPARC, COL6A3) are related with tumours in 
general; with the presented model it is conceivable to do an in-depth medical 
examination if the intensities of these genes are high, acting as an indicator of the 
malignancy.   
Table 5.3: Gene Signature for Bladder Cancer Grade in Sanchez-Carbayo Data Set 
Rank Symbol Gene Title 
1 EPHB4 EPH receptor B4 
2 PCSK5 proprotein convertase subtilisin/kexin type 5 
3 SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), 
member 3 
4 STX10 syntaxin 10 
5 SYBU syntabulin (syntaxin-interacting) 
6 GPATCH3 G patch domain containing 3 
7 AGFG1 ArfGAP with FG repeats 1 
8 SFRP4 secreted frizzled-related protein 4 
9 NID2 nidogen 2 (osteonidogen) 
10 TMEM184C transmembrane protein 184C 
11 RNF141 ring finger protein 141 
12 COL11A2 collagen, type XI, alpha 2 
13 GPR116 G protein-coupled receptor 116 
14 CAMK2B calcium/calmodulin-dependent protein kinase II beta 
15 CDC25B cell division cycle 25 homolog B (S. pombe) 
16 COL5A1 collagen, type V, alpha 1 
17 CXCL6 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic 
protein 2) 
18 LAMB4 laminin, beta 4 
19 HIST1H2AJ histone cluster 1, H2aj 
20 TMPRSS6 transmembrane protease, serine 6 
21 NOTCH2 notch 2 
22 DHRS11 dehydrogenase/reductase (SDR family) member 11 
23 SPARC uncharacterized LOC100505813 /// secreted protein, acidic, 
cysteine-rich (osteonectin) 
24 COL6A3 collagen, type VI, alpha 3 
25 FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) 
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The results shown in the Table 5.4 are the mean of the 10 models for Accuracy, 
Specificity and Sensitivity.  
Table 5.4: Prediction of Grade using 5 rules and 25 inputs 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
96 98 95 72 77 70 
Standard 
Deviation 
12 6 13 4 8 5 
Blaveri Performance 
(%) 
99 95 99 97 93 98 
Standard 
Deviation 
1  16 1 5 5 6 
Kim Performance 
(%) 
91 97 84 80 82 77 
Standard 
Deviation 
3 2 7 5 7 12 
Contrary to the results obtained for Stage, the performance with the Sanchez-
Carbayo data set is the lowest and Blaveri is the highest. Sanchez-Carbayo, Blaveri and 
Kim had a similar behaviour when the balance in the performance is considered. A 
more detailed discussion of the results is given in section 5.5.4. 
5.5.2 Prediction of patient survival in bladder cancer   
This section is focused on the prediction of Cancer Survival; the main focus is to 
identify the best possible combination for prediction of Survival by combining all the 
available information from each data set.  
In this study, the same RBF Neural-Fuzzy model is applied to the Sanchez-
Carbayo, Blaveri and Kim data set to predict the Survival rate. At the same time clinical 
data (cancer stage and grade) is added to the model to assess if adding such data could 
enhance the performance or if a prediction can be made using simply clinical data. 
a) Prediction of patient survival using only clinical data  
The initial question of this Section is; is it possible to predict survival in bladder 
cancer using only clinical data? Is this information sufficient to produce an accurate 
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model? Is it essential the microarray data to generate a prediction? To respond this 
enquiry a model based only in clinical data must be produced and from the results a 
hypothesis that might be relevant and aid us enhance the model can be formulated. The 
model would be a combination of microarray and clinical data. As an initial attempt 
only Stage was modelled. The results shown in Table 5.5 demonstrate that it is not 
possible to make an accurate prediction of survival using only this input. If a model has 
an acceptable performance, the standard deviation is massive. Also the measurements of 
performance (accuracy, sensitivity and specificity) are not balanced.  
Table 5.5: Prediction of Survival using Stage Only 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
72 62 90 62 43 86 
Standard 
Deviation 
8 16 32 2 21 30 
Blaveri Performance 
(%) 
58 39 85 36 26 51 
Standard 
Deviation 
2 3 2 4 6 7 
Kim Performance 
(%) 
59 78 47 59 80 45 
Standard 
Deviation 
1 34 29 4 31 28 
The results shown in Table 5.6 exhibit similar results to the ones found for 
Stage, it is not possible to make an accurate prediction of Survival using only this input. 
The performances are either excessively low or less than average but with a large 
standard deviation.   
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Table 5.6: Prediction of Survival using Grade Only 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
59 62 60 58 57 58 
Standard 
Deviation 
3 33 52 2 37 50 
Blaveri Performance 
(%) 
57 38 84 39 27 55 
Standard 
Deviation 
2 2 1 5 5 5 
Kim Performance 
(%) 
71 62 89 62 42 86 
Standard  6 13 31 1 20 30 
The last attempt is to combine Stage and Grade to make the prediction of 
Survival. Table 5.7 shows the results for each data set.  
It is essential to highlight that regardless of the fact that the performance is not 
high or better that the previously published results for the same data sets, a certain 
degree of improvement is shown if the results are compared to Table 5.5 and 5.6. The 
results show that it is not possible to make an accurate prediction of Survival using only 
these inputs and that the best model is a combination between Stage and Grade.   
Table 5.7: Prediction of Survival using Stage and Grade Only 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
78 68 98 64 42 92 
Standard 
Deviation 
4 8 4 2 4 2 
Blaveri Performance 
(%) 
65 92 20 58 86 19 
Standard 
Deviation 
5 15 5 6 27 10 
Kim Performance 
(%) 
66 92 20 58 86 40 
Standard 
Deviation 
7 12 42 1 20 19 
Based on the results presented in Chapter 3, it can be concluded that the RBF-
Neural-Fuzzy model can obtain improved performances than the ones presented in this 
section, nevertheless, the model can beneficiate from a combination of Stage and/or 
Chapter 5: A new fuzzy entropy model-based feature selection framework                                107 
 
 
 
Grade to enhance the performance of the model.  This assumption will be investigated 
in Section c) Prediction of Survival in bladder cancer via microarray data and clinical 
data.  
b) Prediction of patient survival via microarray data  
An RBF-NF model was developed as described in Section 5.2 and 5.4 using 
only microarray data intensities. The methodology was applied to the Sanchez-Carbayo, 
Blaveri and Kim Data-set, to reduce the number of features. The classification functions 
of Specificity, Sensitivity and Accuracy are used as measures of performance [147].   
The developed model consisted of 5 rules and 25 inputs. The data samples were 
randomly separated into ‘training’ (70% of the patients) and ‘testing’ (30 % of the 
patients) data-sets.  
This procedure was repeated ten (10) times as a form of k-fold cross-validation. 
The results shown in Table 5.8 include the mean of the ten models for Accuracy, 
Specificity and Sensitivity respectively, along with the standard deviation of each k-
fold. The obtained results showed that Sanchez-Carbayo and Blaveri have similar levels 
of performance, using the exact number of inputs. Kim had a lower and more 
unbalanced performance. Section b) will try to improve the performances achieved in 
this section by adding clinical data to the model. Survival was encoded according to 
Table 3.2 from Chapter 3.  
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Table 5.8: Survival Prediction using Microarray Data, 5 rules and 25 inputs 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
97 100 94 84 86 79 
Standard 
Deviation 
1 0 3 4 7 8 
Blaveri Performance 
(%) 
99 99 99 79 75 83 
Standard 
Deviation 
1 1 1 3 9 5 
Kim Performance 
(%) 
86 89 81 67 74 64 
Standard 
Deviation 
2 4 4 6 10 13 
c) Prediction of patient survival in bladder cancer via microarray data 
and clinical data.  
Clinical data are then added to the database for the prediction of survival in 
bladder cancer. The clinical data, which consist of the stage and grade of cancer could 
improve the modelling performance – providing these new feature are selected by the 
algorithm.  
The cancer Stage and Grade values are ‘encoded’ into -1 and 1 according to 
Table 3.3 and 3.4.  
In comparison, the addition of stage and grade results in improved testing 
performance (generalisation), which is a very important aspect for survival outcome 
modelling (the ability to generalise and perform well in unseen data). The three 
measures of performance, Accuracy, Specificity and Sensitivity (shown in Table 5.10) 
also appear to be better balanced (evidence of model reliability - robustness). It was also 
observed that the number of iterations to train the model and the number of features 
could be reduced while maintaining a very good and balanced overall performance. The 
resulting gene signature consists of 23 genes, and with the inclusion of the two clinical 
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features it results to the final 25-input model. The model itself consists of just five (5) 
rules which represent a very simple modelling structure.  
As it shown in the next section, the developed model and signature outperform 
existing signatures and models in the literature for the same datasets, while the 
presented signature consists or considerably less genes and/or is much simpler as shown 
in the comparison in the following section. The identified gene signature is shown in 
Table 5.9. It has been confirmed with oncology experts that the identified gene 
signature represents a clinically feasible marker. Some of the selected genes related with 
cancer are: CHPT1 related with prostatic and breast cancer; CDH16 is related with renal 
cancer; FGF14 is associated with breast cancer and melanoma; GLI1 is associated with 
pancreatic and gastric cancer; MDC1 is associated with prostatic, cervical, breast, 
pancreatic and lung cancer and leukaemia; IGHV5-78 is associated with leukaemia; 
POLE2 is associated with colorectal cancer; SEC14L2 prostate cancer; HGFAC is 
associated with prostate, renal, pancreatic cancer; RNF5 is associated with breast 
cancer; LPHN2 is associated with breast cancer. Similar to the gene signatures for Stage 
and Grade, there exist several genes that are not certainly linked to any type of cancer 
but are linked to tumours; this is a remarkable occasion to collaborate with medical 
expertise and discover new markers related to a type of cancer. A comparable 
circumstance is presented with a large portion of the proteins included in the gene 
signature, the model links the prediction of survival to those markers but from a medical 
perspective the markers are unknown in terms of relation to a certain type of cancer; the 
same opportunity for the analysis of the markers presents.  
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Table 5.9: Gene Signature for Bladder Cancer Survival in Sanchez-Carbayo Data Set 
Rank Gene 
Symbol 
Gene Title  
1 CHPT1 choline phosphotransferase 1 
2 CDH16 cadherin 16, KSP-cadherin 
3 PPIAL4A//PP
IAL4B//PPIA
L4C//PPIAL4
G 
peptidylprolyl isomerase A (cyclophilin A)-like 4A /// peptidylprolyl isomerase A 
(cyclophilin A)-like 4B /// peptidylprolyl isomerase A (cyclophilin A)-like 4C /// 
peptidylprolyl isomerase A (cyclophilin A)-like 4G 
4 FGF14 fibroblast growth factor 14 
5 GLI1 GLI family zinc finger 1 
6 FBL fibrillarin 
7 RGS9 regulator of G-protein signaling 9 
8 CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
9 MDC1 mediator of DNA-damage checkpoint 1 
10 CNR1 cannabinoid receptor 1 (brain) 
11 KLHDC8A kelch domain containing 8A 
12 ISL1 ISL LIM homeobox 1 
13 CALML5 calmodulin-like 5 
14 PYROXD1 pyridine nucleotide-disulphide oxidoreductase domain 1 
15 IGHV5-78 immunoglobulin heavy variable 5-78 (pseudogene) 
16 BICD2 bicaudal D homolog 2 (Drosophila) 
17 POLE2 polymerase (DNA directed), epsilon 2, accessory subunit 
18 SEC14L2 SEC14-like 2 (S. cerevisiae) 
19 KIAA1211L Chromosome 2 open reading frame 55 
20 HGFAC HGF activator 
21 MIP major intrinsic protein of lens fiber 
22 RNF5 ring finger protein 5, E3 ubiquitin protein ligase 
23 LPHN2 latrophilin 2 
24 stage  
25 grade  
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Table 5.10: Prediction of Survival using Stage, Grade and Microarray data, 5 rules and 25 inputs 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
99 98 99 88 89 87 
Standard 
Deviation 
8 1 1 2 3 4 
Blaveri Performance 
(%) 
98 100 95 80 73 85 
Standard 
Deviation 
1 0 2 5 11 5 
Kim Performance 
(%) 
88 84 91 73 66 79 
Standard 
Deviation 
3 6 4 3 10 8 
 
5.5.3 Fuzzy Logic-type linguistic rule-base 
Apart from the very good performance and modelling structure simplicity, the 
models presented in this chapter maintain a transparent Fuzzy Logic-type linguistic 
rule-base. Figure 5.6 shows a sample of the rule-base describing the behaviour of the 
model. For simplicity, just two rules are shown (one for ‘negative outcome’ and one for 
‘positive outcome’); these are shown for five out of the 23 genes in the gene signature 
(complete signature shown in Table 5.9) Two of the linguistic IF-THEN rules that 
describe the model are shown below to demonstrate the transparency (interpretability) 
of the modelling method. The corresponding numerical values of the linguistic hedges 
‘high’, ‘medium’ etc. are determined by the optimisation algorithm via the training 
data-set. The equivalent linguistic-numerical interpretation of the normalised gene 
intensity is shown in Table 3.5. 
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Rule 2 (NED): 
IF the intensity of  
the Gene ‘Major Intrinsic protein lens fibre’ is Low Medium  and 
the Gene ‘Fibrillarin’ is Low Medium and 
the Gene ‘Immunoglobulin heavy variable 5-78 finger’ is Low Medium and 
the Gene ‘mediator of DNA-damage checkpoint 1’ is Low Medium and 
the Gene ‘Cannabinoid receptor 1 (brain)’ is Low Medium  
THEN the Patient will survive as results of the disease   
Rule 3 (DOD): 
IF the intensity of  
the Gene ‘Major Intrinsic protein lens fibre’ is Medium  and 
the Gene ‘Fibrillarin’ is Medium and 
Figure 5.6: Example of a RBF-NF rule base, here for simplicity just two rules are shown, one for a 
positive outcome and one for a negative. 
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the Gene ‘Immunoglobulin heavy variable 5-78 finger’ is Medium and 
the Gene ‘mediator of DNA-damage checkpoint 1’ is Medium and 
the Gene ‘Cannabinoid receptor 1 (brain)’ is Medium High 
THEN the Patient will decease as results of the disease   
5.5.4 Comparative Study 
In this section the performance of the developed model and associated gene 
signature are compared to previously published results on the same datasets. Due to the 
availability of published results and different scope of the various research studies it is 
not possible to compare all aspects of the presented modelling and feature selection 
approach.  
Therefore, the following comparisons are performed: 
 Prediction of stage and grade outcome compared to the Lauss [113] model and 
the previous model presented in Chapter 3.  
 Prediction of survival outcome compared to the Sanchez-Carbayo [106] model 
and gene signature 
 Prediction of survival outcome – muscle invasive tumours only:  
o Compared to the Blaveri [110] model and gene signature 
o Compared to the Riester [114] model and signature. 
o Compared to the model presented in Chapter 3.  
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a) Comparison of patient stage and grade 
Tables 5.8-5.11 show the performance obtained from prediction of Stage and 
Grade. The RBF Neural-Fuzzy makes accurate predictions but the main advantage is 
that it is possible to perform input selection at the same time.  
The presented model obtained better or comparable performances to previously 
published results but with the advantage of a ranking of the inputs based in the 
performance they have in the model [113] with a SVM approach using 150 genes. Table 
5.11 shows a comparison between a SVM model with 150 inputs and the RBF model 
with 25 inputs. The RBF model performed better for the Sanchez-Carbayo data set but 
for Blaveri Lauss had a better performance. No results for Kim were found to make a 
comparison.  
Table 5.11: Comparison of results from the prediction of Stage to existing publications in the 
literature 
 Lauss (SVM-150 genes) [113] RBF Neural-Fuzzy (25 
genes) 
Sanchez-Carbayo 
 
87 % 93 % 
Blaveri 85 % 70 % 
Kim - 76 % 
Compared to the results shown in Chapter 3 for Stage, the presented model 
obtained better performances but with the advantage of a ranking of the inputs based in 
the performance they have in the model and using 25 genes. Table 5.12 shows a 
comparison between the RBF Neural Fuzzy model with t-test used in Chapter 3 and the 
RBF Neural Fuzzy model with the Fuzzy Entropy Feature Selection presented in this 
Chapter. The RBF model performed better or comparably for the Sanchez-Carbayo, 
Blaveri and Kim data. 
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Table 5.12: Comparison of results from the prediction of Stage to the results shown in Chapter 3 
 RBF Neural Fuzzy with t-test 
(150 Genes) 
RBF Neural-Fuzzy (25 
genes) 
Sanchez-Carbayo 
 
94 % 93 % 
Blaveri 60 % 70 % 
Kim 70 % 76 % 
Table 5.13 shows a comparison between the Lauss SVM model with 150 genes 
and the RBF Neural-Fuzzy Entropy model with 25 genes. The RBF model performed 
better for the Blaveri data set but for Sanchez-Carbayo Lauss had a better performance. 
No results for Kim were found to make a comparison.  
Table 5.13: Comparison of results from the prediction of Grade to existing publications in the 
literature (Accuracy) 
 Lauss (SVM-150 genes) [113] RBF Neural-Fuzzy (25 genes) 
Sanchez-Carbayo 
 
80 % 72 % 
Blaveri 86 % 97 % 
Kim - 80 % 
Table 5.14 displays a comparison between the RBF Neural Fuzzy model with t-
test used in Chapter 3 and the RBF Neural Fuzzy model with the Fuzzy Entropy Feature 
Selection presented in this Chapter. The RBF model performed comparably for the 
Blaveri and Kim data. Sanchez-Carbayo had a significant decrease in the performance.  
Table 5.14: Comparison of results from the prediction of Grade to the results shown in Chapter 3 
 RBF Neural Fuzzy with t-test (150 genes) RBF Neural-Fuzzy (25 genes) 
Sanchez-Carbayo 
 
94 % 72 % 
Blaveri 97 % 97 % 
Kim 80 % 80 % 
b) Survival Outcome Model 
In [171], the authors apply Bayesian Networks for predicting the prognosis in 
breast cancer cases. They showed how the inclusion of the clinical data to the 
microarray data boosts the modelling performance. In this Chapter, a new model-based 
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feature selection approach is presented, while showing that the addition of Stage and 
Grade (clinical data) to gene signature improves performance in the prediction of 
bladder cancer. The resulting simple structure (five rules and 25 inputs) also aids the 
computational efficiency of the model. 
Table 5.15 shows the performance of the RBF Neural-Fuzzy model compared to 
existing results from Sanchez-Carbayo [106]. In [25] a SVM modelling structure was 
utilised with a linear Kernel and the use 250 genes as inputs to the model. The 
methodology presented in this chapter outperforms the one presented in [25] while, 
crucially, achieving this with a much simpler structure (25 inputs as opposed to 250). 
Here only the accuracy measure is compared as sensitivity and specificity measures 
were not presented in [25]. 
Table 5.15: Accuracy of Survival using Stage, Grade and microarray data as inputs 
  Sanchez-Carbayo (SVM)  
250 genes [106] 
RBF Neural-Fuzzy 
25 Inputs (23 genes + 2 clinical) 
Sanchez-Carbayo 72 % 88 % 
 
i. Survival Outcome Model - Muscle Invasive Only  
The majority of the previously published results for survival in bladder cancer 
only include muscle invasive cases in order to simplify the modelling 
approach/structure. Also, from a clinical perspective, these cases are the most important 
ones to predict in terms of patient survival.  
The model developed in this chapter is more generic and includes different 
stages of bladder cancer.   To produce a fair comparison the model was redeveloped 
with just muscle-invasive patient data.  The RBF Neural-Fuzzy model using only 
muscle invasive patient data was compared to the published results of Blaveri [110], 
Riester [114] and the results presented in Chapter 3. 
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Table 5.16 shows the performance of the RBF Neural-Fuzzy model compared to 
existing results from Blaveri [110] using Prediction Analysis for Microarray (PAM) 
which uses a modified version of the nearest centroids classification method  and 25 
genes. 
Table 5.16: Performance of Survival (Accuracy) using Stage, Grade and microarray data as inputs 
 Blaveri (PAM) [110] 
(25 genes) 
RBF Neural-Fuzzy 
 
(23 genes + 2 clinical) 
 Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Blaveri 78 % 65 % 93 % 92 % 66 % 100 % 
Table 5.17 shows the performance of the RBF Neural-Fuzzy model compared to 
previous results published by Riester [114]. The Riester study makes use of three 
independent datasets (Sanchez-Carbayo [106], Blaveri [110]and Kim [107]) to develop  
a hybrid model using both SVM and a clinical nomogram [115] to assist with the 
predictions based on 20 inputs. The RBF-NF model exhibits a better balanced 
performance, Area under the Curve of the Receiver Operating Characteristic (ROC) 
curve, in two of the three data sets.  The RBF-NF model achieves a  similar or better 
performance in all cases with a much simpler modelling structure as the SVM-based 
model has its predictions are further ‘filtered’ by a clinical nomogram. The simplicity of 
the RBF-NF modelling structure might be essential for developing easy to use clinical 
advisory tools.  
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Table 5.17: Performance of Survival using Stage, Grade and microarray data as inputs. For 
comparison purposed the results in this example are shown as the area under the curve (AUC) of a 
ROC plot 
  Survival 
 Riester [114] 
(SVM + Nomogram 
20 genes) 
 
RBF Neural-Fuzzy 
25 Inputs (23 genes + 2 clinical) 
Sanchez-Carbayo 
 
0.74 0.84 
Blaveri 
 
0.76 0.83 
Kim 0.75 0.72 
The results shown in Table 5.18 shows the RBF-NF Entropy model exhibits a 
better balanced performance (AUC of the ROC curve) in two of the three cohorts. It is 
important to note that the RBF-NF Entropy model achieves a superior or performance in 
the Sanchez-Carbayo and Kim case. The addition of stage and grade as an input did 
increase the performance compared to the results shown in Chapter 3 for the same 
model using t-test as input selection.  
Table 5.18: Performance (AUC) of Survival using Stage, Grade and microarray data as inputs 
  Survival 
 RBF Neural-Fuzzy with t-test 
20 Inputs  
RBF Neural-Fuzzy 
25 Inputs (23 genes + 2 clinical) 
Sanchez-Carbayo 
 
0.82 0.84 
Blaveri 
 
0.90 0.83 
Kim 0.67 0.72 
In summary, the simulation results (Tables 5.11-5.18) show that in most of the 
cases (where the performance is similar) the accuracy is better than the previously 
published results for both muscle invasive and non-invasive cases. 
  One of the main advantages of using the proposed approach is that, as the results 
demonstrate, via using the RBF-NF approach one can obtain improved or comparable 
performance but – crucially – via using less number of inputs and with low number of 
rules (reduced model complexity). The latter also results in very fast model computation 
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times, in the range of a few minutes when the algorithms are run on a standard single 
personal computer. 
5.6 Summary 
This Chapter introduces a new feature selection algorithm based on Fuzzy 
entropy and a RBF Neural-Fuzzy structure that links directly the fuzzy entropy to the 
relative significance of the features of the model. Because of the characteristics of the 
RBF-NF TSK output (input weighted polynomial) a new method is proposed to 
correlate the features that are more significant to the model’s prediction. This 
significance measure is used to rank the inputs (genes) of the model, via an iterative 
algorithm.  
The proposed methodology has successfully been applied to the case study of 
bladder cancer prediction for the prediction of the patients’ stage, grade and survival 
outcome.  
Another characteristic of this study is how different markers help to predict 
cancer survival and if they could be used alone (without microarray data). The results 
show that for the RBF Neural-fuzzy model it is not possible to make an accurate 
prediction using only Stage and/or Grade but the model benefits from the less noisy 
nature of that clinical data to generate a more robust prediction output and reduce the 
number of inputs required to make an accurate prediction. Considering that premise, the 
combination of clinical data as additional inputs to the most commonly used microarray 
gene intensities was assessed, finding that the addition of stage and grade improves the 
overall performance (with various levels of improvement). Crucially, the combination 
of Stage and Grade and the low number of genes resulted from the approach in this 
work, helps the model to be developed in simpler structures (low number of rules and 
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genes, thus reducing model complexity), while maintaining comparable or improved 
performance as compared to models with significantly more genes or more complex 
structure. The combination of Stage and Grade also helps the model to reduce the 
training iterations (easier to optimise), helping to reduce the computational cost to just a 
few seconds on a standard single personal computer. Via the presented approach a 
performance equal or better than the work reported in Lauss [113] and Riester [114] is 
achieved, with the added benefit of the feature selection methodology automatically 
producing simple models consisting of only 5 rules and  25 inputs (without any 
significant pre-processing of the data other than the standard normalisation procedures - 
common for microarray data), with an average performance around 80% success rate in 
the prediction of patient survival. 
Also important in the presented feature selection and modelling approach is the 
maintenance of the transparency and interpretability of the resulting modelling 
structure.  
The major benefit of this approach, apart from its good accuracy, is the 
transparency provided by the rule base, converting the rules from the model into a 
graphical output that can be better understood in a visual manner. Such traits can aid the 
development of easy to understand and use model by non-experts (non-engineers) such 
as clinicians in order to directly interrogate the resulting model (human-centric system). 
Even though the presented methodology was produced for the case study of microarray 
bladder cancer data, this method may also be applied to numerous other diseases, 
providing relevant input-output data exist.  
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Chapter’s summary of achievements: 
 Development of a Radial-Basis-Function Neural-Fuzzy (RBF-NF) Fuzzy-
Entropy based Feature Selection algorithm  
 For the first time an embedded RBF-NF model was applied to the feature 
selection and accurate prediction of stage, grade and survival of bladder 
cancer.  
 The model is shown to maintain its good performance using the inputs 
selected by the new Fuzzy-entropy feature selection, even when using just 
25 genes in the gene based signature. 
The achievements summarised above are linked to one conference publication 
(Biostec 2013, The University of Sheffield- INSIGNEO Institute for In-silico Medicine 
Showcase, Sheffield, UK (2014) and The University of Sheffield Engineering 
Symposium - USES 2013, Sheffield, UK (2013). 
 The present chapter presented the power of the RBF NF network to make 
accurate predictions even with a low number of inputs. However, all this analysis has 
been carried on by decreasing the initial data set (consistent of several thousands of 
genes) using first a filter method (t-test) and then a wrapper or the embedded Fuzzy 
Entropy feature selection presented in this chapter.  The biggest challenge though is 
presented in the generalisation ability of such data-driven models as identified by other 
research results too. Models that are trained based on a specific patient cohort should 
be tested against data from other cohorts to establish the developed models’ 
generalisation performance and predictive robustness. In the next Chapter, the 
generalisation issues of data-driven models based on microarray analysis will be 
investigated.  
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Chapter 6: Generalisation 
properties of microarray- 
based models 
 In this Chapter, the generalisation performance of the developed models is 
investigated. The approach studied in this chapter is to cross-validate distinct 
microarray data by applying data integration techniques. Three different data integration 
approaches were analysed: quantile discretisation, median adjust and NN input-output 
mapping. The latter two approaches are introduced for the first time to a bladder cancer 
classification algorithm. The results obtained demonstrate that the data integration 
methods for cross validation of the models helps to significant increase the predictive 
performance. 
6.1 Introduction 
 Previous microarray studies have addressed the possibility of comparing 
different studies (or microarray platforms) [172, 173], concluding that the 
measurements of gene expression cannot be directly compared but instead the 
prediction or classification results obtain from this studies can [174]. Most of the 
research in machine learning algorithms has concentrated on the generation of 
algorithms able to produce viable classifiers with respect of computational time and 
generalisation abilities [175]. The challenge investigated in this chapter is why a model 
that can predict with good accuracy in the same cohort shows poor performance when it 
is tested on a different data set (cross-validated). It is essential to  question if, as stated 
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in [176]: “on several cases drawbacks in the classifier performance could arise not 
because of machine learning algorithms, but due to characteristic intrinsic of the data”. 
Could these intrinsic characteristics be solved? And if so, what would the data require 
for this?  
  In the present chapter, the possibility of creating a general model that can be 
used with any type of microarray data set and still make a prediction with good 
accuracy is investigated. For example, let’s consider three data sets: Sanchez-Carbayo-
Kim and Blaveri. The first problem arises because the top genes selected by the 
classifier do not exist in the different data sets. If only the common genes are used, the 
genes would be a much smaller subset of the original cohort; if the initial number of 
genes in the data set was ten thousand genes by the time the genes are compared and 
only the common genes are used, only two thousand and three hundred genes would 
remain.  According to Table 3.1 from Chapter 3, each data set comes from a different 
platform, and as shown in Figure 6.1 there is no common behaviour between the three 
data sets. The horizontal axis corresponds to 9 common genes found in the three data 
sets; the vertical axis corresponds to the gene intensity values normalised from -1 to 1.  
 
Figure 6.1: Boxplot of behaviour of 3 different data sets. From left to right: Blaveri, Sanchez-
Carbayo and Kim.  
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 In Figure 6.1, the intensities are separated into DOD or NED. In Sanchez 
Carbayo-data set (centre image), a trend of how the median behaves for each of the 
class can be seen. While for DOD the median value stays closer to -0.2, for NED the 
median value is closer to 0. This is a clear example of the behaviour expected from a 
gene; a strong variance in the behaviour from one class to another. In the data set from 
Blaveri and Kim all the gene intensities behave in a dissimilar manner, there is no clear 
trend about the behaviour of the data; neither per class or even analysing each gene 
intensity in the same class.  
 It is clear that the gene expression intensities need to be processed to be 
compared directly, this could be due to differences in technologies or in the technique 
used for the data to be obtained. There are two different approaches to solve this 
problem: a meta-analysis approach and data integration.  
 The meta-analysis (Figure 6.2) approach consists of the use of statistical 
methods to combine results from independent studies [177, 178]. The key approach of 
meta-analysis is to avoid the direct comparison of gene expression values [174]. 
  
Figure 6.2: Meta-analysis approach 
 Many different publications have presented meta-analysis results, aiming to rank 
genes based on confidence measures [179], modelling the unwanted effects of different 
laboratories [180] or calculating a measure of precision for a study [181]. However, as 
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stated before, meta-analysis approaches avoid the direct comparison of gene expression 
values.  
 An alternative approach is to cross-validate distinct microarray data (Figure 6.3) 
by applying data integration techniques. Data integration techniques arise due to the 
high availability of different gene expression data and the opportunity to compare 
different microarray technologies and cross-validate the results from those experiments. 
The main challenge is that researchers use different microarray platforms and pre-
processing algorithms, making difficult to validate the results found on each data study 
[174].  
 
Figure 6.3: Data integration approach 
 In [182-185] researchers analysed the reproducibility of measurements using 
different platforms, finding that there is a high reproducibility between the same 
platforms. There is even a study that introduced a microarray gene expression 
calibration method [186], however this is only for certain types of microarray chips.  
 Multiple different data integration methods based on normalisation exist in the 
literature: [187] proposed a normalisation method using a Z-score, [188] applied 
rescaling of gene expression values, [189] used normalisation to combine different 
microarray platforms, [190]  proposed a gene scaling factor to integrate microarray data 
from different platforms.  
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 An alternative approach is to transform the distribution of the data set. This 
approach was proposed in [174] using quantile discretisation [191] and median rank 
scores in order to transform the microarray data from different platforms so their 
distributions become identical.  The above mentioned methods already proved to work 
well for classification tasks but as mentioned in [192], the methods can suffer from 
information reduction.  
 It must be emphasised that to date, there is no definitive approach for meta-
analysis or data integration because most of the results are data-dependent [177]. One of 
the biggest challenges is that there is no agreement on which pre-processing algorithm 
should be used to produce comparable expression measurements across different 
platforms [193].  
 The approach investigated in this Chapter, is to cross-validate distinct 
microarray data by applying three different data integration techniques. The remainder 
of this Chapter is organised in four more sections as follows: 6.2 Data integration: three 
different data integration methods are investigated; 6.3 Data Integration Simulation 
Results and 6.4 Analysis and comparison of results and Section 6.5 Summary.  
6.2 Data Integration 
 The three different data integration methods, presented in this Chapter: 
1) median adjust  
2) quantile discretisation [191] 
3) NN Input-Output mapping.   
6.2 .1 Median Adjust  
 To adjust by the median value of the gene intensities is a common pre-
processing step for microarray [113] aiming to centre the gene expression values. In the 
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approach presented in this Chapter, as an alternative of median centre the data set with 
its own, a reference data set is used and the median gene expression value for each input 
are adjust to the median of the reference data set. The median adjust approach is 
introduced for the first time in this Chapter. This procedure is done by class; in this case 
two classes (DOD and NED). The resulting data set will have a similar distribution to 
the reference data; afterwards this process a cross-validation of the models is done.   
6.2.2 Quantile discretisation 
 This method was first applied to microarray breast and prostate cancer [174] and 
it is based on equal frequency binning [191]. The aim of this method is to discretise the 
expression values of all arrays into a predetermined number of bins; similar to the 
analysis investigated in [174], the number of bins is equal to eight for the current 
investigation. According to the description investigated in [174], for each data set 𝑞 
subsets with equal number of values are determined using the quantiles of the 
expression value as cut-off points. They defined a cut-off point as the expression value 
separating an ordered set of expression values into two subsets. The two bins located at 
the centre are combined into one central bin. The expression values are then substituted 
by an integer value equivalent to the bin it falls into, a value of zero is given to the 
central bin and the remaining of the bins are numbered consecutively beginning with the 
bins next to the centre, using positive integers for the bins containing values above the 
median and negative values for the rest.  
6.2.3 Input-Output Mapping using a Neural Network 
 The approach presented in this section consists on finding the non-linear relation 
(mapping) of each input (gene) to its corresponding input from a ‘reference set’. 
Recapturing the premise expressed at the beginning of the chapter, [176]: “on several 
cases drawbacks in the classifier performance could arise not because of machine 
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learning algorithms, but due to characteristic intrinsic of the data”. If the analysed data 
sets are substantially different in terms of gene expression behaviour, but a model that 
performed with a good accuracy has already been identified, would it be possible to 
select that data set as a reference and map the gene intensities to its corresponding gene 
intensity from the ‘reference set’? If this premise were correct, the resulting gene 
intensities would have a prediction performance similar to the one obtained by the 
‘reference set’. To calculate this relation, a Neural-Network [194] is used.  A Neural-
Network was used because they are known to be universal approximators, able to 
approximate any given mapping from inputs to outputs. One of the drawbacks of NN’s 
is that they behave as black boxes but in this case, the extraction of knowledge from the 
model is not relevant, the objective is to find the input-output relation. To the author’s 
knowledge, no similar approach has been applied for integrating microarray data sets, 
however an approach presented in [195] applies an ANN (Multi-layer perceptron) to 
predict functional relationships between proteins.    
 The NN used in this section is a one hidden-layer feed forward network. An NN 
consists of several layers; each layer contains a number of units [65]. Figure 6.4 shows 
the structure of a single hidden layer NN, it consists of an input layer, hidden layer and 
output layer. 
 
Figure 6.4: One hidden-layer Neural Network 
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  In the example shown in Figure 6.4: 𝑙 are the inputs, 𝑚 the hidden layer units 
and 𝑛 the outputs. The outputs of the hidden unit are a weighted linear combination of 
the inputs.  
𝑎𝑗 = ∑ 𝑤𝑗𝑖
𝑙
𝑖=0
𝑥𝑖 
(6.1) 
  where 𝑤𝑗𝑖 are the weights from the input layer to the hidden layer. 
 The activation of the hidden layer can be calculated by: 
       ℎ𝑗 = 𝑔(𝑎𝑗) (6.2) 
 The linear combination of the output of the hidden layer is obtained by,  
𝑎𝑘 = ∑ 𝑤𝑘𝑗
𝑚
𝑗=0
ℎ𝑗 
(6.3) 
Applying the activation function 𝑔2(𝑥) to 6.3 the value of the 𝑘th output is obtained.  
𝑦𝑘 = 𝑔2(𝑎𝑘) (6.4) 
Combining all the equations, the complete representation of the network is: 
𝑦𝑘 = 𝑔2(∑ 𝑤𝑘𝑗
𝑚
𝑗=0  𝑔 (∑ 𝑤𝑗𝑖
𝑙
𝑖=0 𝑥𝑖)) (6.5) 
 The methodology applied is simple, to map each input from the reference set to 
its correspondent input from the validation data sets. Once the corresponding mapping 
is obtained, the RBF-NF model produced with the reference data set is cross-validated 
with the corresponding mapped data set of validation data sets. A similar performance 
to the one obtained by the validation set when only the reference data set was used to 
produce the model is expected.  
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As a measure of performance of the model the MSE (Mean square error) is used. 
The data was separated by classes (NED or DOD) and the inputs were randomly 
separated into ‘training’ (70% of the genes), ‘testing’ (15% of the genes) and 
‘validation’ (15% of the genes) data-sets. A one hidden-layer Neural-Network is used to 
find the non-linear relation (mapping) of each input (gene) to its corresponding input 
from a ‘reference set’.  
6.3 Data Integration Results 
 In Chapter 5, the results for the prediction of Bladder Cancer’s Survival using 
the fuzzy entropy feature selection method were presented. The first problem arises 
when validating the gene signature obtained with one data set with the gene signature 
obtained with a different data set. For example, if the Top 25 Genes obtained from the 
model using the Sanchez-Carbayo data set are compared with the top 25 Genes obtained 
with Blaveri’s or Kim’s data set (Table 6.1 or Appendix B ) one would find that none of 
the genes are present in both lists. This is a generalised problem in microarray analysis 
because each data set behaves in a different manner [196]. To ensure that the RBF-NF 
feature selection algorithm was working properly, it was tested it with a benchmark data 
set, obtaining a median accuracy in selecting the correct inputs of 80% (Appendix C).   
Table 6.1: Top Genes for the prediction blader cancer’s survival from Sanchez-Carbato, Blaveri 
and Kim  
Rank Top 25 Gene Title for 
Sanchez-Carbayo 
Top 25 Gene Title for Blaveri Top 25 Gene Title for Kim 
1 choline 
phosphotransferase 1 
hypothetical protein PRO1847 grade 
2 cadherin 16, KSP-
cadherin 
enolase 2, (gamma, neuronal) stage 
3 peptidylprolyl isomerase 
A (cyclophilin A)-like 4A 
/// peptidylprolyl 
isomerase A (cyclophilin 
A)-like 4B /// 
peptidylprolyl isomerase 
A (cyclophilin A)-like 4C 
/// peptidylprolyl 
KIAA0672 gene product carbohydrate (N-
acetylgalactosamine 4-0) 
sulfotransferase 8 
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isomerase A (cyclophilin 
A)-like 4G 
4 fibroblast growth factor 
14 
transcription factor 15 (basic 
helix-loop-helix) 
adrenomedullin 2 
5 GLI family zinc finger 1 zinc finger protein 266 ribosome binding protein 1 
homolog 180kDa (dog) 
6 fibrillarin oxytocin receptor cyclin N-terminal domain 
containing 2 
7 regulator of G-protein 
signaling 9 
tubby like protein 3 lipase, endothelial 
8 calcium channel, 
voltage-dependent, P/Q 
type, alpha 1A subunit 
suppressor of Ty (S.cerevisiae) 
4 homolog 1 
chromosome 5 open reading 
frame 46 
9 mediator of DNA-
damage checkpoint 1 
KIAA0410 gene product espin 
10 cannabinoid receptor 1 
(brain) 
glutamyl-prolyl-tRNA 
synthetase 
phosphodiesterase 6B, cGMP-
specific, rod, beta 
11 kelch domain containing 
8A 
syntaxin binding protein 1 transmembrane protein 195 
12 ISL LIM homeobox 1 Homo sapiens cDNA FLJ13303 
fis, clone OVARC1001372, 
highly similar to Homo sapiens 
liprin-alpha4 mRNA 
FAT tumor suppressor homolog 1 
(Drosophila) 
13 calmodulin-like 5 Homo sapiens, clone 
IMAGE:3940519, mRNA, partial 
cds 
family with sequence similarity 
13, member B 
14 pyridine nucleotide-
disulphide 
oxidoreductase domain 
1 
BCL2/adenovirus E1B 19kD-
interacting protein 1 
N-6 adenine-specific DNA 
methyltransferase 2 (putative) 
15 immunoglobulin heavy 
variable 5-78 
(pseudogene) 
Rag D protein plexin domain containing 2 
16 bicaudal D homolog 2 
(Drosophila) 
Stage chromosome 1 open reading 
frame 186 
17 polymerase (DNA 
directed), epsilon 2, 
accessory subunit 
KIAA0027 protein homeobox and leucine zipper 
encoding 
18 SEC14-like 2 (S. 
cerevisiae) 
proteasome (prosome, 
macropain) subunit, beta type, 
1 
chromosome 7 open reading 
frame 41 
19 Chromosome 2 open 
reading frame 55 
guanine nucleotide binding 
protein 4 
aspartylglucosaminidase 
20 HGF activator mitochondrial ribosomal 
protein L12 
similar to programmed cell death 
2 
21 major intrinsic protein of 
lens fiber 
chromosome 2 open reading 
frame 8 
chloride channel 3 
22 ring finger protein 5, E3 
ubiquitin protein ligase 
Grade nuclear receptor subfamily 2, 
group C, member 1 
23 latrophilin 2 KIAA0981 protein N-acetylneuraminate pyruvate 
lyase 2 (putative) 
24 Stage alanyl-tRNA synthetase arrestin domain containing 4 
25 Grade Homo sapiens cDNA FLJ10447 
fis, clone NT2RP1000851 
G protein-coupled receptor 98 
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 From previous results (Chapter 3, 4 and 5) it is possible to conclude that the 
RBF Neural Fuzzy Model shows a good performance within the same data set. But 
several experiments must be conducted to conclude that the model can generalise well 
with a different cohort. To test the generalisation capabilities of the model 3 models 
were produced (Figure 6.5), the same RBF Neural-fuzzy model is applied to 2300 
common genes between Sanchez-Carbayo, Blaveri and Kim data set to predict Survival 
rate. In addition to the gene intensities, the parameters of cancer Stage classification and 
cancer Grade classification were considered as inputs to the predictive model. This 
analysis is investigated in Section 6.3.1. 
 
Figure 6.5: Methodology followed for the analysis of the Individual models  
 The reason to use this approach is to observe how the performance of each 
individual model is affected by using only the common genes between the three data 
sets. As shown in Table 6.1, if the three lists of the Top 25 genes selected by the fuzzy 
entropy feature selection model are compared it is possible to become conscious that 
none of the genes are repeated in the three data sets.  The common genes between the 
three data sets, which are 2300 in total, are genes that were discarded in the initial stage 
of pre-processing by t-test. This means that they do not even show a strong linear 
dependence to the survival outcome. Not only a much smaller subset of the original set 
remains but also, the quality of the remaining genes is not the ideal to make an accurate 
prediction. Here, the performance expectation would reduce to around 70% of accuracy.     
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 Once the analysis of how the use of only the common genes to produce a model 
is done, a reference set will be chosen to cross validate the models and adjusted them to 
a reference data set. The data set that shows the highest performance across all the 
results will be chosen as a reference set, which indicates that is the most reliable and 
with fewer variations in intensities data set.  
 The remaining 2 data sets will be cross-validated with the reference data set’s 
model and afterwards, three different data integrations methods will be applied (Figure 
6.6): 
 Median adjusted 
 Discretisation 
 Mapping Input-Output using a NN 
 
Figure 6.6: Methodology followed for the cross-validation of the models 
This analysis is presented in Section 6.3.2 
6.3.1 Produce models with common genes 
 The RBF-NF model is developed as described in section 5.2 and 5.4. The 
methodology described below was applied to analyse each one of the data sets. The first 
step was to make a gene input selection using t-test. The gene input selection using t-
test was done separately for the 3 data sets and the number of genes was reduced from 
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2300 genes to 250. The RBF-NF models were trained with the 250 genes and 5 rules; 
afterwards the Fuzzy entropy feature selection algorithm was used on each top 250 
genes list. With each data set a model that was trained with the 3 sets of Top 25 Genes 
selected by the Fuzzy Entropy feature selection was produced. This means that the 
Sanchez-Carbayo data set was trained 3 times, one with the top genes from his fuzzy 
entropy feature selection, a second time with the genes selected by Blaveri and a third 
and final time with the genes from Kim gene selection. The methodology was applied to 
the Sanchez-Carbayo, Kim and Blaveri datasets for the prediction of survival of bladder 
cancer. The classification functions of Specificity, Sensitivity and Accuracy are used as 
measures of performance [147]. The resulting model consisted of 5 rules and 25 inputs. 
The data samples were randomly separated into ‘training’ (70% of the patients) and 
‘testing’ (30% of the patients) data-sets. The training set is only used to train the model, 
and the testing data-set is only used after the model training is finished to test the 
generalisation performance of the model, as a form of cross-validation [147]. The 
results shown in Table 6.3 are the mean % of the 10 models for Accuracy, Specificity 
and Sensitivity respectively. The highest performance was obtained with the Sanchez-
Carbayo Data Set, the lowest with Kim. The Gene Signature for the prediction of 
Survival using the Sanchez-Carbayo data set is shown in Table 6.2. Table 6.2 shows the 
25 top ranked genes.   
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Table 6.2:  Gene Signature for Bladder Cancer Survival in Sanchez-Carbayo Data Set 
Rank Gene 
Symbol 
Gene Title 
1 FUT6 fucosyltransferase 6 (alpha (1,3) fucosyltransferase) 
2 FBL fibrillarin 
3 TOP2B topoisomerase (DNA) II beta 180kDa 
4 CNR1 cannabinoid receptor 1 (brain) 
5 MDK midkine (neurite growth-promoting factor 2) 
6 STAT5B signal transducer and activator of transcription 5B 
7 NPTX1 neuronal pentraxin I 
8 PTK7 protein tyrosine kinase 7 
9 GRIA1 glutamate receptor, ionotropic, AMPA 1 
10  grade 
11 BAIAP2 brain-specific angiogenesis inhibitor 2 
12 PTHLH parathyroid hormone-like hormone 
13 VEGFA hepatic leukemia factor 
14 TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 
15 ECE1 endothelin converting enzyme 1 
16 GRP gastrin-releasing peptide 
17 TACC2 transforming, acidic coiled-coil containing protein 2 
18 TFF3 trefoil factor 3 (intestinal) 
19 DGCR2 DiGeorge syndrome critical region gene 2 
20 C8A complement component 8, alpha polypeptide 
21 SPAG16 sperm associated antigen 16 
22 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-
specific cross reacting antigen) 
23 IGFBP3 insulin-like growth factor binding protein 3 
24 SH3GL3 SH3-domain GRB2-like 3 
25  stage 
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The results shown in Table 6.3 displays that the RBF-NF Entropy model 
produced with Sanchez-Carbayo’s data set exhibit a superior performance. These results 
are not surprising since a superior performance for the data set used for making the gene 
selection is expected, as opposed to the other two data sets that were used for 
comparison.  
Table 6.3: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
91 95 86 84 91 71 
Standard 
Deviation 
1 2 4 5 11 21 
Blaveri Performance 
(%) 
92 90 94 56 49 60 
Standard 
Deviation 
6 6 7 9 20 19 
Kim Performance 
(%) 
87 92 81 54 63 42 
Standard 
Deviation 
3 3 4 4 7 13 
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Table 6.4 shows the 25 top ranked genes for Blaveri’s data set. 
Table 6.4:  Gene Signature for Bladder Cancer Survival in Blaveri Data Set 
Rank Gene 
Symbol 
Gene Title 
1 AARS alanyl-tRNA synthetase 
2 TULP3 tubby like protein 3 
3 TCF15 transcription factor 15 (basic helix-loop-helix) 
4 CYLC2 cylicin, basic protein of sperm head cytoskeleton 2 
5 MYF6 myogenic factor 6 (herculin) 
6 DAD1 defender against cell death 1 
7 ZNF266 zinc finger protein 266 
8 TANK TRAF family member-associated NFKB activator 
9 HAS2 hyaluronan synthase 2 
10 SLC4A2 solute carrier family 4, anion exchanger, member 2 (erythrocyte 
membrane protein band 3-like 1) 
11 SNRPB small nuclear ribonucleoprotein polypeptides B and B1 
12 FOXO1 forkhead box D1 
13 DNAJB2 DnaJ (Hsp40) homolog, subfamily B, member 9 
14 TERF2 telomeric repeat binding factor 2 
15 STXBP5 syntaxin binding protein 1 
16 ELK1 ELK1, member of ETS oncogene family 
17 BTG3 BTG family, member 3 
18 NR1H2 nuclear receptor subfamily 1, group H, member 2 
19 EPRS glutamyl-prolyl-tRNA synthetase 
20 TPD52L2 tumor protein D52-like 2 
21 CUBN cubilin (intrinsic factor-cobalamin receptor) 
22 BCL3 B-cell CLL/lymphoma 3 
23 SYN2 synapsin II 
24  stage 
25  grade 
 
 
 
 
Chapter 6: Analysis of generalisation of microarray based models                                               138 
 
 
 
 
The results shown in Table 6.5 shows the RBF-NF Entropy model produced 
with Blaveri’s data set exhibits a higher Accuracy, if the results are compared to the 
results obtained using Sanchez-Carbayo’s and Kim’s data set. Nevertheless, for the 
results obtained using Blaveri’s data set, the Specificity and Sensitivity appear to be 
unbalanced and with a high standard deviation. The performance obtained by the RBF-
NF model using Kim’s data set was similar to the one shown in Table 6.3.  
Table 6.5: Prediction of Survival using 5 rules and 25 inputs with Blaveri’s Top 25 Inputs 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
90 89 91 69 72 64 
Standard 
Deviation 
6 11 3 7 9 21 
Blaveri Performance 
(%) 
99 100 98 71 48 80 
Standard 
Deviation 
1 0 2 5 20 9 
Kim Performance 
(%) 
86 91 80 54 63 44 
Standard 
Deviation 
6 6 8 6 9 10 
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The Gene Signature for the prediction of Survival of bladder cancer using Kim’s 
data set is shown in Table 6.6. No common genes between the three data sets (Sanchez-
Carbayo, Kim and Blaveri) were found. 
Table 6.6:  Gene Signature for Bladder Cancer Survival in Kim Data Set 
Rank Gene 
Symbol 
Gene Title 
1  grade 
2 FGFR4 fibroblast growth factor receptor 4 
3 LMNB1 lamin B1 
4 SFN stratifin 
5 FOLR3 folate receptor 3 (gamma) 
6 ARC activity-regulated cytoskeleton-associated protein 
7 HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 
8 IFI27 interferon, alpha-inducible protein 27 
9 DHCR24 24-dehydrocholesterol reductase 
10 XRCC3 X-ray repair complementing defective repair in Chinese hamster 
cells 3 
11 TNFRSF9 tumor necrosis factor (ligand) superfamily, member 9 
12 CLK3 CDC-like kinase 3 
13 TFCP2 transcription factor CP2 
14 MAP7 microtubule-associated protein 7 
15 CFTR ATP-binding cassette, sub-family C (CFTR/MRP), member 5 
16 CDA cytidine deaminase 
17 PTPN13 protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 
(Fas)-associated phosphatase) 
18 RFX5 regulatory factor X, 5 (influences HLA class II expression) 
19 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 
20 GABRP gamma-aminobutyric acid (GABA) A receptor, pi 
21 ALDH1A1 aldehyde dehydrogenase 1 family, member A1 
22 SNCA synuclein, alpha (non A4 component of amyloid precursor) 
23 CAT catalase 
24 ACVR1 activin A receptor, type I 
25  stage 
Similar to the results shown in Table 6.5, the results shown in Table 6.7 exhibit 
a superior performance for RBF-NF model produced using Sanchez-Carbayo’s data set. 
This indicates a trend of superior performance when Sanchez-Carbayo data set is used. 
No matter which data set was used for making the gene selection, if an RBF-NF model 
using those genes was produced using Sanchez-Carbayo’s data set it would give the 
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highest validation performance among the three new data sets. These could be due to 
intrinsic characteristic of the data, the calibration of the instruments at the moment of 
taking the measurements or simply the processing of the microarray images. This also 
becomes clear if the distribution of the three data sets shown in Figure 6.1 is analysed. 
Certainly the same pre-processing of the data was used but they all behave in a different 
manner. From the results obtained it can be concluded that Sanchez-Carbayo’s data set 
is more ‘cleaner’ of outlier values and did not have to be filled in for missing values.  
Table 6.7: Prediction of Survival using 5 rules and 25 inputs with Kim’s Top 25 Inputs 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
96 98 93 75 83 62 
Standard 
Deviation 
2 2 5 6 6 15 
Blaveri Performance 
(%) 
98 99 98 55 24 68 
Standard 
Deviation 
2 1 4 13 21 15 
Kim Performance 
(%) 
86 92 78 52 63 39 
Standard 
Deviation 
3 5 3 5 11 9 
 Before cross validating the results into a different data set, a logical approach 
would be to make a meta-analysis or combination of the results from the Top genes 
from each data set and produce one ‘Top Global Genes List’ (shown in Table 6.8). 
From the results shown in Tables 6.3, 6.5 and 6.7, it is clear that the models produced 
using Sanchez-Carbayo’s data set had the best performance, therefore it would be logic 
to include a higher number of Top Genes from this data set than from Blaveri or Kim. 
Since 25 inputs are used in the rest of the models and 2 are already designated for Stage 
and Grade, it is necessary to divide the rest 23 inputs to give a majority to Sanchez-
Carbayo and represent equally Kim and Blaveri. It was decided to use Stage and Grade 
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plus 13 inputs from Sanchez-Carbayo and 5 inputs from Kim and Blaveri, respectively 
to give a total of 25 inputs. 
Table 6.8: Top Global Genes List 
 Rank Gene 
Symbol 
Gene Title 
1 FUT6 fucosyltransferase 6 (alpha (1,3) fucosyltransferase) 
2 FBL fibrillarin 
3 TOP2B topoisomerase (DNA) II beta 180kDa 
4 CNR1 cannabinoid receptor 1 (brain) 
5 MDK midkine (neurite growth-promoting factor 2) 
6 STAT5B signal transducer and activator of transcription 5B 
7 NPTX1 neuronal pentraxin I 
8 PTK7 protein tyrosine kinase 7 
9 GRIA1 glutamate receptor, ionotropic, AMPA 1 
10 BAIAP2 brain-specific angiogenesis inhibitor 2 
11 PTHLH parathyroid hormone-like hormone 
12 VEGFA hepatic leukemia factor 
13 TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 
14 AARS alanyl-tRNA synthetase 
15 TULP3 tubby like protein 3 
16 TCF15 transcription factor 15 (basic helix-loop-helix) 
17 CYLC2 cylicin, basic protein of sperm head cytoskeleton 2 
18 MYF6 myogenic factor 6 (herculin) 
19 FGFR4 fibroblast growth factor receptor 4 
20 LMNB1 lamin B1 
21 SFN stratifin 
22 FOLR3 folate receptor 3 (gamma) 
23 ARC activity-regulated cytoskeleton-associated protein 
24  grade 
25  stage 
 As shown in Table 6.9, there is no significant advantage of using this Top 
Global Gene list, in fact the performance for Sanchez-Carbayo’s model decreased 
considerably for the Specificity. While Kim and Blaveri showed lower and unbalanced 
performances.  
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Table 6.9: Prediction of Survival using 5 rules and 25 inputs with Top Global Gene List 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
92 89 96 70 45 83 
Standard 
Deviation 
16 30 1 3 17 8 
Blaveri Performance 
(%) 
86 90 93 47 76 23 
Standard 
Deviation 
1 2 3 3 7 5 
Kim Performance 
(%) 
93 92 92 51 70 43 
Standard 
Deviation 
4 7 8 12 13 19 
In the next sections the effect of integrating data sets using Sanchez-Carbayo’s 
data set as a reference to try to ‘adjust’ Blaveri and Kim data sets to improve the 
Generalisation performance (Testing in unseen and cross validated data set) is 
investigated.  
6.3.2 Cross-validate models 
 Since the Top Global Genes list did not bring any benefit in performance it was 
decided to simplify the methodology and use only one data set as the reference. To 
cross validate the models and adjusted them to a reference data set, the Sanchez-
Carbayo’s data set was chosen. This data set showed the highest performance across all 
the results, which indicates that is the most reliable and with fewer variations in 
intensities data set.  
 The first approach consists of using the RBF-NF model developed with 
Sanchez-Carbayo’s data set. The data samples were randomly separated into ‘training’ 
(70% of the patients) and ‘testing’ (30% of the patients) data-sets. The training set is 
only used to train the model, and the testing data-set is only used after the model 
training is finished to test the generalisation performance of the model, as a form of 
cross-validation.  Instead of using the Testing data from Sanchez-Carbayo, Blaveri and 
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Kim’s complete data are used as Testing to review the generalisation of the model. 
Additionally, three different data integrations approaches are analysed:  
 Median adjusted 
 Discretisation 
 Input-Output Mapping using a NN 
a) Cross-Validate Results 
 As explained above, the methodology is to cross-validate (use as Testing) 
Blaveri and Kim’s complete data set to review the generalisation of the model. The data 
from Blaveri and Kim are cross validated with model created with Sanchez-Carbayo’s 
data. It must be emphasised that all the data sets had the same pre-processing. Table 
6.10 shows the performance obtained when using Sanchez-Carbayo’s data set to 
produce the model.  
Table 6.10: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs 
   Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Performance 
(%) 
91 95 86 84 91 71 
Standard 
Deviation 
1 2 4 5 11 21 
 
 Table 6.11 and 6.12 shows the Testing performance obtained when using 
Blaveri and Kim’s data set. Both accuracies were considerably low. 
 
Table 6.11: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs Cross validated with Blaveri as Testing 
   Testing model using Blaveri data 
set 
  Accuracy Specificity Sensitivity 
Blaveri Performance 
(%) 
42 76 14 
Standard 
Deviation 
2 5 7 
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Table 6.12: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs Cross validated with Kim as Testing 
  Testing model using Kim data set 
  Accuracy Specificity Sensitivity 
Kim Performance 
(%) 
56 93 05 
Standard 
Deviation 
3 17 17 
b) Median Adjusted  
 The median adjust approach is introduced for the first time in this Chapter. As 
an alternative of median centre the data set with its own median gene expression value 
for each input (gene), a reference data set (Sanchez-Carbayo) is used and the different 
data sets are adjust to the median value of the input from reference data set. This 
procedure is done by class; in this case two classes DOD and NED are used. The 
resulting data set will have a similar distribution to the reference data, afterwards this 
process the models are cross-validated per data set, in a similar way as the cross-
validation done in the previous sub-section of this chapter.  
 The performance presented in Table 6.13 is similar to the performance seen 
when the Blaveri data set was used as Testing without any processing of the data for the 
model produced with Sanchez-Carbayo’s data.  
Table 6.13: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs with Data Integration Cross-validated with Blaveri 
  Testing model using Blaveri data 
set 
  Accuracy Specificity Sensitivity 
Blaveri 
Median 
Adjusted 
Performance 
(%) 
53 55 51 
Standard 
Deviation 
5 8 3 
 
 Similar results were obtained when Kim’s data set was used for testing the 
model produced with Sanchez-Carbayo’s data. An increase in the performance is seen 
for the median adjusted model compared to the performance presented in Table 6.14.  
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Table 6.14: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs with Data Integration Cross-validated with Kim 
  Testing model using Kim data set 
  Accuracy Specificity Sensitivity 
Kim 
Median 
Adjusted 
Performance 
(%) 
62 82 33 
Standard 
Deviation 
2 12 10 
 By adjusting the median value across all the samples the data sets are forced to 
have a similar distribution to Sanchez-Carbayo’s data set (Figure 6.7, 6.8 and 6.9). The 
horizontal axis represents the gene intensities and the vertical axis the number of 
samples. Before any processing of the data, all the data sets had the same pre-
processing. 
 
Figure 6.7: Median adjusted for the three data sets using as reference Sanchez-Carbayo. 
Distribution from Sanchez-Carbayo data set. 
 
 
Figure 6.8: Median adjusted for the three data sets using as reference Sanchez-Carbayo. 
Distribution from Blaveri data set. 
Chapter 6: Analysis of generalisation of microarray based models                                               146 
 
 
 
 
 
Figure 6.9: Median adjusted for the three data sets using as reference Sanchez-Carbayo. 
Distribution from Kim data set. 
c) Quantile discretisation 
  The aim of this method is to discretise the expression values of all arrays into a 
predetermined number of bins. For each data set 𝑞 subsets with equal number of values 
are determined using the quantiles of the expression value as cut points. They defined a 
cut-off point as the expression value separating an ordered set of expression values into 
two subsets. The two bins located at the centre are combined into one central bin. The 
expression values are then substituted by an integer value equivalent to the bin it falls 
into, a value of zero is given to the central bin and the remaining of the bins are 
numbered consecutively beginning with the bins next to the centre, using positive 
integers for the bins containing values above the median and negative values for the 
rest.  
 As shown in Table 6.15, the performance from Sanchez-Carbayo when the 
quantile discretisation method is applied was slightly lower compared to the results 
presented in Table 6.10.  
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Table 6.15: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs with Data Integration 
  Training Testing 
  Accuracy Specificity Sensitivity Accuracy Specificity Sensitivity 
Sanchez-
Carbayo 
Discretisation 
Performance 
(%) 
98 97 99 76 77 74 
Standard 
Deviation 
1 1 1 7 8 16 
 When the Blaveri data set is used as Testing for the model produced with 
Sanchez-Carbayo’s data, a higher performance was achieved using the discretisation 
method (Table 6.16) as opposed as the results shown for median adjust (Table 6.13). 
Table 6.16: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs with Data Integration Cross-validated with Blaveri 
  Testing model using Blaveri data 
set 
  Accuracy Specificity Sensitivity 
Blaveri 
Discretisation 
Performance 
(%) 
61 50 71 
Standard 
Deviation 
7 11 12 
 
 Similar results are obtained using Kim data set (Table 6.17); it can be seen an 
increase in the performance for the quantile discretisation model compared to the 
performance investigated in Table 6.14. 
Table 6.17: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs with Data Integration Cross-validated with Kim 
  Testing model using Kim data set 
  Accuracy Specificity Sensitivity 
Kim 
Discretisation 
Performance 
(%) 
62 68 53 
Standard 
Deviation 
2 6 3 
 By applying quantile discretisation, the data sets are forced to have a similar 
distribution to Sanchez-Carbayo’s data set (Figure 6.10, 6.11 and 6.12). The horizontal 
axis represents the gene intensities and the vertical axis the number of samples. 
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Figure 6.10: Quantile discretisation for the three data sets using as reference Sanchez-Carbayo. 
Distribution from Sanchez-Carbayo Data set data set. 
 
Figure 6.11: Quantile discretisation for the three data sets using as reference Sanchez-Carbayo. 
Distribution from Blaveri data set. 
 
Figure 6.12: Quantile discretisation for the three data sets using as reference Sanchez-Carbayo. 
Distribution from Kim data set. 
d) Input-Output Mapping using a Neural-Network 
 The Sanchez-Carbayo data set was chosen as the reference data set to map the 
input-output mapping of two data sets. When the Blaveri data set was used as Testing 
for the model produced with Sanchez-Carbayo’s data a similar performance to the one 
presented in Table 6.10 is seen. The accuracy, specificity and sensitivity presented in 
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Table 6.18 are comparable to the corresponding values of Accuracy, Sensitivity and 
Specificity presented in Table 6.10. The standard deviation is higher for the accuracy 
performance, which means that there was more variation in performance between the 10 
folds.  
Table 6.18: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs with Data Integration Cross-validated with Blaveri 
  Testing model using Blaveri data 
set 
  Accuracy Specificity Sensitivity 
Blaveri  Performance 
(%) 
85 94 77 
Standard 
Deviation 
11 16 10 
  
 Figures 6.13 and 6.14 display the behaviour of the MSE used as a measure of 
performance of the model. The best validation performance is obtained at 2 epochs for 
NED class and 3 epochs for DOD.  
 
Figure 6.13: Class NED best validation performance 
0 1 2 3 4 5 6 7 8
10
-1
10
0
Best Validation Performance is 0.24605 at epoch 2
M
e
a
n
 S
q
u
a
re
d
 E
rr
o
r 
 (
m
s
e
)
8 Epochs
 
 
Train
Validation
Test
Best
Chapter 6: Analysis of generalisation of microarray based models                                               150 
 
 
 
 
 
Figure 6.14: Class DOD best validation performance 
 Similar results are obtained when Kim’s data set is used for testing the model 
produced with Sanchez-Carbayo’s data. It is possible to perceive an increase in the 
performance compared to the results presented in Tables 6.14 (median adjusted) and 
6.17 (quantile discretisation) compared to the performance investigated in Table 6.19.  
Table 6.19: Prediction of Survival using 5 rules and 25 inputs with Sanchez-Carbayo’s Top 25 
Inputs with Data Integration Cross-validated with Kim 
  Testing model using Kim data set 
  Accuracy Specificity Sensitivity 
Kim Performance 
(%) 
79 92 62 
Standard 
Deviation 
17 23 22 
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Figures 6.15 and 6.16 display the behaviour of the MSE used as a measure of 
performance of the model. The best validation performance is obtained at 6 epochs for 
NED class and 5 epochs for DOD.  
 
Figure 6.15: Class NED best validation performance 
 
Figure 6.16: Class DOD best validation performance 
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e) Analysis and comparison of results. 
Table 6.20 shows a comparison of performance between the different data 
integration approaches presented in this chapter. The RBF-NF models (Sanchez-
Carbayo NN Input-Output mapping and Sanchez-Carbayo Discretisation) exhibit a 
higher performance (AUC of the ROC curve) in the three cohorts as compared to the 
results for cross-validation, median adjust and discretisation.  
Table 6.20: Comparison of results between RBF-NF models with 5 rules and 25 inputs 
 Testing 
Bladder 
Cancer 
AUC 
Sanchez 
AUC 
Blaveri 
AUC 
Kim 
Performance 
Cross-
validation 
0.81 0.45 0.49 
Performance 
Sanchez-
Carbayo 
Median 
Adjust   
0.81 0.53 0.66 
Performance 
Sanchez-
Carbayo 
Discretisation  
0.75 0.60 0.60 
Performance 
Sanchez-
Carbayo 
NN mapping   
0.81 0.86 0.78 
6.5 Summary 
 In this Chapter, the generalisation performance of the developed models is 
investigated. The question that investigated in this chapter is why a model that can 
predict with good accuracy in the same cohort is bad when it is tested on a different data 
set (cross-validated). Is this challenge arising due to characteristic intrinsic of the data? 
The approach studied in this chapter is to cross-validate distinct microarray data by 
applying data integration techniques. Three different data integration approaches are 
analysed: quantile discretisation, median adjust and NN input-output mapping. The 
latter two approaches are introduced for the first time to a bladder cancer classification 
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algorithm. The results obtained demonstrate that the data integration methods for cross 
validation of the models helps to have a considerable increase in the accuracy.  
 The first challenge arises because the top genes selected by the classifier do not 
exist in the different data sets. The common genes between the data sets tend to be a 
much smaller subset of the original cohort; typically reduced from ten or twenty 
thousand to a couple of thousand.  
 The approach studied in this chapter is to cross-validate distinct microarray data 
by applying data integration techniques. The main challenge is that researchers use 
different microarray platforms and pre-processing algorithms, making difficult to 
validate the results found on each data study [174]. Three different data integration 
approaches are analysed: quantile discretisation, median adjust and NN input-output 
mapping. The last two approaches are introduced for the first time to a bladder cancer 
classification algorithm.  
 The results obtained (Tables 6.13-6.19) demonstrate that the data integration 
methods for cross validation of the models give an increase in the performance. If the 
results from the data integration methods are compared to previously published results it 
can be seen that the NN mapping and Discretisation and median adjust have a higher 
performance in terms of AUC of a ROC curve. The obtained results demonstrate how 
data integration methods for model cross-validation can have a significant increase in 
the generalisation performance, and enable previously developed models to be used in 
different patient cohorts.  
Despite the fact that more information can be extracted from microarray models, the 
generalisation issue makes them still unreliable for clinicians.  
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 At moment, there is no definitive approach for data integration because most of 
the results are data-dependent. One of the biggest challenges is that there is no 
agreement on which pre-processing algorithm should be used to produce comparable 
expression measurements across different platforms.  
Chapter’s summary of achievements: 
 Improve the generalisation performance in microarray bladder cancer data  
 Two different data integration approaches are presented for the first time: 
median adjust and NN mapping of input-output.  
 The results obtained prove that the data integration methods for cross 
validation of the models helps to have a significant increase in the accuracy. 
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Chapter 7: Conclusions 
and future research 
directions  
Through this entire thesis, it has been emphasised why the study of predicting 
cancer is of great significance. The main reasons are: to help decrease the mortality 
rate, to make a prompt and correct classification of the type of cancer that would later 
translate into avoiding unnecessary treatment and save costs. Because traditional 
prediction tools have struggled to make an accurate classification at the early stages of 
cancer, new technologies have emerged for the study of cancer. Microarray gene 
expression data is one of these new technologies. The main challenge that these types 
of studies run across is the high dimensionality, translated in thousands of genes but a 
small number of samples. As there are no physics/biology based equations that 
represent the behaviour of the genes, a predictor model (data-driven) must be 
produced.  
 An RBF-NF methodology for the case study of bladder cancer prediction with 
respect to the patient’s stage, grade and survival was proposed. RBF-Neural-Fuzzy 
models offer balance of performance and simplicity (while being tolerant to 
imprecision); these are traits that are important in healthcare informatics. The focus of 
this research is to produce a model to identify the parameters significant to the process 
(genes) maintain simplicity and transparency while at the same time makes an accurate 
prediction of cancer survival. The major benefit of this approach, apart from its good 
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accuracy, is the transparency given by the rule base, converting the rules from the model 
into a graphical output that can be better understood in a visual manner. Such traits can 
aid the development of easy to understand and use model by non-experts (non-
engineers) such as clinicians in order to directly interrogate the resulting model (human-
centric system). 
Compared to previous modelling attempts from Martin Lauss [113] and Riester 
[114] based on SVM, the developed RBF-NF method shows improved performance in 
the same datasets. However, the attractiveness of this method is on the transparency that 
the rule-base exhibits and the good generalisation performance (even with just 20 genes 
and 5 rules) as compared to previous modelling attempts on the same dataset. The rule-
base’s transparency and interpretability, can aid the clinicians to directly interrogate the 
resulting model (human-centric system) and examine how the model uses individual 
genes and their intensity to provide predictions on the stage, grade and survival of 
bladder cancer.  
The scaling-up performance of Radial Basis Function (RBF) Neural-Fuzzy 
models is also investigated. The aim was to find the rational limit for the maximum 
number of useful inputs (genes) to use in the model while still maintaining low 
computational complexity and high accuracy. An enhanced rule-base extraction 
framework is proposed to improve the model’s performance for high-dimensional low 
sample size data.   
 From the results obtained it can be concluded that the RBF model using FCM 
alone performs best when less than 300 genes are used. Due to the characteristics of 
high-dimension low sample size data, as the number of genes increases but number of 
samples remains the same, the WFCM and WFCM with the validity index are needed to 
model the microarray data with a good level of accuracy.  
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 The developed models maintain the simple structure with just five (5) rules, but 
with very good performance (up to 2000 genes). The training time for the models can 
still be up to 3-4 days on a high performance computing server; however other more 
efficient-optimisation algorithm can be used instead.  
One of the main contributions of this research is the introduction of a new input 
selection method; this new method is based on the polynomial output of the RBF-NF 
model. The hypothesis behind the new Input selection is to monitor the values of the 
output weights and membership degree during the training of the structure. Because of 
the polynomial output of the model, it is conceivable to distinguish how much a gene is 
involved in the final output and if that rule is important for the system.   
The new feature selection algorithm is based on Fuzzy entropy and a RBF 
Neural-Fuzzy structure that links directly the fuzzy entropy to the relative significance 
of the features of the model. Because of the characteristics of the RBF-NF TSK output 
(input weighted polynomial) it is possible to correlate the features that are more 
significant to the model’s prediction. This significance measure is used to rank the 
inputs of the model via an iterative algorithm.  
Another contribution of this research is how the combination of clinical data 
(stage and grade) as additional inputs to the most commonly used microarray gene 
intensities improves the overall performance (with various levels of improvement). 
Crucially, the combination of Stage and Grade and the low number of genes resulted 
from the approach helps the model to be developed in simpler structures (low number of 
rules and genes, thus reducing model complexity), while maintaining comparable or 
improved performance as compared to models with significantly more genes or more 
complex structure. The combination of Stage and Grade also helps the model to reduce 
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the training iterations (easier to optimise), helping to reduce the computational cost to 
just a few seconds on a standard single personal computer.  
 The biggest challenge though is presented in the generalisation ability of such 
data-driven models as identified by other research results too. Models that are trained 
based on a specific patient cohort should be tested against data from other cohorts to 
establish the developed models’ generalisation performance and predictive robustness. 
The possibility of creating a general model that can be used with any type of 
microarray data set and still make a prediction with respectable accuracy (around 75%) 
was also investigated.  
 The first challenge arises because the top genes selected by the classifier do not 
exist in the different data sets. The common genes between the data sets tend to be a 
much smaller subset of the original cohort; typically reduced from ten or twenty 
thousand to a couple of thousand. The main challenge is that researchers use different 
microarray platforms and pre-processing algorithms making difficult to validate the 
results found on each data study [174]. Three different data integration approaches are 
analysed: quantile discretisation, median adjust and NN input-output mapping. The 
latter two approaches are introduced for the first time to a bladder cancer classification 
algorithm.  
 The results obtained demonstrate that the data integration methods for cross 
validation of the models give an increase in the performance. If the results from the data 
integration methods are compared to previously published results it can be seen that the 
NN mapping and Discretisation have a higher performance in terms of AUC of a ROC 
curve. The obtained results demonstrate how data integration methods for model cross-
validation can have a significant increase in the generalisation performance, and enable 
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previously developed models to be used in different patient cohorts. Despite the fact 
that more information can be extracted from microarray models, the generalisation issue 
makes them still unreliable for clinicians. 
The generalisation performance of the predictive methods is the main limitation of this 
study.  
  The limitations of this study are given by the nature of microarray data: missing 
values, noise or error from scanners. The results obtained from this study are data-
dependent and are closely related to the quality of the microarray data. It must not be 
forgotten that the different analysis techniques applied in this study are not a remedy for 
low quality data.   
7.1 Future research directions 
 The work conducted revealed a number of weaknesses of existing 
methodologies (hence engineering challenges) for the reliable prediction of cancer from 
the clustering methods, input selection or the model selected to make the prediction.  
As explained in Chapter 2 of this Thesis, every aspect of the a data-driven 
modelling approach is important and in the past years it was discovered how 
normalisation can affect significantly the data, the number of inputs a method can work 
with (complexity dependant) and asses predictive performance via a Neural-Fuzzy 
approach. Even though the presented methodology is produced via the use of 
microarray bladder cancer data as a case study, this method may also be applied to 
numerous other diseases.  
 The aim of future work might consist of using the developed input selection and 
new modelling techniques to construct a multidimensional Patient Prognostic Map. This 
‘map’ will be a framework that uses the developed hybrid model, the gene selection, 
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and expert knowledge to provide to the clinicians linguistic advice on cancer 
progression.  
7.1.1 Future research directions for the RBF NF model 
i. Fusion the microarray data with clinical screening data as well as temporal 
data (hybrid model) 
 The aim is to integrate the microarray data with clinical screening data and 
Temporal Data (hybrid model). The term Temporal Data refers to a new design of 
experiments, in which a number of individuals of various cell classes are involved and 
gene expression is measured for each individual during a time course. In other words, 
the new experiments measure temporal gene expression multiple times for each cell 
class, but each time the measurement is performed on different individuals of that cell 
class. 
 As described above a hybrid model will be built based on the combination of the 
data sets, however expert knowledge will need to be embedded into the system to allow 
the fusion of the two sources of information. Furthermore, Fuzzy Fusion approach will 
be used to amalgamate all the information produced by the modelling scheme (patient 
map) and present this in a linguistic form.  
ii. Use a diagnosis of stage/grade/survival and based on that diagnosis to inform 
a treatment therapy 
 Based in the Predictions of survival, a Medical Diagnosis tool can be developed 
to assist therapy and treatment for the disease. 
  The prediction of the malignancy of the cancer will help to avoid unnecessary 
surgery, improving the life quality of the patient by only receiving absolutely necessary 
treatment for the disease. Another important improvement is the reduction in the overall 
therapy costs. 
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Figure 7.1 shows the overall architecture of the Multidimensional Patient Prognostic 
Map.  
 
Figure 7.1: Multidimensional Patient Prognostic Maps 
  In Figure 7.1, a diagram that represents the model is shown. The data to analyse 
comes from the fusion of Microarrays data set, clinical screening and Temporal Data. 
The fusion is possible thanks to the Medical knowledge and the Systems approach 
work. The role of the Medical expertise is going to be needed to help us amalgamate the 
medical screenings with the data sets and based on that fusion develop the Patient Maps. 
The proposed model is going to predict Stage, Grade and Survival based on that 
prediction a Clinical Diagnosis and Therapy will be develop.  
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7.1.2 Future research directions for microarray analysis  
 The generalisation performance of new predictive methods needs to be studied. 
As discussed in this Thesis, the real test for most data-driven cancer prediction models 
is the test of generalisation, i.e. when the model is confronted with a new patient cohort. 
The healthcare professionals community (medical, biology, chemistry, and engineering) 
is required to work together to produce a standard that unifies the analysis of tissue 
samples, image processing, normalisation and representation of gene intensities. 
  There are problems with microarray that perhaps will never get solved; however 
there is still place for improvement, for example:  
 Noise or error from scanners need to be reduced to the minimum 
 Reduction of the number of missing gene expression values  
 Because microarray analysis has been conducted since several years ago, it is 
important to re-use different studies (data sets) and validate the results previously 
obtained. It is also important to continue the research in the area of meta-analysis and 
data integration methods towards robust classification results.    
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Appendix A 
Results with 1000 inputs and 5 rules 
Ninety (90) of the included genes that are related with bladder cancer are: Gene NOS2, 
PRKCD, ALOX5, RBM3, CREBBP, RANBP3, GLB1, UQCRC2, CSE1L, GAST, 
HNRNPM, CSRP1, ASB8, SH3BGR, S100A7, MIF, HADHB, FER, HIF1AN, RGS2, 
LDHB, ENAH, MXD1, PRKACA, F3, ADA, CCL5, MVP, UPK2, IRF1, AR, TDG, 
CALU, MGMT, POLD1, AFF3, BCHE, XBP1, USP22, S100A10, ST3GAL1, VEGFA, 
HLA-B, CDCP1, GH2, ALDH1A2, CEACAM3, GALNS, HOPX, ADRB3, 
SERPINE1, STAT6, KIF20B, DNM2, FOXC1, SEMA3C, GABPB1, SOAT2, TNC, 
PPARG, TRADD, ITFG1, EGR1, NR3C1, OPCML, NAE1, ARHGDIB, POU4F2, 
MAP3K11, SEMA3A, JUN, MUC5B, TBX21, IGF1, DMBT1, DUSP10, ERCC3, 
IRF2, TP63, LGALS1, KLF4, PRDX3, DRAM1, MMP9, RECQL4, RPA2, LRP6, 
CAV2, AMACR, ME1.  
Results with 2000 inputs and 5 rules 
Additionally, 181 of the included genes that are related with bladder cancer are: Gene 
SUN2, SCYL2, BLNK, RHOC, HSPD1, FAAH, MMP11, TXNRD1, POLR2C, 
LZTS1, RNASE4, HLA-DRA, CDT1, AREG, IGFBP6, PLD3, IMP3, TLR4, GRHL2, 
NOTCH1, LEPREL4, L1TD1, PDE2A, ZNF135, MED12, CANT1, RNF43, HNF1A, 
EPCAM, FILIP1L, CALCOCO2, CCNE2, ATP5B, LGALS8, CST3, MSN, TEK, 
SCAMP3, ATPAF2, FIBP, PPFIBP1, SOCS3, TRPV2, CTH, CD59, EDNRA, S100A8, 
KAT7, ALPK3, LUM, MTHFR, USH2A, CYR61, XDH, PCDH17, ACVRL1, 
SLCO1B3, WWOX, RARB, SETD2, TERF2, ENPEP, NNMT, OXCT1,ERO1LB, 
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SULT1A1, YBX1, IL1R1,GDF9, TP73, FANCE, SHH, TP53I3, SULT1A2, HNF1B, 
DDX21, RCOR1, MAP4, RHOA, SELP, ACADM, EREG, MME, RAB15, ATPIF1, 
IL12A, GLIPR1, BMP6, CD44, SLIT2, FHIT, OS9, DIO2, BIRC7, FGF6, EIF3I, 
CD81, PSG1, HSPA4, SOX9, NID2, PLK2, HSP90B1, PBX3, RHOT1, FLNA, NQO1, 
CCL21, FGF1, MUC7, TERF1, OGT, NR5A1, TERT, ENO2, AKR1B10, TPM2, 
PSMB5, TAGLN, LY75, SRRM1, NCL, ADRA1A, TOP2A, F11R, ATP1A1, 
KIR2DS4, PDGFRB, OPRD1, GEMIN4, ESRP2, THBS2, DSP,TNKS, NFIL3, 
RANGAP1, PRKCSH, DES, ABCC4, 7-Sep, CAV1, COL1A1, STC1, HSPBAP1, 
WDR47, DFFB, TOMM34, CGA, TRAP1, TRIT1, POU5F1B, ZNF143, TAPBP, GLS, 
POLQ, GSTM5, STAM, CASK, CAT, FOXA1, FAH, PLAU, ACAT2, RACGAP1, 
GTF2I, MYH9, NFKBIB, PIN1, NR2F6, RGS6, GAA, CXADR, PAK6, RPA3, ADD3, 
IGFBP2, HRH1, CD36, MT3, VEGFC, CASP8. 
Results with 5000 inputs and 5 rules  
 The Gene Signature obtained for the prediction of Survival contains the 5000 top 
ranked genes. A total of eight hundred and thirty eight (838) of the included genes that 
are related to bladder cancer are shown in Appendix A. 
Table A.1:  Genes related with Bladder Cancer 
 Genes related with Bladder Cancer 
1 2,4-dienoyl CoA reductase 1, mitochondrial 
2 24-dehydrocholesterol reductase 
3 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled 
4 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled 
5 A kinase (PRKA) anchor protein 13 
6 actin related protein 2/3 complex, subunit 1B, 41kDa 
7 actin related protein 2/3 complex, subunit 2, 34kDa 
8 actin, alpha, cardiac muscle 1 
9 actinin, alpha 1 
10 activin A receptor type II-like 1 
11 ADAM metallopeptidase domain 12 
12 ADAM metallopeptidase with thrombospondin type 1 motif, 1 
13 adducin 3 (gamma) 
Appendix A                            189 
 
 
 
14 adenosine deaminase 
15 adenylate cyclase 10 (soluble) 
16 adrenergic, beta, receptor kinase 2 
17 adrenoceptor alpha 1A 
18 adrenoceptor beta 3 
19 AE binding protein 1 
20 AHNAK nucleoprotein 
21 aldehyde dehydrogenase 1 family, member A2 
22 aldehyde dehydrogenase 1 family, member A3 
23 aldehyde dehydrogenase 3 family, member A2 
24 aldo-keto reductase family 1, member A1 (aldehyde reductase) 
25 aldo-keto reductase family 1, member B10 (aldose reductase) 
26 aldolase A, fructose-bisphosphate 
27 alkaline phosphatase, placental  
28 alpha-1-microglobulin/bikunin precursor 
29 alpha-methylacyl-CoA racemase 
30 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 
31 aminolevulinate, delta-, synthase 1 
32 amphiregulin 
33 amyloid beta (A4) precursor protein 
34 anaphase promoting complex subunit 5 
35 androgen receptor 
36 angiogenin, ribonuclease, RNase A family, 5 
37 angiopoietin-like 2 
38 angiotensin II receptor, type 1 
39 annexin A1 
40 annexin A10 
41 annexin A5 
42 anthrax toxin receptor 1 
43 apolipoprotein A-I 
44 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A 
45 apoptotic chromatin condensation inducer 1 
46 apoptotic peptidase activating factor 1 
47 aquaporin 8 
48 arachidonate 5-lipoxygenase 
49 arginine and glutamate rich 1 
50 argininosuccinate synthase 1 
51 ARP2 actin-related protein 2 homolog (yeast) 
52 ataxia telangiectasia mutated 
53 ATP citrate lyase 
54 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 
55 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1 
56 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit 9) 
57 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit d 
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58 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6 
59 ATPase inhibitory factor 1 
60 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
61 ATPase, Cu++ transporting, alpha polypeptide 
62 ATPase, Cu++ transporting, beta polypeptide 
63 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
64 ATP-binding cassette, sub-family A (ABC1), member 7 
65 ATP-binding cassette, sub-family B (MDR/TAP), member 6 
66 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 
67 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 
68 aurora kinase A 
69 AXL receptor tyrosine kinase 
70 baculoviral IAP repeat containing 7 
71 basic helix-loop-helix family, member e40 
72 basic leucine zipper and W2 domains 1 
73 B-cell CLL/lymphoma 11A (zinc finger protein) 
74 BCL2-antagonist/killer 1 
75 BCL2-associated agonist of cell death 
76 BCL2-associated X protein 
77 BCL2-like 1 
78 BCL2-like 10 (apoptosis facilitator) 
79 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) 
80 betaine--homocysteine S-methyltransferase 
81 Bloom syndrome, RecQ helicase-like 
82 bone marrow stromal cell antigen 2 
83 bone morphogenetic protein 6 
84 bone morphogenetic protein 7 
85 bone morphogenetic protein receptor, type II (serine/threonine kinase) 
86 bradykinin receptor B2 
87 brain-derived neurotrophic factor 
88 BRCA1 associated RING domain 1 
89 breakpoint cluster region 
90 breast cancer 1, early onset 
91 breast cancer metastasis suppressor 1 
92 butyrylcholinesterase 
93 Ca++-dependent secretion activator 
94 cadherin 11, type 2, OB-cadherin (osteoblast) 
95 cadherin 2, type 1, N-cadherin (neuronal) 
96 cadherin 3, type 1, P-cadherin (placental) 
97 calcium binding and coiled-coil domain 2 
98 calcium/calmodulin-dependent serine protein kinase (MAGUK family) 
99 calcium-sensing receptor 
100 caldesmon 1 
101 calmodulin binding transcription activator 1 
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102 calpain 1, (mu/I) large subunit 
103 calpain 2, (m/II) large subunit 
104 calpastatin 
105 calumenin 
106 cannabinoid receptor 1 (brain) 
107 CAP, adenylate cyclase-associated protein 1 (yeast) 
108 carboxypeptidase A3 (mast cell) 
109 carboxypeptidase E 
110 carcinoembryonic antigen-related cell adhesion molecule 3 
111 carcinoembryonic antigen-related cell adhesion molecule 5 
112 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting 
antigen) 
113 casein kinase 1, alpha 1 
114 casein kinase 1, delta 
115 caspase 10, apoptosis-related cysteine peptidase 
116 caspase 2, apoptosis-related cysteine peptidase 
117 caspase 8, apoptosis-related cysteine peptidase 
118 catalase 
119 catenin (cadherin-associated protein), beta 1, 88kDa 
120 cathelicidin antimicrobial peptide 
121 cathepsin H 
122 cathepsin S 
123 caudal type homeobox 1 
124 caveolin 1, caveolae protein, 22kDa 
125 caveolin 2 
126 CCCTC-binding factor (zinc finger protein) 
127 CD164 molecule, sialomucin 
128 CD36 molecule (thrombospondin receptor) 
129 CD3e molecule, epsilon associated protein 
130 CD4 molecule 
131 CD40 molecule, TNF receptor superfamily member 5 
132 CD44 molecule (Indian blood group) 
133 CD59 molecule, complement regulatory protein 
134 CD81 molecule 
135 CD82 molecule 
136 CD99 molecule 
137 cellular retinoic acid binding protein 1 
138 chaperonin containing TCP1, subunit 2 (beta) 
139 chaperonin containing TCP1, subunit 3 (gamma) 
140 chaperonin containing TCP1, subunit 4 (delta) 
141 chaperonin containing TCP1, subunit 6A (zeta 1) 
142 chaperonin containing TCP1, subunit 7 (eta) 
143 checkpoint kinase 1 
144 chemokine (C-C motif) ligand 2 
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145 chemokine (C-C motif) ligand 21 
146 chemokine (C-C motif) ligand 22 
147 chemokine (C-C motif) ligand 5 
148 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 
149 chitinase 3-like 1 (cartilage glycoprotein-39) 
150 chloride channel accessory 2 
151 chloride intracellular channel 4 
152 cholecystokinin B receptor 
153 choline kinase alpha 
154 choline O-acetyltransferase 
155 cholinergic receptor, muscarinic 3 
156 chromodomain helicase DNA binding protein 1-like 
157 citrate synthase 
158 clathrin, heavy chain (Hc) 
159 clathrin, light chain A 
160 claudin 10 
161 CNDP dipeptidase 2 (metallopeptidase M20 family) 
162 coagulation factor II (thrombin) receptor-like 2 
163 coagulation factor III (thromboplastin, tissue factor) 
164 coatomer protein complex, subunit alpha 
165 collagen, type I, alpha 1 
166 collagen, type V, alpha 1 
167 collagen, type VI, alpha 1 
168 collagen, type VI, alpha 2 
169 collagen, type VI, alpha 3 
170 collagen, type VII, alpha 1 
171 collagen, type XVI, alpha 1 
172 colony stimulating factor 1 (macrophage) 
173 complement component 1, q subcomponent binding protein 
174 contactin 2 (axonal) 
175 cortactin 
176 coxsackie virus and adenovirus receptor 
177 c-ros oncogene 1 , receptor tyrosine kinase 
178 crystallin, alpha B 
179 CSE1 chromosome segregation 1-like (yeast) 
180 C-terminal binding protein 1 
181 cyclin A1 
182 cyclin A2 
183 cyclin B2 
184 cyclin E2 
185 cyclin G1 
186 cyclin L1 
187 cyclin-dependent kinase 2 associated protein 1 
188 cyclin-dependent kinase 4 
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189 cyclin-dependent kinase 7 
190 cyclin-dependent kinase inhibitor 1C (p57, Kip2) 
191 cystathionase (cystathionine gamma-lyase) 
192 cystatin C 
193 cysteine and glycine-rich protein 1 
194 cysteine-rich, angiogenic inducer, 61 
195 cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family 
C, member 7) 
196 cytochrome c oxidase subunit VIc 
197 cytochrome P450, family 1, subfamily A, polypeptide 2 
198 cytochrome P450, family 2, subfamily A, polypeptide 13 
199 cytochrome P450, family 2, subfamily C, polypeptide 19 
200 cytochrome P450, family 2, subfamily D, polypeptide 6 
201 cytochrome P450, family 4, subfamily B, polypeptide 1 
202 cytochrome P450, family 7, subfamily B, polypeptide 1 
203 damage-specific DNA binding protein 2, 48kDa 
204 dCMP deaminase 
205 DEAH (Asp-Glu-Ala-His) box polypeptide 35 
206 death associated protein 3 
207 death-associated protein 
208 death-associated protein kinase 1 
209 death-associated protein kinase 2 
210 deiodinase, iodothyronine, type I 
211 deleted in malignant brain tumors 1 
212 desmin 
213 desmoglein 3 
214 desmoplakin 
215 destrin (actin depolymerizing factor) 
216 dihydropyrimidinase-like 3 
217 DNA (cytosine-5-)-methyltransferase 1 
218 DNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated DNase) 
219 DnaJ (Hsp40) homolog, subfamily B, member 1 
220 dopamine beta-hydroxylase (dopamine beta-monooxygenase) 
221 dopamine receptor D2 
222 drosha, ribonuclease type III 
223 dual specificity phosphatase 1 
224 dynamin 2 
225 E2F transcription factor 1 
226 E2F transcription factor 3 
227 early growth response 1 
228 ectonucleoside triphosphate diphosphohydrolase 3 
229 ectonucleoside triphosphate diphosphohydrolase 4 
230 EGF containing fibulin-like extracellular matrix protein 1 
231 EGF containing fibulin-like extracellular matrix protein 2 
Appendix A                            194 
 
 
 
232 EGF-like repeats and discoidin I-like domains 3 
233 EGF-like-domain, multiple 6 
234 ELK1, member of ETS oncogene family 
235 enabled homolog (Drosophila) 
236 endothelin 1 
237 endothelin receptor type A 
238 endothelin receptor type B 
239 enolase 2 (gamma, neuronal) 
240 EPH receptor B4 
241 ephrin-A1 
242 epidermal growth factor receptor 
243 epidermal growth factor receptor pathway substrate 8 
244 epiregulin 
245 epithelial cell adhesion molecule 
246 epithelial membrane protein 1 
247 epoxide hydrolase 2, cytoplasmic 
248 ERGIC and golgi 3 
249 estrogen receptor 1 
250 estrogen receptor 2 (ER beta) 
251 eukaryotic translation elongation factor 2 
252 eukaryotic translation initiation factor 3, subunit I 
253 eukaryotic translation initiation factor 4 gamma, 2 
254 eukaryotic translation initiation factor 4E binding protein 1 
255 eukaryotic translation initiation factor 4H 
256 eukaryotic translation initiation factor 5 
257 eukaryotic translation initiation factor 5A 
258 ezrin 
259 family with sequence similarity 215, member A (non-protein coding) 
260 Fanconi anemia, complementation group A 
261 Fanconi anemia, complementation group F 
262 far upstream element (FUSE) binding protein 1 
263 far upstream element (FUSE) binding protein 3 
264 fatty acid amide hydrolase 
265 fatty acid binding protein 1, liver 
266 FBJ murine osteosarcoma viral oncogene homolog B 
267 fer (fps/fes related) tyrosine kinase 
268 ferrochelatase 
269 fibrillarin 
270 fibroblast growth factor 1 (acidic) 
271 fibroblast growth factor 6 
272 fibroblast growth factor 7 
273 fibroblast growth factor receptor 3 
274 filamin A interacting protein 1-like 
275 filamin A, alpha 
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276 FK506 binding protein 4, 59kDa 
277 folate hydrolase (prostate-specific membrane antigen) 1 
278 folate receptor 1 (adult) 
279 follistatin-like 1 
280 forkhead box A1 
281 forkhead box C1 
282 fragile histidine triad 
283 fructose-1,6-bisphosphatase 1 
284 fucosidase, alpha-L- 1, tissue 
285 fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group) 
286 fucosyltransferase 6 (alpha (1,3) fucosyltransferase) 
287 fused in sarcoma 
288 FXYD domain containing ion transport regulator 1 
289 FXYD domain containing ion transport regulator 3 
290 FYN oncogene related to SRC, FGR, YES 
291 G protein-coupled estrogen receptor 1 
292 galactosamine (N-acetyl)-6-sulfate sulfatase 
293 gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
294 gap junction protein, alpha 1, 43kDa 
295 gastrin 
296 GDP-mannose 4,6-dehydratase 
297 gem (nuclear organelle) associated protein 4 
298 general transcription factor IIi 
299 GLI family zinc finger 1 
300 GLI family zinc finger 3 
301 GLI pathogenesis-related 1 
302 glioma tumor suppressor candidate region gene 2 
303 glucan (1,4-alpha-), branching enzyme 1 
304 glutamic-pyruvate transaminase (alanine aminotransferase) 
305 glutaminase 
306 glutamyl aminopeptidase (aminopeptidase A) 
307 glutamyl-prolyl-tRNA synthetase 
308 glutathione peroxidase 1 
309 glutathione peroxidase 2 (gastrointestinal) 
310 glutathione peroxidase 3 (plasma) 
311 glutathione reductase 
312 glutathione S-transferase alpha 3 
313 glutathione S-transferase alpha 4 
314 glutathione S-transferase pi 1 
315 glyceraldehyde-3-phosphate dehydrogenase 
316 glycoprotein (transmembrane) nmb 
317 glycoprotein hormones, alpha polypeptide 
318 golgi phosphoprotein 3 (coat-protein) 
319 gonadotropin-releasing hormone receptor 
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320 granulin 
321 growth arrest and DNA-damage-inducible, beta 
322 growth differentiation factor 15 
323 growth differentiation factor 9 
324 growth hormone 2 
325 growth hormone inducible transmembrane protein 
326 growth hormone receptor 
327 guanine nucleotide binding protein (G protein), gamma 11 
328 guanosine monophosphate reductase 2 
329 guanylate kinase 1 
330 H2A histone family, member X 
331 H3 histone, family 3A 
332 heat shock 60kDa protein 1 (chaperonin) 
333 heat shock 70kDa protein 4 
334 heat shock protein 90kDa alpha (cytosolic), class A member 1 
335 heat shock protein 90kDa alpha (cytosolic), class B member 1 
336 heat shock protein 90kDa beta (Grp94), member 1 
337 hemochromatosis 
338 heparanase 
339 heparin-binding EGF-like growth factor 
340 hepatocyte growth factor (hepapoietin A; scatter factor) 
341 heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 
37kDa) 
342 heterogeneous nuclear ribonucleoprotein D-like 
343 heterogeneous nuclear ribonucleoprotein F 
344 heterogeneous nuclear ribonucleoprotein H1 (H) 
345 high density lipoprotein binding protein 
346 high mobility group box 1 
347 histamine receptor H1 
348 histone deacetylase 9 
349 HNF1 homeobox B 
350 HOP homeobox 
351 HSPB (heat shock 27kDa) associated protein 1 
352 HtrA serine peptidase 1 
353 hyaluronan synthase 2 
354 hyaluronan-mediated motility receptor (RHAMM) 
355 hyaluronoglucosaminidase 1 
356 hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), beta subunit 
357 hydroxyprostaglandin dehydrogenase 15-(NAD) 
358 hydroxysteroid (17-beta) dehydrogenase 2 
359 hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) 
360 hypoxia inducible factor 1, alpha subunit inhibitor 
361 immunoglobulin superfamily containing leucine-rich repeat 
362 InaD-like (Drosophila) 
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363 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
364 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 
365 inositol 1,4,5-trisphosphate receptor, type 1 
366 inositol hexakisphosphate kinase 2 
367 insulin receptor 
368 insulin receptor substrate 1 
369 insulin-like growth factor 1 (somatomedin C) 
370 insulin-like growth factor 1 receptor 
371 insulin-like growth factor 2 mRNA binding protein 3 
372 insulin-like growth factor binding protein 2, 36kDa 
373 insulin-like growth factor binding protein 3 
374 insulin-like growth factor binding protein 6 
375 integrin alpha FG-GAP repeat containing 1 
376 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
377 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
378 integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; 
alpha polypeptide) 
379 integrin, alpha V 
380 integrin, beta 5 
381 integrin-linked kinase 
382 intercellular adhesion molecule 2 
383 interferon regulatory factor 1 
384 interferon regulatory factor 3 
385 interferon, gamma 
386 interleukin 1 receptor antagonist 
387 interleukin 1 receptor, type I 
388 interleukin 1, alpha 
389 interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte 
maturation factor 1, p35) 
390 interleukin 13 
391 interleukin 17 receptor A 
392 interleukin 17A 
393 interleukin 5 (colony-stimulating factor, eosinophil) 
394 interleukin 6 (interferon, beta 2) 
395 interleukin 6 signal transducer (gp130, oncostatin M receptor) 
396 interleukin 7 receptor 
397 interleukin 8 
398 interleukin enhancer binding factor 3, 90kDa 
399 ISL LIM homeobox 1 
400 Janus kinase 1 
401 jumping translocation breakpoint 
402 jun proto-oncogene 
403 karyopherin (importin) beta 1 
404 keratin 1 
405 keratin 14 
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406 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 4 
407 kinesin family member 16B 
408 kinesin family member 20B 
409 Kruppel-like factor 4 (gut) 
410 Kruppel-like factor 5 (intestinal) 
411 lactate dehydrogenase B 
412 laminin, alpha 3 
413 laminin, beta 2 (laminin S) 
414 laminin, gamma 2 
415 laminin, gamma 3 
416 latent transforming growth factor beta binding protein 1 
417 lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase) 
418 lectin, galactoside-binding, soluble, 1 
419 lectin, galactoside-binding, soluble, 3 binding protein 
420 lectin, galactoside-binding, soluble, 8 
421 lectin, galactoside-binding, soluble, 9 
422 legumain 
423 leucine zipper, putative tumor suppressor 1 
424 ligase IV, DNA, ATP-dependent 
425 LIM domain and actin binding 1 
426 LIM domain only 2 (rhombotin-like 1) 
427 LINE-1 type transposase domain containing 1 
428 lipase, hepatic 
429 lipocalin 2 
430 lipopolysaccharide-induced TNF factor 
431 low density lipoprotein receptor-related protein 5 
432 low density lipoprotein receptor-related protein 6 
433 low density lipoprotein receptor-related protein associated protein 1 
434 lumican 
435 lymphocyte antigen 6 complex, locus E 
436 lymphocyte antigen 75 
437 lysosomal-associated membrane protein 2 
438 lysozyme 
439 lysyl-tRNA synthetase 
440 macrophage migration inhibitory factor (glycosylation-inhibiting factor) 
441 major histocompatibility complex, class I, A 
442 major histocompatibility complex, class I, B 
443 major histocompatibility complex, class II, DR alpha 
444 major intrinsic protein of lens fiber 
445 major vault protein 
446 mannose-binding lectin (protein C) 2, soluble 
447 mannose-P-dolichol utilization defect 1 
448 MAP7 domain containing 1 
449 MAP-kinase activating death domain 
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450 matrix Gla protein 
451 matrix metallopeptidase 10 (stromelysin 2) 
452 matrix metallopeptidase 11 (stromelysin 3) 
453 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 
454 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) 
455 mechanistic target of rapamycin (serine/threonine kinase) 
456 melanoma antigen family D, 2 
457 membrane metallo-endopeptidase 
458 metallothionein 1F 
459 metallothionein 1X 
460 metallothionein 2A 
461 metallothionein 3 
462 metastasis suppressor 1 
463 methyl CpG binding protein 2 (Rett syndrome) 
464 methylenetetrahydrofolate reductase (NAD(P)H) 
465 microtubule-associated protein 4 
466 midkine (neurite growth-promoting factor 2) 
467 mitochondrial calcium uptake 1 
468 mitogen-activated protein kinase 3 
469 mitogen-activated protein kinase 8 
470 mitogen-activated protein kinase associated protein 1 
471 mitogen-activated protein kinase kinase 2 
472 mitogen-activated protein kinase kinase 4 
473 mitogen-activated protein kinase kinase 7 
474 moesin 
475 mortality factor 4 like 2 
476 motilin 
477 mucin 16, cell surface associated 
478 mucin 3A, cell surface associated 
479 mucin 5B, oligomeric mucus/gel-forming 
480 mucin 7, secreted 
481 SDA1 domain containing 1 
482 RAB5B, member RAS oncogene family 
483 aldo-keto reductase family 1, member A1 (aldehyde reductase) 
484 growth arrest-specific 7 
485 downstream neighbor of SON 
486 insulin induced gene 2 
487 makorin ring finger protein 2 
488 mitogen-activated protein kinase kinase kinase kinase 4 
489 bystin-like 
490 SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) 
491 small nucleolar RNA, H/ACA box 5B /// transforming growth factor beta regulator 4 
492 transmembrane and ubiquitin-like domain containing 2 
493 NKF3 kinase family member 
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494 gon-4-like (C. elegans) 
495 transmembrane protease, serine 11D 
496 BAH domain and coiled-coil containing 1 
497 transient receptor potential cation channel, subfamily C, member 1 
498 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 
499 peptidase domain containing associated with muscle regeneration 1 
500 myosin, light chain 12A, regulatory, non-sarcomeric 
501 A kinase (PRKA) anchor protein 17A 
502 transmembrane protein 120B 
503 HLA complex group 26 (non-protein coding) 
504 nitric oxide synthase 2, inducible 
505 uncharacterized FLJ13197 
506 proteasome (prosome, macropain) subunit, beta type, 10 
507 protein kinase C, delta 
508 KN motif and ankyrin repeat domains 2 
509 transmembrane protein 126B 
510 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, 
subunit 1 
511 paired related homeobox 2 
512 thiosulfate sulfurtransferase (rhodanese) 
513 visinin-like 1 
514 arachidonate 5-lipoxygenase 
515 collagen, type VI, alpha 3 
516 DEAD (Asp-Glu-Ala-Asp) box polypeptide 19A 
517 calcineurin binding protein 1 
518 dickkopf 3 homolog (Xenopus laevis) 
519 GTP binding protein 3 (mitochondrial) 
520 RNA binding motif (RNP1, RRM) protein 3 
521 DnaJ (Hsp40) homolog, subfamily C, member 28 
522 ABHD14A-ACY1 readthrough (non-protein coding) /// aminoacylase 1 
523 CREB binding protein 
524 chromosome 5 open reading frame 25 pseudogene 
525 lysine-rich coiled-coil 1 
526 ubiquitin-like 4A 
527 LIM homeobox 3 
528 HAUS augmin-like complex, subunit 4 /// microRNA 4707 
529 complement component 8, alpha polypeptide 
530 zinc finger protein 329 
531 integrin, beta 5 
532 Yes-associated protein 1 
533 neuronal pentraxin I 
534 FRY-like 
535 fermitin family member 1 
536 SMAD specific E3 ubiquitin protein ligase 2 
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537 solute carrier family 7 (orphan transporter), member 4 
538 uncharacterized LOC100508797 
539 chromosome 3 open reading frame 36 
540 myomesin 1, 185kDa 
541 small proline-rich protein 1B 
542 MOK protein kinase 
543 tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death 
domain 
544 ring finger protein 114 
545 spermine synthase 
546 N-acetylated alpha-linked acidic dipeptidase-like 1 
547 secretoglobin, family 2A, member 1 
548 RAN binding protein 3 
549 MANSC domain containing 1 
550 myosin, light chain 1, alkali; skeletal, fast 
551 zinc finger protein 711 
552 RALY RNA binding protein-like 
553 adrenoceptor alpha 2A 
554 RAB8A, member RAS oncogene family 
555 chromodomain helicase DNA binding protein 8 
556 potassium channel tetramerisation domain containing 15 
557 four and a half LIM domains 5 
558 galactosidase, beta 1 
559 ubiquinol-cytochrome c reductase core protein II 
560 thromboxane A2 receptor 
561 transmembrane protein 30A 
562 TRM1 tRNA methyltransferase 1 homolog (S. cerevisiae) 
563 leucine rich repeat containing 41 
564 CSE1 chromosome segregation 1-like (yeast) 
565 protein phosphatase 1, regulatory subunit 16B 
566 early growth response 3 
567 complexin 2 
568 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 
569 ATP-binding cassette, sub-family B (MDR/TAP), member 8 
570 zinc finger CCCH-type containing 3 
571 methyl-CpG binding domain protein 1 
572 RNA binding motif protein 14 
573 pleckstrin homology domain containing, family G (with RhoGef domain) member 6 
574 secretoglobin, family 1A, member 1 (uteroglobin) 
575 TM2 domain containing 3 
576 kallikrein-related peptidase 13 
577 ankyrin repeat and SOCS box containing 6 
578 coiled-coil domain containing 22 
579 proteasome (prosome, macropain) inhibitor subunit 1 (PI31) 
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580 immunoglobulin lambda light chain-like 
581 single-stranded DNA binding protein 2 
582 gastrin 
583 cyclin-dependent kinase 10 
584 homeobox A6 
585 protein phosphatase 1, regulatory subunit 9A 
586 heterogeneous nuclear ribonucleoprotein M 
587 astrotactin 2 
588 tumor necrosis factor receptor superfamily, member 12A 
589 tyrosyl-tRNA synthetase 2, mitochondrial 
590 zinc finger, CW type with PWWP domain 1 
591 cysteine and glycine-rich protein 1 
592 nascent polypeptide-associated complex alpha subunit 2 
593 myosin light chain kinase 
594 DiGeorge syndrome critical region gene 11 (non-protein coding) 
595 glutamate receptor, ionotropic, N-methyl D-aspartate 2D 
596 THAP domain containing 7 
597 ankyrin repeat and SOCS box containing 8 
598 DDB1 and CUL4 associated factor 10 
599 chromodomain helicase DNA binding protein 1-like 
600 centrosomal protein 250kDa 
601 transcription elongation factor A (SII), 1 
602 RWD domain containing 2A 
603 F-box protein 5 
604 tubulin, alpha 1c 
605 MAP7 domain containing 3 
606 transcription factor 4 
607 chromosome 15 open reading frame 39 
608 nucleolar protein 10 
609 SH3 domain binding glutamic acid-rich protein 
610 S100 calcium binding protein A7 
611 fructosamine 3 kinase 
612 protein phosphatase 3, catalytic subunit, alpha isozyme 
613 leucine rich repeat containing 19 
614 fibronectin leucine rich transmembrane protein 1 
615 ribosomal protein L9 
616 ADP-ribosylation factor-like 4A 
617 MON1 homolog B (yeast) 
618 cryptochrome 2 (photolyase-like) 
619 exocyst complex component 7 
620 ring finger protein 139 
621 chromosome 19 open reading frame 80 
622 adaptor-related protein complex 3, sigma 2 subunit /// C15orf38-AP3S2 readthrough 
623 twinfilin, actin-binding protein, homolog 2 (Drosophila) 
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624 PBX/knotted 1 homeobox 1 
625 macrophage migration inhibitory factor (glycosylation-inhibiting factor) 
626 deoxyribonuclease I-like 2 
627 frizzled family receptor 2 
628 lysophosphatidic acid receptor 2 
629 heterogeneous nuclear ribonucleoprotein H2 (H) /// RPL36A-HNRNPH2 readthrough 
630 fucosyltransferase 5 (alpha (1,3) fucosyltransferase) 
631 gonadotropin-releasing hormone 2 
632 exosome component 1 
633 gremlin 2 
634 phosphorylase kinase, gamma 1 (muscle) 
635 blocked early in transport 1 homolog (S. cerevisiae)-like 
636 SMAD family member 7 
637 T-cell lymphoma invasion and metastasis 2 
638 hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase 
(trifunctional protein), beta subunit 
639 fer (fps/fes related) tyrosine kinase 
640 hypoxia inducible factor 1, alpha subunit inhibitor 
641 regulator of G-protein signaling 2, 24kDa 
642 lactate dehydrogenase B 
643 vav 1 guanine nucleotide exchange factor 
644 FtsJ methyltransferase domain containing 2 
645 microRNA 1292 /// NOP56 ribonucleoprotein homolog (yeast) /// small nucleolar RNA, 
C/D box 110 /// small nucleolar RNA, C/D box 57 /// small nucleolar RNA, C/D box 86 
646 enabled homolog (Drosophila) 
647 MAX dimerization protein 1 
648 SET binding protein 1 
649 PR domain containing 4 
650 partner of NOB1 homolog (S. cerevisiae) 
651 G protein-coupled receptor 161 
652 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 
653 TBC1 domain family, member 29 
654 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1 /// 
killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 /// 
killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 3 /// 
killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 4 /// 
killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5 /// 
killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 3 
655 T-box 4 
656 X antigen family, member 1A /// X antigen family, member 1B /// X antigen family, 
member 1C /// X antigen family, member 1D /// X antigen family, member 1E 
657 polymerase (RNA) III (DNA directed) polypeptide E (80kD) 
658 trafficking protein particle complex 12 
659 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 
660 protein kinase, cAMP-dependent, catalytic, alpha 
661 coagulation factor III (thromboplastin, tissue factor) 
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662 multimerin 2 
663 N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 
664 bicaudal C homolog 1 (Drosophila) 
665 potassium channel, subfamily K, member 15 
666 olfactory receptor, family 1, subfamily G, member 1 
667 sphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase) 
668 PH domain and leucine rich repeat protein phosphatase 2 
669 midkine (neurite growth-promoting factor 2) 
670 protein tyrosine phosphatase, non-receptor type 6 
671 gasdermin D 
672 pleckstrin homology-like domain, family A, member 2 
673 zinc finger protein 292 
674 adenosine deaminase 
675 ATP-binding cassette, sub-family F (GCN20), member 1 
676 misato homolog 1 (Drosophila) /// misato homolog 2 pseudogene 
677 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) 
678 myotubularin related protein 2 
679 ER degradation enhancer, mannosidase alpha-like 3 
680 amyloid beta (A4) precursor-like protein 1 
681 chemokine (C-C motif) ligand 5 
682 DEAD (Asp-Glu-Ala-Asp) box polypeptide 19A /// DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 19B 
683 spermatogenesis associated 1 
684 major vault protein 
685 5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled 
686 poly(rC) binding protein 1 
687 chondroitin polymerizing factor 
688 aspartyl aminopeptidase 
689 enhancer of rudimentary homolog (Drosophila) 
690 bolA homolog 1 (E. coli) 
691 coiled-coil domain containing 144A 
692 ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 
693 uroplakin 2 
694 interferon regulatory factor 1 
695 CD96 molecule 
696 ubiquitin protein ligase E3 component n-recognin 5 
697 androgen receptor 
698 thymine-DNA glycosylase 
699 endothelial PAS domain protein 1 /// uncharacterized LOC100652809 
700 CDKN2A interacting protein 
701 solute carrier family 10 (sodium/bile acid cotransporter family), member 2 
702 glycerol-3-phosphate dehydrogenase 1-like 
703 calumenin 
704 keratin 12 
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705 Ras suppressor protein 1 
706 recombination activating gene 2 
707 G protein-coupled receptor 15 
708 uncharacterized LOC257152 
709 FtsJ RNA methyltransferase homolog 2 (E. coli) 
710 origin recognition complex, subunit 3 
711 O-6-methylguanine-DNA methyltransferase 
712 polymerase (DNA directed), delta 1, catalytic subunit 
713 regulatory factor X-associated ankyrin-containing protein 
714 guanine nucleotide binding protein (G protein), alpha z polypeptide 
715 CCR4-NOT transcription complex, subunit 2 
716 hCG1732469 
717 microfibrillar-associated protein 2 
718 SND1 intronic transcript 1 (non-protein coding) 
719 D site of albumin promoter (albumin D-box) binding protein 
720 AF4/FMR2 family, member 3 
721 SPO11 meiotic protein covalently bound to DSB homolog (S. cerevisiae) 
722 akirin 1 
723 ASMTL antisense RNA 1 (non-protein coding) 
724 chaperonin containing TCP1, subunit 4 (delta) 
725 guanine nucleotide binding protein (G protein), beta 5 
726 methyltransferase like 9 
727 uncharacterized LOC100506190 
728 butyrylcholinesterase 
729 slowmo homolog 2 (Drosophila) 
730 transmembrane 4 L six family member 5 
731 X-box binding protein 1 
732 ubiquitin specific peptidase 22 
733 dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) 
734 phosphatidylinositol transfer protein, membrane-associated 1 
735 cell division cycle 123 homolog (S. cerevisiae) 
736 olfactory receptor, family 1, subfamily F, member 1 
737 S100 calcium binding protein A10 
738 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 
739 nitrogen permease regulator-like 2 (S. cerevisiae) 
740 lymphocyte antigen 6 complex, locus G6E (pseudogene) 
741 IKAROS family zinc finger 5 (Pegasus) 
742 purinergic receptor P2X, ligand-gated ion channel, 6 
743 exocyst complex component 6B 
744 polymerase (RNA) I polypeptide C, 30kDa 
745 vascular endothelial growth factor A 
746 major histocompatibility complex, class I, B 
747 centromere protein F, 350/400kDa (mitosin) 
748 SH3 domain containing, Ysc84-like 1 (S. cerevisiae) 
Appendix A                            206 
 
 
 
749 CUB domain containing protein 1 
750 proline synthetase co-transcribed homolog (bacterial) 
751 growth hormone 2 
752 epidermal growth factor receptor pathway substrate 8 
753 acylphosphatase 2, muscle type 
754 THO complex 2 
755 aldehyde dehydrogenase 1 family, member A2 
756 tripartite motif containing 8 
757 carcinoembryonic antigen-related cell adhesion molecule 3 
758 WD repeat domain 77 
759 centrosomal protein 85kDa 
760 aminopeptidase-like 1 /// STX16-NPEPL1 readthrough (non-protein coding) 
761 zinc finger, DHHC-type containing 7 
762 protein phosphatase, Mg2+/Mn2+ dependent, 1E 
763 TAR (HIV-1) RNA binding protein 2 
764 galactosamine (N-acetyl)-6-sulfate sulfatase 
765 nucleoporin 98kDa 
766 Rho GTPase activating protein 15 
767 vaccinia related kinase 1 
768 zinc finger, BED-type containing 4 
769 thyrotropin-releasing hormone degrading enzyme 
770 membrane-spanning 4-domains, subfamily A, member 4A 
771 HOP homeobox 
772 ATPase, Ca++ transporting, plasma membrane 1 
773 adrenoceptor beta 3 
774 smg-5 homolog, nonsense mediated mRNA decay factor (C. elegans) 
775 vacuolar protein sorting 13 homolog D (S. cerevisiae) 
776 SLIT and NTRK-like family, member 3 
777 glucose 6 phosphatase, catalytic, 3 
778 succinate-CoA ligase, GDP-forming, beta subunit 
779 snail homolog 1 (Drosophila) 
780 vacuolar protein sorting 33 homolog B (yeast) 
781 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 
member 1 
782 signal transducer and activator of transcription 6, interleukin-4 induced 
783 RUN and FYVE domain containing 3 
784 solute carrier family 6 (neurotransmitter transporter, glycine), member 5 
785 signal sequence receptor, gamma (translocon-associated protein gamma) 
786 uncoupling protein 2 (mitochondrial, proton carrier) 
787 zinc finger protein 674 
788 HIG1 hypoxia inducible domain family, member 1A 
789 olfactory receptor, family 7, subfamily C, member 1 
790 ankyrin repeat domain 34C 
791 general transcription factor IIH, polypeptide 2B (pseudogene) 
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792 ATP5S-like 
793 coiled-coil domain containing 81 
794 hepatoma-derived growth factor, related protein 3 
795 transmembrane channel-like 7 
796 spastic paraplegia 11 (autosomal recessive) 
797 kinesin family member 20B 
798 190 kDa guanine nucleotide exchange factor 
799 chromosome 11 open reading frame 24 
800 dynamin 2 
801 CREB/ATF bZIP transcription factor 
802 mannosidase, alpha, class 2A, member 1 
803 G patch domain containing 3 
804 troponin I type 2 (skeletal, fast) 
805 EPH receptor A3 
806 CD3g molecule, gamma (CD3-TCR complex) 
807 ring finger protein 32 
808 zinc finger, MYND-type containing 8 
809 forkhead box C1 
810 phosphoribosyl pyrophosphate synthetase-associated protein 1 
811 ATPase, aminophospholipid transporter, class I, type 8B, member 3 
812 melanocortin 5 receptor 
813 family with sequence similarity 168, member A 
814 RAB21, member RAS oncogene family 
815 guanylate cyclase 1, soluble, beta 3 
816 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3C 
817 cerebellar degeneration-related protein 2, 62kDa 
818 NAG18 mRNA 
819 GA binding protein transcription factor, beta subunit 1 
820 late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 
821 Ral GTPase activating protein, beta subunit (non-catalytic) 
822 Sin3A-associated protein, 130kDa 
823 alkylglycerone phosphate synthase 
824 collagen, type XIII, alpha 1 
825 WD repeat domain 46 
826 pleckstrin and Sec7 domain containing 
827 sterol O-acyltransferase 2 
828 tenascin C 
829 crystallin, mu 
830 pseudouridylate synthase 3 
831 chromosome 1 open reading frame 50 
832 lin-7 homolog B (C. elegans) 
833 G protein-coupled receptor 98 
834 peroxisome proliferator-activated receptor gamma 
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835 TNFRSF1A-associated via death domain 
836 NUAK family, SNF1-like kinase, 1 
837 pyruvate dehyrogenase phosphatase catalytic subunit 1 
838 macrophage erythroblast attacher 
209 
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Table B.1:  Top Genes 25 Blaveri Stage 
Rank Gene Title  
1 KIAA0914 gene product 
2 fibromodulin 
3 extracellular matrix protein 1 
4 matrix metalloproteinase 11 (stromelysin 3) 
5 MHC class II transactivator 
6 EGF-containing fibulin-like extracellular matrix protein 1 
7 integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) 
8 Microfibril-associated glycoprotein-2 
9 S100 calcium-binding protein A7 (psoriasin 1) 
10 aquaporin 5 
11 membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive 
antigen) 
12 KIAA0494 gene product 
13 AE-binding protein 1 
14 natural killer cell group 7 sequence 
15 inhibin, beta A (activin A, activin AB alpha polypeptide) 
16 contactin associated protein 1 
17 ESTs, Moderately similar to JC4969 pig-c protein [H.sapiens] 
18 duodenal cytochrome b 
19 KIAA1077 protein 
20 Human clone 23719 mRNA sequence 
21 myosin regulatory light chain interacting protein 
22 retinoic acid receptor responder (tazarotene induced) 2 
23 RAB31, member RAS oncogene family 
24 endothelin receptor type A 
25 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 
 
Table B.2:  Top Genes 25 Blaveri Grade 
Rank Gene Title  
1 keratin 19 
2 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 
3 nuclear cap binding protein subunit 1, 80kD 
4 major histocompatibility complex, class II, DR alpha 
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5 N-acetylneuraminic acid phosphate synthase 
6 erythrocyte membrane protein band 7.2 (stomatin) 
7 regulator of G-protein signalling 10 
8 FXYD domain containing ion transport regulator 3  
9 pre-alpha (globulin) inhibitor, H3 polypeptide 
10 ribosomal protein L5 
11 ret finger protein 2 
12 Homo sapiens MAIL mRNA, complete cds 
13 calumenin 
14 MAD (mothers against decapentaplegic, Drosophila) homolog 5 
15 protein tyrosine phosphatase, receptor type, F 
16 proteoglycan 1, secretory granule 
17 microfibrillar-associated protein 2 
18 STAT induced STAT inhibitor 3 
19 Tubulin, alpha, brain-specific 
20 major histocompatibility complex, class II, DQ alpha 1 
21 leucine aminopeptidase 
22 calponin 3, acidic 
23 mannose receptor, C type 1 
24 cathepsin L 
25 inositol 1,3,4-triphosphate 5/6 kinase 
 
Table B.3:  Top Genes 25 Blaveri Survival 
Rank Gene Title  
1 hypothetical protein PRO1847 
2 enolase 2, (gamma, neuronal) 
3 KIAA0672 gene product 
4 transcription factor 15 (basic helix-loop-helix) 
5 zinc finger protein 266 
6 oxytocin receptor 
7 tubby like protein 3 
8 suppressor of Ty (S.cerevisiae) 4 homolog 1 
9 KIAA0410 gene product 
10 glutamyl-prolyl-tRNA synthetase 
11 syntaxin binding protein 1 
12 Homo sapiens cDNA FLJ13303 fis, clone OVARC1001372, highly similar to Homo 
sapiens liprin-alpha4 mRNA 
13 Homo sapiens, clone IMAGE:3940519, mRNA, partial cds 
14 BCL2/adenovirus E1B 19kD-interacting protein 1 
15 Rag D protein 
16 alanyl-tRNA synthetase 
17 KIAA0027 protein 
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18 proteasome (prosome, macropain) subunit, beta type, 1 
19 guanine nucleotide binding protein 4 
20 mitochondrial ribosomal protein L12 
21 chromosome 2 open reading frame 8 
22 Homo sapiens cDNA FLJ10447 fis, clone NT2RP1000851 
23 KIAA0981 protein 
24 stage 
25 grade 
 
Table B.4:  Top Genes 25 Kim Stage 
Rank Gene Title  
1 dynamin 1 
2 extra spindle pole bodies homolog 1 (S. cerevisiae) 
3 cytoskeleton associated protein 2-like 
4 defective in sister chromatid cohesion 1 homolog (S. cerevisiae) 
5 chromosome 17 open reading frame 53 
6 trophinin associated protein (tastin) 
7 IQ motif containing GTPase activating protein 3 
8 citron (rho-interacting, serine/threonine kinase 21) 
9 cysteine-rich protein 1 (intestinal) 
10 E2F transcription factor 1 
11 CDC45 cell division cycle 45-like (S. cerevisiae) 
12 centromere protein A 
13 nucleolar and spindle associated protein 1 
14 cyclin-dependent kinase inhibitor 3 
15 monocyte to macrophage differentiation-associated 
16 cell division cycle 20 homolog (S. cerevisiae) 
17 aurora kinase A; aurora kinase A pseudogene 1 
18 non-SMC condensin I complex, subunit G 
19 cyclin B2 
20 Holliday junction recognition protein 
21 centrosomal protein 55kDa 
22 chromosome 1 open reading frame 175 
23 pyridine nucleotide-disulphide oxidoreductase domain 2 
24 chromosome 8 open reading frame 16 
25 interferon, epsilon 
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Table B.5:  Top Genes 25 Blaveri Grade 
Rank Gene Title  
1 GINS complex subunit 4 (Sld5 homolog) 
2 septin 3 
3 E2F transcription factor 1 
4 dimethylarginine dimethylaminohydrolase 2 
5 24-dehydrocholesterol reductase 
6 extra spindle pole bodies homolog 1 (S. cerevisiae) 
7 histone cluster 1, H1c 
8 histone cluster 1, H2bk 
9 eukaryotic translation initiation factor 4E binding protein 1 
10 olfactory receptor, family 2, subfamily B, member 6 
11 inositol(myo)-1(or 4)-monophosphatase 2 
12 RecQ protein-like 4 
13 defective in sister chromatid cohesion 1 homolog (S. cerevisiae) 
14 BCL2-like 12 (proline rich) 
15 cell division cycle associated 5 
16 p53 and DNA-damage regulated 1 
17 aurora kinase A; aurora kinase A pseudogene 1 
18 similar to ferritin, light polypeptide; ferritin, light polypeptide 
19 myelin protein zero-like 1 
20 chromosome 9 open reading frame 140 
21 solute carrier family 29 (nucleoside transporters), member 4; similar to solute 
carrier family 29 (nucleoside transporters), member 4 
22 thymidine kinase 1, soluble 
23 chromosome 1 open reading frame 112 
24 chromosome 15 open reading frame 48 
25 cell division cycle associated 8 
 
Table B.6:  Top Genes 25 Blaveri Survival 
Rank Gene Title  
1 grade 
2 stage 
3 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 
4 adrenomedullin 2 
5 ribosome binding protein 1 homolog 180kDa (dog) 
6 cyclin N-terminal domain containing 2 
7 lipase, endothelial 
8 chromosome 5 open reading frame 46 
9 espin 
10 phosphodiesterase 6B, cGMP-specific, rod, beta 
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11 transmembrane protein 195 
12 FAT tumor suppressor homolog 1 (Drosophila) 
13 family with sequence similarity 13, member B 
14 N-6 adenine-specific DNA methyltransferase 2 (putative) 
15 plexin domain containing 2 
16 chromosome 1 open reading frame 186 
17 homeobox and leucine zipper encoding 
18 chromosome 7 open reading frame 41 
19 aspartylglucosaminidase 
20 similar to programmed cell death 2 
21 chloride channel 3 
22 nuclear receptor subfamily 2, group C, member 1 
23 N-acetylneuraminate pyruvate lyase 2 (putative) 
24 arrestin domain containing 4 
25 G protein-coupled receptor 98 
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Appendix C: Synthetic 
Data Set  
 A Synthetic Data Set was produced to test the new RBF Neural-Fuzzy Feature 
selection.  
 There are several factors to take in account to produce a synthetic Data Set: 
 The output of the system is only linked to the relevant genes 
 Add some noise to the data 
 Produce genes that are correlated to relevant genes 
 The synthetic data set consists in 100 patients and 150 genes. From the Synthetic 
Data Set 150 genes were selected, 100 irrelevant and 50 relevant. The expectation is that 
the RBF Method selects only the 50 relevant.  
 The RBF-NF model was developed as described in section 5.2 and 5.4. The 
output values were ‘encoded’ into -1 and 1. The classification function of Accuracy is 
used as measure of performance. The results shown are the mean % of the 10 models 
for Accuracy in selecting relevant features. 
The results of the new method based in the Entropy, Output Weights and Membership 
Functions applied to the Synthetic Data are shown below: 
Table C.1:  Accuracy in selecting relevant features 
  Accuracy 
in 
selecting 
relevant 
features 
5 
rules 
 (%) 80.2 
Standard 
Deviation 
3.8 
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Appendix D: Input-output 
mappings across 
different microarray 
technologies, showing 
the non-linear behaviour 
  
 Figure D.1: Blaveri Input-Output Mapping Gene 1 
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Figure D.2: Blaveri Input-Output Mapping Gene 2 
 
 
Figure D.3: Blaveri Input-Output Mapping Gene 3 
 
Appendix D                                                                                                                                               217 
  
 
 
 
 
Figure D.4: Kim Input-Output Mapping Gene 1 
 
 
Figure D.5: Kim Input-Output Mapping Gene 2 
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Figure D.6: Kim Input-Output Mapping Gene 3 
 
